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 IX
Zusammenfassung 
Die MALDI-TOF Massenspektrometrie (MS) ist eine etablierte Technologie, die sich für die Analyse zahlreicher 
Biomoleküle wie etwa Nukleinsäuren, Proteinen und deren posttranlsationalen Modifizierungen bewährt hat. 
In der vorliegenden Arbeit wurde eine neue Methode mittels MALDI-TOF Massenspektrometrie entwickelt, um bei 
Addukten an Nukleinsäuren einerseits die Chemikalien zu analysieren, die zu einer Interaktion mit den 
Nukleinsäuren führen und zum anderen auch die daraus resultierenden DNA-Addukte nachzuweisen. 
Für die Entwicklung dieser Methode, war es vor allem erforderlich eine neue Probenpräparation für die 
massenspektrometrische Analyse zu etablieren. Diese neue „matrix layer“ Probenpräparation hat sich als sehr 
geeignet für die Analyse der o.g. Biomoleküle erwiesen, da sowohl ein zuverlässiger Nachweis mit hoher 
Nachweisempfindlichkeit, sowie eine umfassende Charakterisierung der molekularen Beschaffenheit dieser 
Biomoleküle möglich ist.  
Hervorzuheben ist die vielseitige Verwendbarkeit der MALDI-TOF MS Technologie in Kombination mit der neu 
entwickelten Methode zur Probenpräparation, welche eine umfassende und detaillierte Analyse von Proteinen 
auch mit hohem Probendurchsatz ermöglicht, wie es für die meisten Proteomstudien erforderlich ist (Kapitel I). 
Darüber hinaus wurden vereinfachte und robuste Verfahren entwickelt, die eine Anreicherung und Aufreinigung 
der zu analysierenden Biomoleküle mittels MALDI-TOF MS ermöglichen, wodurch die Identifizierung und 
molekulare Charakterisierung von DNA-Addukten erfolgen kann, als auch die Ermittlung von Phosphorylierungen 
an Proteinen (Kapitel II & III). 
Für den Nachweis und die Identifizierung von phosphorylierten Proteinen wurde zudem eine neue Methode 
entwickelt, die auf der Kombination von zweidimensionaler Gelelektrophorese, einer Immundetektion und der 
Verwendung von MALDI-TOF MS beruht (Kapitel III). 
Mit der vorliegenden Arbeit konnte gezeigt werden, dass die Entwicklung einer optimierten Methode zur 
Probenpräparation eine analytische Technologie wie die Massenspektrometrie effizient nutzbar macht, um mit 
hoher Nachweisempfindlichkeit verschiedenartige Krebs-relevante Biomoleküle nachzuweisen sowie deren 
molekulare Struktur zu charakterisieren. Die Anwendung dieser neuen MALDI MS basierten Methode für den 
Nachweis, die Identifizierung und Charakterisierung von so unterschiedlichen Biomolekülen wie Proteinen, 
phosphorylierten Proteinen und Addukten von Nukleinsäuren stellt daher einen vielversprechenden Beitrag in der 
Krebsforschung dar.  
 
Schlagwörter: MALDI-TOF, Massenspektrometrie; Protein-Analyse; Proteomik, Protein-Phosphorylierung; DNA-
Addukte. 
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Abstract 
MALDI-TOF is versatile mass spectrometric technology which can be applied to the study of a variety of 
molecules such as nucleic acids, proteins and their post translational modifications. 
In this thesis novel MALDI-TOF mass spectrometry (MS) based methods were developed to improve 
detection of chemicals interacting with nucleic acid and to identify and characterize DNA adducts, 
proteins, and protein posttranslational modifications. This necessitated the development of a new 
“matrix layer” sample preparation that showed be extremely useful for sensitive detection and molecular 
characterization of these biomolecules. The versatility of MALDI-TOF MS technology in combination 
with the new developed methods permitted in-depth analyses of proteins and automated data 
acquisition allowing high throughput required in proteomic studies (Chapter I). Furthermore, simplified 
and robust procedures for analyte enrichment/purification were implemented with MALDI tandem MS for 
the identification and molecular characterization of DNA adducts and determination of protein 
phosphorylation sites (Chapter II & III). Moreover a method was developed for the reliable detection and 
identification of phosphorylated proteins based on a combination of Two-dimensional gel 
electrophoresis, immunodetection and MALDI tandem MS (Chapter III).  
Noteworthy, with this doctoral thesis it was demonstrated that a single mass spectrometric technology 
enables sensitive detection and reliable identification through molecular characterization of these 
cancer-related biomolecules. The new developed MALDI MS based methods provide the capability to 
detect, identify and qualify protein, protein phosphorylation and DNA-adducts in a high sensitive manner 
on a systematic scale, and therefore, can be applied to biomedical and cancer research.   
 
Keywords: MALDI-TOF; mass spectrometry, protein analysis; Proteomics, protein phosphorylation; 
DNA adducts. 
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Preface 
Cancer is one of the leading causes of morbidity and mortality accounted for arount 13% of all death 
worldwide 1. In Europe, more then 3.4 million new cases are diagnosed and 1.8 million men and women 
died of cancer in 2008 2 , Prognosis for lung and liver cancer patients is poor with 5-year survival rates 
being less than 10% and 5%, respectively 3. The exceptionally high mortality of most neoplasms is 
partialy due to our inability to diagnose the diseases at an early stage. In fact, 50% of patients already 
have distant metastases at diagnosis 4. Curative surgery is efficacious only for those patients who are 
diagnosed sufficiently early in the disease process. If lung cancer, for example, is localized at the time of 
diagnosis and treated promptly by surgery, the 5-year survival rate increases to 52% 5. Therefore, early 
detection is vital for the effective treatment of neoplasms, providing evidence to substantiate the need of 
analytical methods for cancer biomarkers discovery. These biomarkers can be used in population-wide 
screening programs and diagnostic purposes in the hope to reduce mortality and morbidity in cancer 6. 
The knowledge about the causative factors and their role in carcinogenesis is crucial to understand the 
evolution of the disease. This knowledge will drive the development analytical method to search, select 
and isolate cancer-related biomolecules which can be used as biomarker for monitoring and screening 
purposes. However, the etiology of most neoplasms is not always evident. For instance, in lung cancer 
tobacco smoking is the primary etiological factor 7, but development of neoplasms is the result of a 
combination of several causes 8. Numerous environmental and industrial produced toxicants and life 
stile factors involving mutagens and carcinogens exposure are known to be causative elements of 
cancer. Specifically, molecules such as polycyclic aromatic hydrocarbons (PAH), nitrosamine, 
halogenated aromatic hydrocarbons, polychlorinated biphenyls (PCB), dioxin and aromatic amines are 
ubiquitous environmental pollutants and in part components of cigarette smoke. Indeed, increased risk 
of lung, skin and bladder cancer has been associated with exposure to these carcinogens 9-13. However, 
most carcinogens require metabolic activation to exert their carcinogenic effects. Moreover, the balance 
between metabolic activation and detoxification differs among individuals and affects cancer risk 14. 
Metabolic activation of carcinogens leads to intermediates that might react with nucleic acid and 
proteins leading to DNA, RNA, and protein adduct formation and consequently to mutation. The 
absolute central role of carcinogens and their DNA adducts in chemical-induced cancer is illustrated by 
the scheme in Figure 1 7,8. If DNA adducts escape cellular repair mechanisms and persist, they may 
lead to miscoding, resulting in permanent mutations. Cells with damaged DNA may be removed by 
apoptosis. If a permanent mutation occurs in a critical region, it can lead to activation of oncogenes or 
deactivation of tumor suppressor genes. Consequently, aberrant cell formation with loss of normal 
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growth control can lead to cancer development, as shown in the central track of the scheme in Figure 1 
15,16. Therefore, carcinogens are the key connection between environmental/industrial produced 
toxicants, life stile factors and cancer. The upper track of the scheme in Figure 1 depicts that 
carcinogens such as PAH, PCB and tobacco-specific nitrosamines can bind directly to certain receptors 
like Aryl hydrocarbon receptor (AhR) 17 leading to activation of cellular regulatory factors such as AKT 
and protein kinase A (PKA) 7,17,18. This can result ultimately in decreased apoptosis and increased 
angiogenesis as well as cell transformation. These changes may enhance the effects of carcinogens 
and their DNA adducts. Furthermore, co-factors such as co-carcinogens, tumor promoters and 
irradiation may amplify the activity of carcinogens through a variety of mechanisms 19,20, as illustrated in 
the lower track of the scheme in Figure 1.  
  
 
Figure 1. Scheme linking exposure to carcinogens and cancer. Adapted from ref. 7
,8. 
 
The development of cancer is generally considered a multistep process driven by carcinogen-induced 
genetic and epigenetic damage and activation of cellular regulatory factors of the network of signaling 
pathways in susceptible cells, which as result gain a selective growth advantage. Simultaneous and 
persistent multiple events of this type lead to aberrant cells with loss of normal growth control and 
ultimately to cancer 15,16. While carcinogenesis if normally caused by genomic mutations the subsequent 
translational changes in the protein products indicate both the molecular mechanisms and potential 
markers of neoplasia 21. Notably, the interactions and regulation of proteins function in intricate networks 
are indicative of biological complexity downstream from the alterations within the genes of the neoplastic 
cells. There are evidences which demonstrated relationships between environmental and chemical 
carcinogens and DNA adducts formation which leads to changes in the regulation of protein 
posttranslational modifications (PTM). For instance, the phosphorylation of the H2A histone variant 
H2AX has been directly related with the exposure to PAH 22-24. Studies on cultured cell lines treated with 
PAH demonstrated direct and indirect changes of phosphorylation status of insulin growth factor 
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signaling pathways 25, epidermal growth factor (EGF)-receptor signaling 26, protein kinase C 27,28 as well 
as mitogen activated protein kinase (MAPK) such as extra cellular receptor kinase (ERK) 1/2 and p38 
19,29. Indeed, reversible protein phosphorylation is a ubiquitous cellular mechanism for the control of 
protein functions and signal transduction networks that regulates diverse biological processes. The 
phosphorylation/deposphorylation can change the protein’s enzyme activity, the cellular location, 
increase protein–protein interactions and target proteins for degradation, all of which induce many 
essential cell processes such as signal transduction, cell differentiation, proliferation, metabolic 
maintenance, cell division, and apoptosis 30. Notably, receptor tyrosine kinase signal transduction 
pathways are the major regulators of cell proliferation and are frequently found to be mutated and 
activated during tumor development 31. Moreover, the protein kinase activities, regulated through 
phosphorylation in turn, plays an important role in cancer and it has been well described to be involved 
in development of malignancies by generating inappropriate signals 32-34. 
Taken collectively, understanding carcinogenesis, tumor progression, and metastasis requires not only 
the knowledge of the critical triggering events at the DNA level but also a careful analysis of effectors 
molecules such as proteins and their PTM, which act as regulatory components of the network of 
signaling pathways that drive neoplasia 14,34. The availability of methods for investigation at the levels of 
DNA, protein and PTM and their regulation on a global scale has tremendous potential to enhance the 
knowledge of the cellular events that occur in response to causing agents. The study of cancer-related 
biomolecules will permit to understand the regulatory roles, to interpreting signaling pathways and other 
cellular processes that contribute to cancer development and metastasis. Therefore, the search for 
biomarkers for an early detection of cancer needs reliable methodology for detection of cancer-related 
biomolecules such as DNA-adducts, proteins and phosphoproteins. To gain insides in these processes 
it is important to have the use of experimental methodology for the detection and characterization of 
these cancer-related biomolecules. Although for this purpose a number of analytical methods are 
currently used, there are based on different and in some cases unrelated technologies. It will be helpful 
to have a unique technological platform for the analysis of all these biomolecules. 
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Aims of this doctoral thesis  
The above examples give an overview on the variety of implications related to the DNA adducts 
formation, regulation of protein and protein posttranslational modifications can have in cell biology and 
cancer development. Moreover, underline the importance to develop analytical methodologies for the 
study of these biomolecules.  
MALDI is a versatile mass spectrometry technology which permits high specificity and sensitivity, wide 
applicability, high throughput and is easy to use. The aim of this thesis was to develop more efficient 
methods based on MALDI-TOF MS for the study of proteins, DNA adducts and protein posttranslational 
modifications. These methods could be applied to solve biological questions regarding the roles played 
by these molecules as well as their regulation in normal cell and cancer cell metabolism.  
A major focus was to develop novel MALDI matrix sample preparations to be applied for the 
identification and molecular characterization of proteins, PAH-DNA adducts and protein phosphorylation 
in a robust manner. Moreover, rapid and affordable techniques capable of efficient enrichment for these 
molecules from complex mixture should be developed in order to be implemented with MALDI MS. 
These methods should enable: a) simplified and rapid enrichment procedures; b) higher quality MS 
spectra, and c) acquisition of more MS and MS/MS measurements per sample.  
Therefore, the specific aims of the research projects for this doctoral thesis were: 
 
1. Development of novel MALDI MS sample preparation methods for improved peptide ionization and 
fragmentation, which provide higher quality MS information relevant for increased protein sequence 
coverage. These methods should be compatible to unambiguous peptide and protein identification and 
characterization as well as high throughput analyses (I). 
 
2. Development of simple but efficient procedures for the extraction and enrichment of DNA adduct 
molecules. Moreover, new MALDI MS based methods for sensitive and reliable detection, identification 
and molecular characterization of adducted nucleotides and the alkylating molecules (II) should be 
developed. 
 
3. Development of methods to detect phosphoproteins from tissue protein extracts and to efficiently 
enrich phosphopeptides minimizing sample treatment. Moreover, develop new MALDI-TOF MS sample 
preparation and procedures for improved ionization and fragmentation of phosphopeptides in order to 
characterize the phosphorylation sites (III). 
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 The following chapters intend to familiarize the reader with the merits and pitfalls of the most 
prominent approaches used to study proteins, DNA adducts and protein phosphorylation in order to 
explain how each of these methods can be used to gain insight into the complex world of these 
biomolecules. Contributions of the author with this doctoral thesis to the relatively new fields are 
presented and summarized in the final paragraphs of each chapter. 
 
 
 
 
 
 
 
 
 
Introduction 1
Introduction 
Mass spectrometry for biological sciences  
Mass spectrometry (MS) is one of the most comprehensive analytical technique currently at the disposal 
of scientists35. High sensitivity and specificity are their peculiarities which led the widely use of this 
analytical technique in several areas of physic, chemistry, geology, nuclear science, material science, 
archaeology, petroleum industry, forensic science and environmental science. Indeed, MS provides high 
molecular specificity, analyte molecular ions and structural diagnostic fragment ions can be analyzed. 
MS permits high sensitivity detection, molecules can be detect at the zeptomolar level36. MS is versatile 
and it is applicable to all elements and can be used to determine the structure of most class of unknown 
compounds. The chemical mature of the molecules that could be analyzed is virtually unlimited: volatile 
or non-volatile, polar or non-polar, solid, liquid or gaseous. In addition, when used in combination with 
high resolution separation techniques, MS is qualified to analyze very complex samples36. Therefore, 
MS is applied to molecular mass determination, structure elucidation, mixture analysis and quantification 
at trace level. However, the application of MS to biological fields remained negated for long time, mostly 
because of the lack of suitable ionization technique for molecules of biological origin. The major 
challenge was to generate ions from non polar compounds of large molecular mass without molecular 
fragmentation. Since the introduction of the gentler modes of ionization also the analysis of large 
biomolecules becomes feasible. In the past, the exorbitant costs and the need of skilled operators 
restricted MS to the domain of elite of laboratories37. Currently, a number of different types of MS 
instrumentation for several specific applications are commercially available of reasonably price and user 
friendly. As result, MS has become an essential component of contemporary chemical and biochemical 
research laboratory. This chapter intend familiarize the reader with the basic concepts of biological 
mass spectrometry and in particular of matrix assisted laser desorption/ionization (MALDI), the MS 
technology on which are based the method developed in this doctoral thesis. 
Mass spectrometry  
Mass spectrometry is an analytical technique to determine the molecular mass of free ions. Mass 
spectrometers are extensively used in science. MS is used for determining the masses and for 
elucidating the chemical structures as well as the elemental composition of molecules. In order to be 
measured, individual molecules are converted to ions so that they can be moved and manipulated by 
external electric and magnetic fields for the analysis. Structural information can be generated by 
fragmenting the sample inside the instrument and analyzing the products generated. This is achieved 
using certain types of device, usually those with multiple analyzers which are known as tandem mass 
spectrometers. A mass spectrometer can be divided into three fundamental parts, namely the ionization 
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source, the analyzer, and the detector (Figure 2). First, the sample has to be introduced into the 
ionization source of the instrument. In the ionization source a beam of gaseous ions from the analyte is 
formed, then, in the mass analyzer, the ions are separates according to their mass-to-charge ratios 
(m/z).  
 
 
Figure 2. Schematic representation of a mass spectrometer components. 
 
The separated ions are detected and this relative ion current (signal) sent to a data system, where the 
m/z ratios are stored together with their relative signal abundance to produce a mass spectrum. In 
modern mass spectrometers the entire operations are under complete data system control. 
The sample can be inserted directly into the ionisation source. Alternatively, the sample can undergo 
previous chromatographic (e. g. liquid chromatography, LC; gas chromatography, GC) or electrophoretic 
(capillary electrophoresis, CE; gel electrophoresis: SDS-PAGE, 2-DE) separations into series of analyte 
components. The components are introduced directly (on-line) or sequentially (off-line) into the 
ionization source for individual analysis. 
There are several different ionization techniques, adding or removing an electron to/from the molecules 
is the generally way to ionize the analytes. The analyte can be impacted by a beam of electrons with 
sufficient energy to ionize the molecule (electron impact, EI). The analyte can be exposed to a gentler 
proton transfer process that preserves and promotes the appearance of the molecular ion (chemical 
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ionization, CI), or by using a molecule that contains electron-capturing moieties (negative chemical 
ionization, NCI). The analyte can be bombarded with atoms or ions (fast atom bombardment, FAB), 
irradiated by photons of a high-intensity laser pulse (Laser desorption/ionization, LDI) or using an UV 
adsorbing molecule as matrix to mediate the process of LDI (matrix assisted desorption/Ionization, 
MALDI). A further ion formation process is denoted Electro spray ionization (ESI) which is included in 
the general term "atmospheric pressure ionization" (API) of related techniques capable of creating ions 
at atmospheric pressure rather than in a vacuum35-37.  
Separation and detection of analytes is subsequently exploited by the combination of several types of 
analyzers with suitable detectors. The main function of the mass analyzer is to separate, or resolve, the 
ions formed in the ionization source of the mass spectrometer according to their m/z. For instance, the 
process of ion separation can be performed a) by combining a magnetic and an electric field e.g.: sector 
field instruments; b) inside the radio frequency (RF) field of a quadrupole; c) by a magnetically ion trap 
e.g.: Ion Cyclotron Resonance Cell, ICR; d) after a flight time in an ion flight tube e.g.: Time-Of-Flight 
instruments; TOF; e) by an electrostatically ion trap, e.g. orbitrap. These mass analyzers have different 
features, including the m/z range that can be covered, the mass accuracy, and the achievable 
resolution35-37.  
The detector monitors either the charge induced or the current produced when an ion passes by or hits 
a surface. Because the number of ions leaving the mass analyzer at a particular instant is quite small, 
considerable amplification is necessary to get a signal. Therefore, the type of detector is supplied to suit 
the type of analyzer. Several types of electron multiplier, Faraday cups and micro-channel plate 
detectors are commonly used in modern commercial instruments.  
Finally, the signal is then transmitted to the data system, where it is recorded in the form of mass 
spectra. The m/z values of the ions are plotted against their intensities to show the number of 
components in the sample, the molecular mass of each component, and the relative abundance of the 
various components in the sample.  
Tandem (MS/MS) mass spectrometers are instruments that have more than one analyzer and so can be 
used for structural and sequencing studies. Two, three and four analyzers have all been incorporated 
into commercially available tandem instruments, and the analyzers do not necessarily have to be of the 
same type, in which case the instrument is a hybrid one.  
Notably, with the development of soft ionization techniques such as matrix assisted laser 
desorption/ionization (MALDI) 38,39 and electrospray ionization (ESI) 40,41 the analysis of large 
biomolecules such as proteins became feasible. These ionization techniques are described as “soft” 
because they allow large molecules to be transferred to the gas-phase and ionized without significant 
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fragmentation. The following sections will cover the type of mass spectrometers and applications that 
are relevant for this thesis. 
ESI MS 
Although the phenomena of electrospray (ESI, abbreviations) have been known for hundreds of years, 
only in the late 1980's John Fenn and co-workers demonstrated the basic experimental principles and 
applied methodologies of the ESI technique for large biomolecules 40,41. Using ESI they obtained “soft” 
ionization of non-volatile and thermally labile compounds such as proteins. ESI MS is now a basic tool 
used in probably every biological chemistry laboratory in the world. To perform ESI (Figure 3) the 
analyte is introduced to the source in solution either from a syringe pump or as the eluent flow from a 
chromatograph. The analyte solution flow passes through a metal electrospray needle (the emitter) that 
is subjected to a high potential difference. Typically, about 2-5 kV are applied with respect to the counter 
electrode, i. e. the spectrometer sampling cone. The high potential difference forces the spraying of 
charged droplets carrying a surface charge of the same polarity of the emitter. Liquid protrudes from the 
emitter forming a “Taylor cone”. The droplets are repelled from the emitter towards the counter electrode 
on the source sampling cone. While droplets traverse the space between the emitter the cone solvent 
evaporates. As the solvent evaporation occurs, the droplet shrinks until it reaches the point that the 
surface tension can no longer sustain the charge (the Rayleigh limit) at which point a "Coulombic 
explosion" occurs and the droplet is ripped apart. This produces smaller droplets that can repeat the 
process as well as naked charged analyte molecules.  
There are two accepted theories for the mechanisms in which the ions are freed into the gas phase in 
ESI. The charged residue model (CRM) 42 suggests that droplets undergoes a sequence of Rayleigh 
instabilities (Coulomb fission) together with solvent evaporation leading progeny droplets that contain on 
average one analyte ion. The gas-phase ions are then formed after the remaining solvent molecules 
evaporate, leaving the analyte with the charges that the droplet carried. The ion evaporation model 
(IEM) 43 suggests that the ions are emitted into the gas phase as the droplet reaches a certain radius 
and the field strength at the surface of the droplet becomes large enough to assist the field desorption of 
solvated ions. While there is no definite scientific proof, a large body of indirect evidence suggests that 
small ions are liberated into the gas phase through the ion evaporation mechanism, while larger ions 
form by charged residue mechanism 44.  
ESI is a very soft ionization method as little residual energy is retained by the analyte, resulting in 
reduced (usually none) fragmentation upon ionization. For structural elucidation studies, tandem mass 
spectrometry for analyte molecules fragmentation is then required. 
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Figure 3. Schematic of the electrospray ionization process. The sample is pumped through the open capillary which 
a high voltage is applied. A Taylor cone is formed when charges start to move towards the counter electrode (mass 
spectrometer). When the Rayleigh limit has reached droplets detach from the Taylor cone. When droplets move 
towards the mass spectrometer, ions are freed into the gas phase either entirely by evaporation of the solvent or by 
effects combined from evaporation of the solvent and coulomb fission. From ref. 44. 
 
MALDI MS 
Since the 1970’s, laser devices have been employed in mass spectrometry to achieve a direct 
desorption/ionization (Laser desorption/ionization, LDI) of intact molecules. With LDI MS a layer of 
sample placed on a metal surface is irradiated by a laser pulse to generate analyte ions. However, 
reduced sensitivity, extensive fragmentation and limited detection to molecules below 1000 Da hindered 
the application of LDI MS for the analysis of biomolecules. In 1985, Michael Karas and Franz 
Hillenkamp 45 inspected the correlation process between UV laser irradiation and organic molecules, 
successfully demonstrated the use of a matrix (consisting of a small organic molecule) to circumvent the 
limitation in LDI. A low concentration of the analyte was mixed with this matrix onto a metal plate sample 
probe (the target) and subjected to a pulsed laser beam. Therefore, embedding the sample into suitable 
matrix material, the laser light was strongly absorbed and thus not only higher intensities of the analyte 
ions were obtained but also sample fragmentation was reduced to a minimum. Thus, a substantial burst 
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of ions was produced with each laser pulse. This was the foundation of matrix-assisted laser 
desorption/ionization (MALDI). Later, Koichi Tanaka 39 using a mixture of cobalt nanoparticles and 
glycerol, what he called the “ultra fine metal plus liquid matrix method of laser desorption ionization”, 
was able to demonstrate the application to a whole range of biological macromolecules. This led him to 
receive a part share with John Fenn on the 2002 Noble prize for chemistry 46. However, the MALDI 
technique was demonstrated (and the name coined) in 1985 by Michael Karas, Doris Bachmann, and 
Franz Hillenkamp 45 but ionization of proteins by MALDI was not reported until 1988 38, immediately 
after Tanaka's results were reported. 
To perform MALDI, the analyte is mixed with a suitable matrix compound absorbing at the used laser 
wavelength on a metal sample plate (the target). Therefore, a co-crystallization process of both matrix 
and analyte material after evaporation of the solvent take place. The target plate have defined positions 
(spots) on which the analyte/matrix are deposited. Then, in the high vacuum area inside the mass 
spectrometer’s ion source the surface of the analyte/matrix sample is then exposed to an intensive 
pulse of short waved laser irradiation. In MALDI a two-step ionization mechanism is the most accepted 
model of ionization. Thus, primary ions are formed after which ion-molecule reactions give rise to 
secondary ions. It is essential for the matrix to be of 1000 to 10 000 times molar excess, thus leading 
the analyte molecules being completely isolated from each other. The incorporation of the sample 
molecules into the lattice structure of the matrix is supposed to be precondition of the functioning of the 
laser desorption/ionization process. Moreover, there are two different theories for the mechanisms in 
which the matrix contributes to ion formation. The cluster model (it began as the ‘‘lucky survivors’’ 
model) supports the suggestion where the matrix is mainly a medium in the desorption/ablation reaction 
47,48. According to this model, the analytes are incorporated into the matrix crystals forming clusters 
(Figure 4). Their charge state is determined by the pH of the solution in which they have been deposited 
onto the MALDI target. During the laser irradiation the clusters are desorbed and the charged analyte is 
freed into the gas phase through sublimation of neutral matrix. In addition, some intra-cluster charge 
transfer and neutralization takes place.  
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Figure 4. The "cluster model" of MALDI ionization.  
Preformed ions, separated in the preparation solution, are contained in clusters ablated from the initial solid 
material. Some clusters contain a net excess of positive charge, others net negative (not shown). If analyte is 
already charged, here by protonation, cluster evaporation may free the ion. In other clusters charge may need to 
migrate from its initial location, e.g. on matrix, to the more favorable location on analyte (secondary reaction). For 
multiply charged analytes, hard and soft desolvation processes may lead to different free ions. Neutralization by 
electrons or counterions takes place to some degree, but is not complete. A = analyte, m = matrix, R- = generic 
counter ion. From ref. 47. 
 
In the pooling model 47,49-51, described in Figure 5, a more active role is proposed for the matrix in 
ionizing the analyte. This model explains the pooling of the energy in the matrix molecules. However, 
excitation migration and pooling have long been known in solid-state aromatics 52, but have been 
studied and demonstrated only in one MALDI matrix, the 2,5-dihydroxybenzoic acid (DHB) 53. Here the 
laser pulse excites two matrix molecules that concentrate energy more to one of the two molecules. This 
combined excitation is enough to transfer the excitation stage of the matrix molecules to a higher level 
and ultimately produces matrix ions. Analyte ions are formed then from the primary matrix ions either by 
A) a proton, B) an electron or C) a cation transfer, producing singly charged analyte ions. 
 
A) Proton transfer: mH+ + A ↔ m + AH+ and (m-H)- +A ↔ m + (A-H)- 
 
B) Electron transfer: m+ + A ↔ m + A+ and m- + A ↔ m + A 
 
C) Cation transfer: e.g. mNa+ + A ↔ m + ANa+ 
m= matrix, A=analyte 
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Figure 5. Unimolecular and biomolecular matrix processes included in the MALDI ionization model. Pooling 
reactions of matrix excited states are key steps in energy concentration and ionization. S1+ S1 pooling (A and B) 
takes place when the laser excites matrix molecules by one photon energy and two neighbouring molecules can 
transfer the energy entirely to another molecule, exciting the third molecule from S0 to Sn.  
S1 + Sn pooling (C and D) takes place when a molecule from S1-S1 pooling (C) receives one photon energy from 
another molecule, thus, forming a matrix ion (D). After this primary ionization the secondary ionization of the 
analyte takes place through photon, electron or cation transfer (see text). S0 = electronic ground state; S1 = the first 
excited state; Sn = higher exited state, twice the energy of the S1. Adapted from ref. 47. 
 
These ionization reactions take place in the desorbed matrix-analyte cloud just above the surface of the 
sample/matrix preparation onto the sample plate (target) (Figure 6). The ions are then extracted into the 
mass spectrometer for analysis. An electrode, which is mounted some millimeter apart opposite to the 
sample position, is used to generate an electrostatic field in the range of some kV/cm. Depending on the 
polarity, positively or negatively charged ions are accelerated from the sample surface towards the 
analyzer. 
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Figure 6. Schematic representation of the desorbed matrix-analyte cloud formation in the source of a MALDI-TOF 
mass spectrometer. 
 
Laser devices employed in MALDI mass spectrometers are pulsed laser systems in the ultraviolet (UV) 
and infrared (IR) spectral ranges. Nowadays various laser types and wavelengths in the UV range are 
available. Nitrogen lasers are widely used in MALDI MS. In these devices, the laser medium is gaseous 
nitrogen (N2), which is excited by means of an electrical discharge between two electrodes and 
produces a laser line. The most intensive laser line at wavelength of λ= 337 nm with pulse durations of 
1-5 ns and operated at repetition rates of 10-50 Hz are used in MALDI MS. Also Excimer lasers which 
typically use a combination of a noble gas such as argon (Ar), krypton (Kr), or xenon (Xe) and a reactive 
gas such as fluorine (F) or chlorine (Cl) are used. Under electrical stimulation, a pseudo-molecule called 
excimer (from the words: excited and dimmer) is created which can only exist in an energized state and 
can give rise to laser light in the ultraviolet range. Excimer laser used in MALDI MS operate at 
wavelengths of λ=193 nm (ArF), at λ=248 nm (KrF) and at λ=308 nm (XeCl), using pulse durations of 2-
20 ns and repetition rates of 1-20 Hz. The Nd:YAG lasers are another type of laser devices used in 
MALDI MS. Nd:YAG are solid-state lasers whose laser medium is a YAG crystal (yttrium aluminum 
garnet:Y3 Al5 O12 ) doped with neodymium ions. The strongest excited laser line lies at a wavelength of 
λ= 1064 nm. This laser frequency can be doubled, tripled or quadrupled by non-linear optical processes. 
Thus, in addition to the fundamental wavelength at λ=1064 nm, wavelengths at λ= 532 nm, λ=355 nm 
and λ=266 nm arise. For MALDI mass spectrometers Nd:YAG lasers with pulse durations of about 5-15 
ns and repetition rates up to 1000 Hz are used.  
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Concerning the MALDI MS in the IR range, Er:YAG (Yttrium-aluminum-garnet-crystals doped with 
erbium) solid-state laser are exploited at a wavelength of λ= 2.94 µm with pulse duration of 90 ns and 
repetition rates of 2-10 Htz. 
The nitrogen lasers with a λ=337 nm and the Nd:YAG lasers at λ=355 nm are the most frequently 
implemented in modern MALDI TOF mass spectrometers. The great advantages of the Nd:YAG 
compared to N2 lasers are the high repetition rate and the low energy fluctuations between individual 
laser pulses as well as the long life time. 
In the mass spectrometer the laser beam is focused by a suitable ion optics onto the sample inside the 
ion source to a diameter of <= 150 µm. The laser power can be adjusted with an attenuator, i.e., a 
metal-coated mirror assembly. The target itself is mounted on a table movable in x and y direction 
allowing the systematic selection of sample positions (spots) for the measurements. Additionally, the 
sample can be observed by video camera to select a specific area of interest on the spot.  
MALDI sources are normally coupled with TOF analyzers. Here the mass determination in the high 
vacuum area is performed by a very precise measurement of the period of time after acceleration 
process of the ions in the source and impact on the detector. An electro-static field accelerates ions 
formed during a short laser pulse inside the source to a kinetic energy of some keV. After leaving the 
source the ions pass a field-free drift region in which they are separated due to their m/z ratio. This 
takes place because at fixed kinetic energy, ions with different m/z values are accelerated in the ion 
source to different velocities. That is, knowing the acceleration voltage and the length of the drift region, 
the m/z ratio can be determined by measuring the flight time. Figure 7 illustrate the principle a TOF 
mass spectrometer measurement in linear mode. Ions formed by the laser pulse being of the same 
charge, but different m/z values are accelerated to different velocities. Large ions with high m/z values 
strike the detector at a later moment than small ions. Therefore, accelerating by means of a certain 
voltage U, the kinetic energy Ek of the ions is defined as: 
   Ek = ½ mv2=zeU      (1)  
However, the velocity v from the ion flight time t through the field-free region L of the flight tube results: 
   v= L/t 
Therefore, replacing v in (1) by the formula given above: 
   ½m(L/t)2 =zeU     (2) 
Then arranging to m/z delivers: 
   m/z = (2eU/L2)t2      (3) 
m = ion mass; v= velocity of the ion after acceleration; z= charge number; e= elementary charge 
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Figure 7. MALDI-TOF measurement in liner mode. Adapted from ref. 54.  
 
Therefore, in a TOF instrument the relation of molecule mass and charge number (m/z) is proportional 
to the flight time. Thus, the related mass can be determined from the measured flight time. Typically, in 
a TOF instrument a drift region is 1-4m long and the flight times span from few to some hundreds 
microseconds. The calibration of the instrument is performed with molecules of known masses used as 
references.  
Notably, not all the ions are desorbed and ionized at the same time and at the same place, thus, 
differences occur related to energy, location and time. Also repulsive electrical forces cause an uneven 
initial energy distribution of the ions. Therefore, ions of the same mass do not have the same kinetic 
energy after passing the acceleration field. Thus, ions leave the source with a certain energy spread, 
resulting in an impact on the detector at slightly different times. This affects in broadening the peak 
width and reducing the resolving power. Using a linear TOF instrument this relative energy spread can 
be compensated by increasing the acceleration voltages, however, with the disadvantage of shorter 
flight times which require a more precise flight time measurements. Moreover, with increasing size of 
the molecules the number of isotopic peaks is enhanced, i.e. more then one peak is detected for the 
molecular ion depending on the relative abundances of the isotope atoms. For large molecules such as 
peptides and proteins the number and relative intensities of isotopes also affect to greater extent the 
peak width in the spectrum. The peak width is an important parameter which indicates the resolving 
power achievable by the instrument. The resolving power ∆M defined the peak separation which allows 
distinguishing two ion species close to each other. There are two main ways to define the minimum 
peak separation ∆M in mass spectrometry: the valley and the peak width definition. The valley system 
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defines ∆M as the closest spacing of two peaks of equal intensity with the valley (lowest value of signal) 
between them less than a specified fraction of the peak height (10% or 50%). This is generally used for 
ion sector and triple quadrupoles instruments. In the peak width definition, the value of ∆M is the width 
of the peak measured at a specified fraction of the peak height (5%, 10% or 50%). Generally, for TOF 
analyzer the resolution is calculated using the full width at half maximum (FWHM), i.e. of the peak width 
at 50% of the peak height. The resolution R of a mass analyzer is defined as the ratio of the mass m 
and the resolving power ∆M.  
The resolution R is calculated as follow: 
    R = m/∆M      (4) 
High resolution MALDI TOF mass spectrometer are implemented with delayed ion extraction (DIE) and 
reflectron devices (Figure 8) to improve the mass resolution. With the DIE the electrical field between 
the sample surface and the related electrode is switched on delayed to the laser pulse 55. Thus, ions 
with a higher initial velocity cover a greater distance from the sample surface and are exposed after 
switching on the electrical field to a less electrical energy than ions with a lower initial velocity. By using 
suitable delay time and field strength the influence of the energy distribution may be compensated at the 
position of the detector. Residual kinetic energy differences can be compensated by applying a 
reflectron. 56. A reflectron is an electronic ion mirror which uses an oppositely polarized static electric 
field to reverse the trajectory of the ions entering it 56. This field is interfaced directly to the field-free drift 
region. Indeed, ions with the same m/z but a higher kinetic energy penetrate deeper into the electric 
field of the reflectron. After reversion of trajectory, high kinetic energy ions reach the slower ones with 
the same m/z at a certain point of the drift region. Therefore, positioning the detector at appropriate 
distance (the focus of the reflectron), ions with the same m/z and different kinetic energies are detected 
simultaneously leading to improve the signals resolution. Applying a reflector, the influence of the 
energy distribution upon the flight time can be compensated at the location of the reflector detector.  
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Figure 8. MALDI-TOF measurements in reflectron mode. Adapted ref. 54. 
 
Resolutions of more than 20,000 (FWHM) within mass range up to 500 kDa and sensitivity of attomole 
(for peptides) can be obtained using commercial high resolution MALDI TOF instruments.  
Tandem mass spectrometry 
In mass spectrometric “soft” ionization processes the analyte posses a very little residual internal energy 
which results in the production of intact molecular ions and less or any analyte fragments. For structural 
elucidation purposes, subsequent analyte decomposition should be performed in order to obtain 
structurally diagnostic fragments. Tandem mass spectrometry also known as MS/MS employs two stage 
of mass analysis in order to selectively detect and generate the fragmentation of a particular analyte 
ions. Indeed, the targeted analyte is ionized and its specific ions are separated and selected in the first 
stage. The selected analyte primary ions are then decomposed to induce fragmentation, and secondary 
ions (fragments), characteristic of the targeted analyte, are detected and analyzed in the second stage. 
Therefore, analyte molecular ion and fragments can then be merged together to generate a tandem 
mass spectrum to obtain structural information regarding the intact molecule. Moreover, tandem mass 
spectrometry also enables specific compounds to be detected in complex mixtures on account of their 
specific and characteristic fragmentation patterns. There are two main categories of instruments that 
allow MS/MS experiments. The first category of instruments uses a sequence of mass spectrometer in 
space, while the second category uses spectrometers with ion storage capability to exploit a sequence 
of events in time. The first category is made up of instruments in which two or more mass spectrometers 
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elements are assembled series to each other. In tandem mass spectrometry in space, the separation 
elements are physically separated and distinct, although there is a physical connection between the 
elements to maintain high vacuum. These elements can be sectors, transmission quadrupole, or time-
of-flight or hybrid combination of analyzers. Three quadrupole elements, two magnetic analyzer 
instruments or hybrids containing one magnetic and one quadrupole, one analyzing quadrupole and one 
time-of-flight are representative cases. The second category of MS/MS instruments comprises analyzer 
capable of storing ions, generally ion traps such as ICR or quadrupole ion trap. With tandem mass 
spectrometry in time, the selected ion can excited and caused to fragment during a selected period of 
time, and the fragment ions can be observed in a mass spectrum. By doing tandem mass spectrometry 
in time, the separation is accomplished with ions trapped in the same place, with multiple separation 
steps taking place over time. This process can be repeated to observe fragments of fragments over 
several generations. Trapping instruments can perform multiple steps of analysis, which is referred to as 
MSn (which the n is the number of steps).  
The ion activation step in the gas-phase is crucial in tandem mass spectrometry and ultimately defines 
what types of products result. Several ion activation techniques have been developed. These 
techniques result in different types of fragmentation and thus different information about the structure 
and composition of the molecule analyzed. Early experiments mainly studied metastable ion 
decompositions. In deed, molecular ions formed in the ion source having sufficient internal energy to 
fragment spontaneously in a field-free region between the source and the analyzer are classified as 
metastable ions. These fragments were initially identified as unknown broadened peaks in the earliest 
mass spectra and later explained as unimolecular decay products formed in the field-free regions of a 
mass spectrometer 57. However, the ability to characterize precursor ions from metastable dissociations 
alone is fairly limited. Therefore, methods that cause ion activation increase internal energy and thus the 
number of precursors that dissociate providing structurally informative fragments were developed. 
Collisions between the precursor ion and a neutral target gas are accompanied by an increase in 
internal energy, which induces decomposition with improved probability of fragmentation as compared 
with metastable unimolecular dissociations. In collision-induced dissociation (CID), the selected 
molecular ions are usually accelerated by electrical potential to a higher kinetic energy and then allowed 
to collide with neutral gas molecules (helium, nitrogen or argon). In the collision some of the kinetic 
energy is converted into internal energy which results in bond breakage and the fragmentation of the 
molecular ion into smaller fragments. The acronyms collisional activated dissociation (CAD) and CID are 
both in use to describe this process. The electrical potential and the gas pressure can be used to get 
additional control on the fragmentation process, i.e. increase the degree of dissociation of higher mass 
ions and particularly stable ions. Therefore, the CID processes can be separated into one of two 
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categories based primarily on the translational energy of the precursor ion: low-energy collisions and 
high energy collisions. Indeed, low-energy collisions occur in the 1–100 eV range of collision energy, 
common in quadrupole and ion trap instruments, whereas, high energy collisions occur in the keV 
range, used in sector and TOF/TOF instruments.  
Several relatively new techniques have been developed to complement conventional CID leading to 
extend the molecules and the kind of fragment obtained. These techniques includes: electron capture 
dissociation (ECD), blackbody infrared radiative dissociation (BIRD), electron transfer dissociation 
(ETD), electron-detachment dissociation (EDD), infrared multiphoton dissociation (IRMPD) and surface-
induced dissociation (SID). Notably, fragmentation techniques can be implemented in a mass 
spectrometer using specific sequences or “routines” in order to selectively detect specific ions. In the 
following paragraphs a briefly description of the techniques relevant for this thesis are presented  
 
MS/MS Routines 
Using the so called routines, selective detection of ions that yield a given fragment or lose a given 
neutral is also possible with the appropriate tandem mass spectrometer. Tandem mass spectrometry 
enables a variety of experimental routines (scan mode or sequences) such as selected reaction 
monitoring (SRM), multiple reaction monitoring (MRM), precursor ion scan (PIS) and constant neutral 
loss scan (CNLS) 
Selected reaction monitoring/multiple reaction monitoring 
(SRM)/(MRM) 
The SRM exploits the unique capabilities of triple quadrupole (TQ) MS for quantitative analysis. In SRM, 
the first mass analyzer specifically selects predefined m/z values corresponding to the analyte ions (e. 
g. a peptide ion). A second mass analyzer then stabilizes the analyte ions while they collide with a gas, 
causing them to fragment (by CID). A third mass analyzer then sorts the fragment ions produced and 
select a specific fragment ion (of the peptide). Therefore, a complete ion spectrum is not acquired but 
only one or two chosen precursor/fragment ion pairs are monitored. The monitoring of more then one 
reaction (precursor/fragment ion pairs) is termed MRM. Several such transitions are monitored over 
time, yielding a set of chromatographic traces with the retention time and signal intensity for a specific 
transition as coordinates. These experiments are used to increase specificity of detection of known 
molecules 58. 
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Precursor ion scan (PIS) 
The PIS provides the identity of al precursor ion that fragment to a preselected product ion. With this 
scan mode the first and second mass analyzers scan across the spectrum as partitioned by a user 
defined m/z value. The precursor ion spectrum is obtained by adjusting the second mass analyzer to 
transit a certain specified product ion, whereas the first mass analyzer is scanning over a certain mass 
range to transit only those precursor ions that generate the specified chosen product in collision cell. 
This experiment is used to detect specific motifs within unknown molecules 59,60. 
Constant neutral loss scan (CNLS) 
With the CNLS both mass analyzers are scanned simultaneously. Indeed, the first mass analyzer scans 
all the masses, whereas, the second mass analyzer also scans, but at a specified mass offset from the 
first mass analyzer 61. This offset corresponds to a neutral loss that is commonly observed for the class 
of compounds under analysis. In a constant neutral loss scan, all precursors that undergo the loss of a 
specified common neutral are monitored. Similar to the precursor-ion scan, this technique is also useful 
in the selective identification of closely related class of compounds in a mixture. 
 
MALDI tandem MS  
MALDI-MS/MS with PSD 
Metastable are molecular ions formed in the ion source having sufficient internal energy to fragment 
spontaneously in a field-free region between the source and the analyzer. The metastable ions 
dissociation process to produce fragment ions is defined post-source decay (PSD). The MALDI-PSD-
MS/MS introduced by Kaufmann et al. is a technique that has been widely used for several years 55,62,63 
for the characterization of proteins and peptide with high sensitivity 64. In a MALDI TOF instrument, if an 
ion fragments within the source, the precursor and product ions acquire the same kinetic energy and 
thus can be differentiated by their velocities and flight times, which are related to their respective 
masses (m/z). When a precursor ion enters the flight tube of a TOF analyzer, PSD of ions (i. e. 
metastable ion dissociation) yields decomposition products reaching a linear detector with the same 
velocity as the original precursor ion. Hence, in TOF MS, ions that decompose during their flight through 
the drift tube are usually detected at the precursor’s m/z. However, these products can be distinguished 
by the application of a reflectron 62,63. All ions enter the reversing/retarding field of the reflectron, but the 
lighter ones penetrate less than the heavier ones. Therefore, fragment ions exit the reflectron earlier 
than their precursors and have characteristic flight times based on their masses 62. A MALDI-PSD-
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MS/MS instrument includes a precursor ion selection step for the ions undergoing PSD, performed with 
a so called timed ion selector (TIS) (Figure 9). Technically, the TIS is an "ion gate" which is composed 
of a series of wires with alternating voltages (e. g. ±1000 V) which, when switched on, prevents the 
transmission of any ions. When the gate is switched off, ions may be transmitted into the mass analyzer. 
Therefore, the ion gate is tuned to select an ion of a specific m/z by switching off the gate at the 
estimated time of arrival of that ion. With the TIS, the precursor is selected and detected with the 
instrument operated in the linear mode. Subsequently, the fragment ions are detected by switching the 
instrument to the reflectron mode. Reducing the reflectron voltage whilst maintaining a constant source 
voltage means that precursor ions become too energetic to be reflected, but fragment ions can be 
reflected to the detector. If the reflectron voltage is reduced to half of the voltage than when the 
precursor ion was focused, an ion of half the mass of the precursor will be detected. Thus, by scanning 
the reflectron voltage, a full range of ions from low to high mass can be observed. This process is 
automated and the instrument is able to scan numerous reflectron voltages and acquire an in-focus 
section of each spectrum from the mass of the selected precursor ion down to the smallest ion species 
observable.  
The above described is the classical method of acquiring PSD, which requires 10–60 min per spectrum. 
An addition drawback of this technique is that in some instrumental combination, i.e. with curved-field 
reflectron 65, demonstrated reduced fragmentation efficiency. 
MALDI-CID-MS/MS 
The first improvement to overcome the described disadvantages of PSD relied on increasing the 
fragmentation yield. PSD products in MALDI-TOF instruments can be increased by either performing the 
experiments under low-vacuum conditions 62 and therefore causing collisions with residual gas to occur 
in the flight tube. Alternatively, a collision cell is placed immediately after the ion source in a TOF 
instrument 66. Some tandem TOF instruments have a high-energy collision cell placed between two TOF 
mass analyzers. High-energy CID generally employs helium as the target gas, but collision yield may be 
increased by using a heavier gas, such as Ar or Xe 67,68. Regarding the sample preparation, in PSD-CID 
the high efficacy of “hot” MALDI matrices, in particular of CHCA, are exploited to enhance metastable 
fragmentation of MALDI generated ions. MALDI-PSD has been applied to synthetic polymers, 
oligonucleotides, and to protein analysis. In particular, the application of MALDI PSD with CID-MS/MS to 
protein and peptides produce fragment ion spectra with backbone, internal and the side chain ions 66,68-
71 .  
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MALDI-LIFT-TOF/TOF  
New developments in MALDI-TOF/TOF instruments are characterized by a co-linear arrangement of 
two TOF mass analyzers, each equipped with an ion source (source 1 and source 2) that allow 
acceleration and focusing of the ions. In a particular solution (which is the instrument used for the 
experimental work of this doctoral thesis) termed MALDI LIFT-TOF/TOF (Figure 9), a combination of low 
initial accelerating voltage (in source 1), used to promote PSD fragmentation, with a post-acceleration 
(in source 2) allow to mass analyze precursor and fragment in one spectrum 72.  
 
 
Figure 9. Schematic diagram of the LIFT-TOF/TOF mass spectrometer. TOF1 ranges from the MALDI ion source to 
the LIFT cell, TOF2 from the second accelerator stage in the LIFT cell to the reflectron. From ref.72. 
 
The basic idea in this instrumental solution relied on the subsequent acceleration, lift, of a selected 
precursor ion together with its fragments in the source 2. With this instrument the laser-induced 
dissociation (LID) is the mainly process to obtain PSD. Indeed, after the initial laser induced ion 
desorption process and expansion of the ion-matrix in high-vacuum MALDI systems there is still a 
substantial amount of internal energy left, which can lead to metastable fragmentation of the analyte 
ions. Therefore, LID fragmentation does not require collision gas but occurs after the acceleration stage 
in the ion source before the reflectron 73. Moreover, acquisition conditions must be adapted to promote 
LID and generate high fragment ion yields. This is done by increasing laser fluence over the threshold, 
which also provides a larger number of precursor ions per shot. In addition, a low acceleration voltage in 
the source 1 leads to long flight time promoting fragmentation. As for traditional PSD MALDI, a TIS is 
used to select precursor and fragment ions by switching off the gate at the appropriate time. When 
precursor and fragment ions enter in the source 2, called “LIFT”, they are post-accelerated, “lifted”, of 
some keV. Here, precursor and fragment ions are subjected to a process similar to the delayed ion 
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extraction (DIE) in a regular MALDI ion source. Therefore, the precursor ions are fully accelerated, i. e. 
the sum of the kinetic energy resulted from the source 1 and LIFT acceleration, whereas, the fragment 
posses only a fraction of energy imparted in the source 2 proportional to their masses. An additional ion 
gate is situated between the LIFT device and reflector, the “post lift metastable suppressor” (PLMS), 
which deflects the remaining intact precursor ions and prevents further fragment ion formation after 
post-acceleration. Therefore, after reversion by the reflectron, the ions are time-focused onto the 
detector to generate a LID-MS/MS spectrum. Practically, a MS/MS spectrum is acquired in two steps: 
first the precursor then all fragment ions. With this instrument the entire procedure to acquire a tandem 
mass spectrum takes only few minutes. This system allows high resolution, mass accuracy and 
increased sensitivity. In case of peptides analysis MALDI-MS/MS spectra are rich in backbone ions a-, 
b-, y- and i-, internal ions and the side chain d- and w-ions, very useful for identification and 
characterization purposes 72.  
MALDI-CID-LIFT-MS/MS 
The MALDI LIFT-TOF/TOF instrument contains a collision cell for high-energy CID (Figure 9), with 
argon as collision gas introduced under computer control, to increase the source pressure to 6×10–6 
mbar. This is useful in combination with LIFT-MS/MS to increase the fragmentation of particularly stable 
molecules. For peptide fragmentation, the CID-MS/MS modus generate high energy w-type ions via 
side-chain fragmentation which can allows to distinguish isobaric amino acid residues 70.  
 
Reflector ISD mode for fragmenting intact proteins 
The in-source decay (ISD) is a very fast fragmentation process occurring in the source region 74 during 
the MALDI process before the ions are accelerated out of the DIE 69. This prevents the dissipation of the 
excitation energy across the peptide that would result in the preferred cleavage of the N-Cα bonds on 
the peptide backbone. In reflector mode (re-ISD), monoisotopic sequence fragment ions can be 
detected, which are predominantly c-ions and to a lower extent also y- and a-ions, well suited for 
sequencing the N-terminal region of intact proteins. 
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Chapter I 
Development of matrix layer: an improved 
MALDI MS sample preparation method for 
proteomic study 
Proteomics  
The last century saw massive progress in knowledge of processes underlying the genetic basis of our 
existence. These progresses ranging from the definition of structure and sequence of DNA to the 
identification of specific disease-associated genetic abnormalities, and their clinical exploitation as the 
basis of trials of gene therapy. In particular, large-scale DNA sequencing has transformed biomedical 
research in a short span of time. With the sequence of human genome, it is now clear that a “global 
approach” is required to address a comprehensive understanding of complex biological processes. The 
life of a cell is a dynamic process in which it is constantly reacting to its environment. If a disease-
inducing element is introduced, it may change how much and when a gene product is made, the type 
and extent of post-translational modifications that occur, and how these events are related together and 
with other genes. Because the study of this dynamic has the potential to reveal new targets for drug 
intervention in disease processes, emphasis is now being placed on understanding how and when 
genome-encoded events occur, e.g., at protein translation level. Moreover, understanding what 
relationship of non-genome-encoded events have to particular physiological states, e.g., 
posttranslational modifications of proteins, interactions between proteins, nucleic acids, lipids, 
carbohydrates, and combinations thereof. Proteomics is a field that promises to bridge the gap between 
genome sequence and cellular behaviour. It aims to study the dynamic protein products of the genome 
and their interactions, rather than focusing on the simple relatively static DNA of a cell. 
The word "proteome" was first coined by Valerie Wasinger in 1995 75 and Marc Wilkins in 1996 76 do to 
the analogy with the term genome, while working on characterization of gene products from 
Mycoplasma genitalium. Indeed, the proteome is the protein content of biological system, cell, organ or 
organism. Later, the term "proteomics" was introduced to make an analogy with genomics, the study of 
genomes 77. Proteomics is the large-scale study of proteins as well as their structures and functions by 
biochemical methods. From a technological standpoint, the essence of proteomics is protein 
identification and characterization. In this sense proteomics already dates back to the late 1970s when 
researchers started to build databases of proteins using the then newly developed technique of two-
dimensional gel electrophoresis (2-DE) 78. The 2-DE technique is capable of resolving total protein 
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extracts from cells into about 10,000 individual protein spots. This resulted in extensive cataloguing of 
spots from two-dimensional gels to create databases of all expressed proteins. However, even when 
such gels could be run reproducibly between laboratories, determining the identity of the proteins was 
difficult because of a lack of sensitive and rapid analytical methods for protein characterization (such as 
the polymerase chain reaction and the automated sequencer for DNA analysis). Although Edman 
degradation is a powerful tool for protein sequencing 79, is mainly deficient in meeting the throughput 
required by proteomics. In the 1990s, biological mass spectrometry emerged as a powerful analytical 
method that removed most of the limitations of protein analysis 80. The most significant breakthrough in 
proteomics has been the mass spectrometric identification of gel-separated proteins, which extends 
analysis far beyond the mere display of proteins. Mass spectrometry has essentially replaced the 
classical technique of Edman degradation even in traditional protein chemistry, because it is much more 
sensitive, can deal with protein mixtures and offers much higher throughput. This development, coupled 
with the availability of the entire human coding sequence in public databases, marks the beginning of a 
new era. Today, the term proteomics covers much of the functional analysis of gene products or 
“functional genomics”, including large-scale identification or localization as well as posttranslational 
modification studies of proteins and interaction studies. Proteomics in the contest of a “global approach” 
is used to paint a “global” picture to allow cell biologists building a complex map of cell function by 
discovering how changes in one signalling pathway affect other pathways, or how proteins within one 
signalling pathway interact with each other. The “global picture” also will allows medical researchers to 
look at the multiplicity of factors involved in diseases, very few of which are caused by a single gene. As 
for genomics, to put forward proteomics continuously needed technical improvements for increase 
sensitivity and specific analytical method for large-scale and highly automated analyses.  
Independently of the specific aims, the main steps of a proteomic project are: proteins preparation, 
protein separation, protein identification and characterization.  
Protein preparation methods 
One of the most crucial steps in proteomics is obtaining and handling the protein sample. Out of the 
entire complement of the genome of about 23,000 genes81, a given cell line may express about 10,000 
genes and an even higher number is expressed in tissues. Furthermore, the dynamic range of 
abundance of proteins in biological samples can be as high as 106 82. There are a number of different 
procedures that can be undertaken during protein sample preparation for proteomic analysis, which can 
influence the quality of the results and number of protein identifications. After protein extraction, further 
sample treatment is often required to reduce the sample complexity prior to MS analysis. Depending on 
the sample origin and the biological questions, these might include subcellular fractionation, protein 
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fractionation, protein digestion, peptide fractionation and desalting. Moreover, additional 
purification/enrichment steps are required when specific classes of proteins are under investigation e. g. 
posttranslational modified proteins or low abundant proteins. Indeed, additional sample handling steps 
to selectively enrich phosphorylated proteins or peptides are discussed more detailed in chapter III. The 
most common technique used to separate proteins is two-dimensional gel electrophoresis (2-DE), 
where proteins are firstly separated according to their isoelectric point (pI) and secondly by their 
apparent molecular weight (MW) 83,84. With this approach a representation of the sample is visualized as 
a distribution of spots. The resulting protein spots are subjected to enzymatic digestion prior to protein 
identification by MS 80,85. Alternatively, protein sample separations in only one dimension (SDS-PAGE) 
can be applied, i.e. separating the proteins solely according to their MW 86,87. The advantages of SDS-
PAGE as a preparation/separation method are that virtually all proteins are soluble in SDS, the range of 
relative molecular mass from 10,000 to 300,000 is readily covered, and extremely acidic and basic 
proteins are easily visualized. In this case, the bands containing proteins are enzymatic digested to 
peptides, and analyzed by tandem MS. To reduce complexity, additional liquid chromatography (LC) 
separations can be applied to the peptide samples prior to tandem MS analysis. Moreover, 
multidimensional LC or Isoelectric focusing (IEF) separations are frequently exploited to fractionate the 
peptide samples. Final peptide separations are mostly performed using reverse phase (RP) 
chromatography. Indeed, increasing concentration of the organic solvent result in sequentially elution of 
peptides from the separation column with respect to their increasing hydrophobicity.  
Two-dimensional gel electrophoresis (2-DE) 
The 2-DE is a powerful and widely used method for the analysis of complex protein mixtures extracted 
from cells, tissues, or other biological samples. This technique separates proteins according to two 
independent properties in two discrete steps. The first-dimension step, the IEF, separates proteins 
according to their isoelectric points (pI). The second-dimension step, the SDS-PAGE separates proteins 
according to their MW 86,87. Each spot on the resulting 2-DE gel potentially corresponds to a single 
protein species in the sample. Thus, thousands of different proteins can be separated, and information 
such as the protein pI, the MW and the amount of each protein can be obtained.  
In the original 2-DE technique, introduced by O’Farrell in 1975 78, the first-dimension separation was 
performed in carrier-ampholyte-containing polyacrylamide gels cast in narrow tubes. However, its 
application has become significant as a result of a number of developments. Indeed, the introduction of 
immobilized pH gradients and Immobiline™ reagents 88 brought superior resolution and reproducibility 
to first-dimension IEF. Based on this concept, Görg and colleagues 89,90 developed the currently 
employed 2-DE technique, where carrier-ampholyte-generated pH gradients have been replaced with 
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immobilized pH gradients, and tube gels replaced with gels supported by a plastic backing: the precast 
IPG strips (Immobiline DryStrip gels) commercially available (from Biorad, GE Healthcare and other). 
Moreover, the 2-D difference in gel electrophoresis (DIGE) 91,92 which offers a method for controlling 
system variations and allowing biological changes in protein expression to be identified with statistical 
confidence. Also development in automation of steps after 2-DE, such as gel image analysis, spot 
picking, spot digestion, and sample preparation for mass spectrometry, have allowed a significant 
increase in the throughput of protein analysis and identification. New mass spectrometry techniques 
developed and data about entire genomes of a number of organisms now available allow rapid 
identification and characterization of very small quantities of peptides and proteins separated by 2-DE. 
The World Wide Web provides simple, direct access to spot-pattern databases for the comparison of 
electrophoresis results and genome sequence databases for assignment of sequence information.  
A large and growing application of 2-DE is within the field of proteomics 76,93. Indeed, the analysis 
involves the systematic separation, identification, and quantization of many proteins simultaneously from 
a single sample. Notably, 2-DE is used in this field due to its unparalleled ability to separate thousands 
of proteins simultaneously. The technique is also unique in its ability to detect post- and co-translational 
modifications, which cannot be predicted from the genome sequence. In addition, once 2-DE separated, 
proteins can also be blot onto membrane and detected using antibody leading to obtain additional 
specific information.  
Mass spectrometry for Protein analysis  
Mass spectrometry is applied in protein analysis using two different approaches: “top-down” and the 
“bottom-up”94. The top-down approach consisted in analyzing intact proteins. Indeed, the mass 
spectrometer is used to determine the proteins mass, whereas, protein sequence and posttranslational 
modification information are obtained due to protein fragmentation by tandem mass spectrometry 95-97, 
this approach has been applied using both ESI or MALDI instruments to characterize proteins. Recently, 
in two studies detailed characterization of the amino acid composition leading to 100 % sequence 
coverage of 15.2 kDa 98 and 13.6 kDa 99 proteins was performed, showing the power of this approach. 
Although this technique is beginning to become more widely used, the most common method for protein 
and proteome analysis is by using the bottom-up approach.  
Bottom-up proteomics is a common approach to identify proteins, characterize their amino acid 
sequences and post-translational modifications by proteolytic digestion of proteins prior to mass 
spectrometry analysis 100,101. Indeed, crude total protein extracts are directly digested using 
endopeptidases specific enzymes (proteases), such as trypsin, or chemical reagents which are also 
used in combination 102. The proteolytic digestion is followed by one or more dimensional separation of 
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the resulting peptides mixture by liquid chromatography coupled to tandem mass spectrometry, a 
technique also known as shotgun proteomics 103. Indeed, with a tandem mass spectrometer, the single 
peptides are selected and fragmented to generate tandem mass spectra. By comparing the tandem 
mass spectra of the proteolytic peptides with those predicted from a sequence database, peptides can 
be identified and multiple peptide identifications assembled into protein identification. Here, ESI tandem 
MS is typically employed on either hybrid quadrupole-TOF (Q-TOF) or various types of ion-trap mass 
spectrometers.  
Alternatively, the proteins may first be separated by gel electrophoresis (SDS-PAGE or 2-DE) resulting 
in one or a few proteins in each proteolytic digest. Generally, trypsin is the protease utilized because of 
its high cleavage specificity and stablity under a wide variety of conditions. The mass spectrum of the 
peptide mixture resulting from a proteolytic digest of a protein produced a characteristic peptides profile 
providing a fingerprint of great specificity. So specific, that it is often possible to identify the protein from 
this information alone. This characteristic peptide profile is termed: “peptide mass fingerprint” (PMF) of 
the protein 80,104-109. The peptide signals in the PMF are then selected and tandem mass spectrometry is 
used to obtain peptide fragments spectra. Peptides fragment along the amino acid backbone give 
sequence information and produced a characteristic peptides fragment profile termed: “peptide fragment 
fingerprint” (PFF) 110-112.  
The proteolytic digests can be analyzed either by ESI or MALDI tandem MS with different types of mass 
spectrometers. MALDI-TOF/TOF tandem mass spectrometry is often the preferred technology because 
it allows high sample throughput, and several hundred samples can be analyzed in a single experiment. 
High confident identification and characterization of proteins is performed by correlating the PMF and 
PFF information with sequence databases, which has become the de facto the method for protein 
identification nowadays. Several algorithms and software have been developed to match generated 
PMF and PFF spectra against “in-silico-derived” spectra from protein and amino acid sequences in 
proteomics and genomics databases 113-115.  
Peptide fragmentation  
Regarding the peptide fragmentation, peptides yield a wide array of product ions depending on the 
quantity of vibrational energy they posses and the time-window allowed for dissociation. The ion types 
formed and the abundance pattern observed are influenced by the peptide sequence, the ionization 
technique, the charge state, the collisional energy (if any), the method of activation as well as the type of 
the analyzer. There are three different types of bonds that can fragment along the amino acid backbone: 
the NH-CH, CH-CO, and CO-NH bonds. One of the theories proposes peptide fragmentation through 
the “mobile proton” 116,117. In this model any of the amide bonds in the peptide backbone can be 
protonated by a mobile proton making it more susceptible to fragmentation. The energy for this cleavage 
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comes from activation method used. Each bond breakage gives rise to two species, one neutral and the 
other one charged, and only the charged species is monitored by the mass spectrometer. The charge 
can stay on either of the two fragments depending on the chemistry and relative proton affinity of the 
two species. Hence, there are six possible fragment ions for each amino acid residue and these are 
labeled according to the accepted nomenclature in the diagram of Figure 10. The nomenclature for 
peptide fragments was first proposed by Roepstorff and Fohlmann 118 and later modified by Johnson et 
al. 119. Indeed, the a, b, and c" ions having the charge retained on the N-terminal fragment, and the x, y", 
and z ions having the charge retained on the C-terminal fragment. The numbering indicates which 
peptide bond is cleaved counting from the N- and C-terminus, respectively. A subscript indicates the 
number of residues in the fragment. The number of hydrogens transferred to or lost from the fragment is 
indicated with apostrophes to the right and the left of the letter, respectively.  
The cleavage along the backbone at the CO-NH bonds give rise to the b and/or the y" ions. Thus, the 
mass difference between two adjacent b ions, or y"; ions, is indicative of a particular amino acid residue.  
 
 
Figure 10. Diagram of the fragments formed through bond cleavages along the backbone of protonated linear 
peptides. 
 
The very low mass (<150 m/z) region of CID spectra often contains valuable information in the form of 
ions generated from the individual amino acids present in the peptide, the immonium ions. Typically, 
high-energy CID mass spectra are richer in these ions. The immonium (HN=CH-R; labeled in a 
spectrum with the single letter code of the particular amino acid), are ions with a mass of 27 m/z lower 
than that of the amino acid residue (amino acid mass -CO+H). Each amino acid residue leads to a 
diagnostic immonium ion, with the exception of the two pairs leucine (L) and iso-leucine (I), and lysine 
(K) and glutamine (Q), which produce immonium ions with the same m/z ratio, i.e. 86 m/z for I and L, 
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101 m/z for K and Q. The immonium ions are useful for detecting and confirming many of the amino 
acid residues in a peptide, although no information regarding the position of these amino acid residues 
in the peptide sequence can be ascertained. 
Internal fragment are ions which contain neither the N-terminus nor the C-terminus of the peptide, and 
their mass usually corresponds to a structure with a y-type cleavage at one end and a b-type cleavage 
at the other. Internal fragment ions are often labeled as yi bj, in keeping with the sequence ion 
nomenclature and numbering. Low-energy CID spectra frequently contain abundant internal fragment 
ions 120, which are the result of multiple collisions that increase the probability of cleavage of two amide 
bonds. 
Trypsin is a useful protease in mass spectrometry study as it generates peptides with a C-terminal 
arginine or lysine with masses in the preferred mass range for effective fragmentation 121. This C-
terminal positioning of basic residue has consequences for fragment ion formation. According to the 
“mobile proton” model, dissociation upon excitation is initiated by a proton that weakens an amide bond 
in the peptide backbone 116,117,120,122,123. The proton affinity/gas phase basicity of the two conjugate 
fragments will then dictate which fragment will inherit the amide-breaking proton, leading to the 
formation of b- or y-ions, respectively 117. In MALDI-MS/MS of singly charged tryptic peptides, 
fragmentation results in complex spectra containing not only b- and y-ions but also some a- and 
immonium ions, internal fragments and ions resulting from neutral loss of ammonia or water 68,124,125. 
Thus, all these fragment ions are used in typical database search strategies for protein and peptides 
identification. 
MALDI MS Sample Preparation 
The matrix 
The matrix plays an essential role in the MALDI ionization process 47-51. Therefore, the choice of matrix 
for the sample preparation is crucial for success in MALDI MS experiments. In this regard the MALDI 
matrix must meet a number of generally requirements: (1) be able to embed and isolate analytes 
molecules (e.g., by co-crystallization), (2) be able to absorb at the laser wavelength, (3) be able to 
cause desorption and promote analyte ionization upon laser irradiation, (4) be vacuum stable. Initially, 
Karas and Hillenkamp reported that nicotinic acid was a suitable matrix for the desorption and ionization 
of intact protein molecules using 266-nm laser irradiation 38. Since then, a large number of compounds 
have been screened as potential matrices, and a number of new matrix materials of substantial utility 
have been reported.  
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Figure 11. Structures, chemical names, trivial names, and abbreviations of frequently used MALDI matrices. 
Adapted from ref. 47. 
 
Figure 11 gives the structures of frequently used MALDI matrices, their chemical names, trivial names, 
and abbreviations. Derivatives of benzoic acid, cinnamic acid, and related aromatic compounds were 
recognized early on as good MALDI matrices for proteins 126. Matrices such as 2,5-dihydroxybenzoic 
acid (DHB) and several cinnamic acid derivatives, including ferulic, caffeic, and sinapinic acids (SA), 
have made MALDI analysis possible at longer wavelengths including the following: 308, 337, and 355 
nm, accessible with excimer, nitrogen, and Nd: YAG lasers, respectively 126-129. The α-cyano-4-
hydroxycinnamic acid (CHCA) has been shown to be an effective matrix for MALDI analysis of both 
peptides and glycopeptides 130. Juhasz et al. introduced 2-(4-hydroxyphenyazo)-benzoic acid (HABA) as 
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a matrix for peptides, proteins, and glycoproteins up to 250 kDa 131. For oligonucleotides, 3-
hydroxypicolinic acid (3-HPA) 132,133, glycerol 134, and succinic acid 135 are used as matrices in the UV 
and in the IR, respectively. However, many common UV matrices work well in the infrared too 136 and 
not all matrices are carboxylic acids. For example, 2,4,6-trihydroxyacetophenone (THAP) 137 has been 
shown to be useful for studying oligonucleotides, 138, 139. 140  
In one of the earliest MALDI experiments Tanaka et al. used very fine cobalt particles mixed with liquid 
glycerol 39 to ionize large biomolecules. After a long lapse, liquid matrices and liquid/solid two-phase 
matrices (also called surface-assisted laser desorption/ionization, SALDI, to differentiate it from the 
MALDI using solid matrices) were proposed in attempt to circumvent some of the limitations associated 
with solid crystalline matrices 141-143. For instance, some solid matrices are characterized by the 
production of non-homogeneous analyte/matrix crystals. Indeed, signal of the analyte are obtained only 
from restricted areas of the sample preparation resulting in the formation of the “sweet spot“ (also 
known as “hot spot”) phenomenon. Liquid matrices can continuously refresh their surfaces, therefore, 
partially circumvent the “sweet spot“ phenomenon, chemical background in the low mass range as well 
as the co-crystallization and solubility requirements known for solid matrices. Moreover, if an absorbing 
solid material, e.g. a MALDI matrix, is added to a non-absorbing liquid, the advantages of liquid matrices 
are retained and the limitations of solid matrix reduced 144-147 148-151 142,152,153. 
Compounds that are not easily protonated can be cationized instead, often by adding a small quantity of 
alkali cations, copper or silver salts to the sample preparation. Indeed, transition metals such as Cu or 
Ag are expected to bind to the phenylic π-system with electrons from the metal d-orbitals. 154,155.  
The choice of matrix is also important for the control of fragmentation. A small number of matrices have 
been studied with regard to their propensity to induce fragmentation and, thereby, are classified as “hot” 
or “cold.” Karas et al. 156,157 have found that, for protonated glycoproteins, post-source decay decreases 
in the order SA > DHB > HPA. This order agrees with Spengler et al. 62, who also described SA as a 
“hotter” matrix than DHB. Moreover, in MALDI mass spectrometry of oligodeoxynucleotides, DHB has 
also been found to induce more fragmentation than 3-HPA 158. One proposed explanation for the “hot” 
and “cold” nature of matrices is simply the temperature at which they sublime, hence, desorbs the 
analyte 159. Therefore, the selection of the matrix can be used to control degree the analyte 
fragmentation permitting additional control over the MALDI MS experiment.  
To reduce unwanted salt adduct formation and to increase the homogeneity of the analyte/matrix 
preparation a large variety of matrix additives are used. Most of these matrix “dopant” are salt of mono- 
and bi- basic acids which function by improving co-crystallization and by sequestering excess salts.  
Difficulties with MALDI analyses can stem from many sources, not only ionization problems. 
Incorporation of analyte into a solid matrix and formation of suitable matrix crystallites are among the 
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most frequent difficulties with MALDI analyses. However, knowledge about ion formation pathways can 
now contribute to rational matrix selection. A fundamental consideration is the type of analyte ion 
expected or desired. Based on prior knowledge of the acidity or basicity of the analyte, secondary 
protonation or deprotonation reactions can be enhanced by selecting the appropriate matrix. This may 
be the most important and yet easiest type of optimization that can be carried out for MALDI MS. If 
cationized analytes are expected, the matrix should be chosen so as not to compete with analyte for the 
selected cations in the condensed or in the gas phase. Therefore, matrices that are good complexing 
agents, such as those with ortho-hydroxy carbonyl units, should be avoided. Divalent cations are 
preferable in general, due to higher electrostatic binding energies.  
However, appropriate matrices for a particular analytical problem are often found only after screening of 
a large number of candidate compounds 133,140. 
MALDI MS sample preparation methods 
An optimal sample preparation method should provide a broad mass range for detection of the analyte 
ions, high sensitivity and mass accuracy as well as reproducibility of sample/matrix crystal preparation 
to obtain reliable mass spectra 160. Moreover, the feasibility of automated spectra acquisition and data 
analysis are mandatory for the high throughput required in large proteomics studies  
However, factors such as the choice of the matrix, the solvent composition, the pH or temperature and 
the preparation method can influence the rates of analyte/matrix co-crystallization and, thus, the quality 
and sensitivity of the MALDI sample preparations 130,161. In addition, contaminants like buffers, salts and 
detergents brought in by the sample are further important factors influencing the quality of MALDI-MS 
analysis 162. 
In the following paragraphs the available matrix sample preparations for MALDI MS are described in 
details and the pitfalls are discussed, together with the improvement brought in this filed by this doctoral 
thesis work. 
Dried-Droplet (DD) 
The dried-droplet is the original simple sample preparation procedure introduced in 1988 by Hillenkamp 
and Karas 38, which has mostly remained intact. The matrix compound dissolved in aqueous solution is 
mixed with analyte solution, deposited onto the sample plate metal support (the target) and dried. The 
target with the resulting solid deposit spot of analyte/matrix crystals on it is introduced into the mass 
spectrometer for analysis. Generally, the DHB, sinapinic acid (SA), and CHCA are the matrices used in 
DD sample preparation. The DD is a working horse method which tolerates the presence of salts and 
buffers very well. It is usually a good choice for samples containing more than one protein or peptide 
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component. However, the DD preparations are characterized by the formation of large crystals with a 
three-dimensional structure of the spot on the target surface limiting the resolution and spot-to-spot 
reproducibility of the spectra. In addition this method produces non-homogeneous distribution of 
analyte/matrix crystals with formation of “sweet spots”. Indeed, only in restricted area of the preparation, 
the “sweet spots”, analyte signals of acceptable signal-to-noise (S/N) and spectra of reliable quality can 
be obtained. These are the major drawbacks of the method impeding the implementation for automated 
spectra acquisition in high throughput analysis. 
Fast-Evaporation, Thin Layer (TL) 
The fast-evaporation method 163 was introduced with the main goal of improving the resolution and 
mass accuracy of MALDI measurements. In this method, matrix and sample are handled separately. An 
essential requirement is that the matrix compound should be insoluble in aqueous solution. The matrix, 
(CHCA, or THAP) is applied to the sample target in highly volatile solvent, e.g., acetone, to obtain very 
fast evaporation. The analyte prepared in aqueous solution is applied on top of the matrix and allowed 
to dry. Once the preparation has dried the target is introduced into the mass spectrometer for analysis. 
The preparation delivers stable thin films of matrix on the surface of the target, for this reason became 
known also as “thin layer”(TL) 160. This method allows high resolution and enhanced spot-to-spot 
reproducibility, therefore, is suited for automated MALDI MS spectra acquisition. Notably, TL sample 
preparation often results in considerable oxidation of methionine and tryptophan side chains. A limitation 
of this preparation is that the matrix is rapidly ablated by the laser, limiting the amount of laser 
shots/spot allowed. To overcome this limitation a method with an additional “on-spot” re-crystallization 
step was introduced. Unfortunately, re-crystallization reduced drastically the sensitivity. However, the 
main drawback of this method is the extreme intolerance towards impurities brought in by the analyte 
preparation (such as those from in-gel digests) which seriously hamper the analyte/matrix crystallization 
process, and therefore the performance. Consequently, time consuming analyte pre-purification step are 
required.  
Sandwich 
The sandwich method 164 is derived from the fast evaporation method and the two-layer method. A 
sample droplet is applied on top of a fast-evaporated matrix bed as in the fast-evaporation method, 
followed by the deposition of a second layer of matrix in a traditional (non-volatile) solvent. The sample 
is basically sandwiched between the two matrix layers. This method was first used for the analysis of 
single mammalian cell lysates. The sandwich technique is compatible with HCCA and SA matrices and 
often yields significantly better peptide mapping spectra than those obtained with the DD method. With 
the sandwich method reduced oxidation of methionine and tryptophan side chains has reported 
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compared to TL method. However, reduced sensitivity and spot-to-spot reproducibility are the major 
limitations of this method.   
Two-Layer 
The two-layer method 165,166 involves the use of fast solvent evaporation to form the first layer of small 
crystals, followed by deposition of a mixture of matrix and analyte solution on top of the crystal layer. 
The difference between the sandwich and the two-layer method is in the composition and the inclusion 
of the analyte in the second-layer solution. The addition of matrix to the second step is believed to 
provide improved results, particularly for proteins and of peptide mixtures containing. Despite an 
increased tolerance towards impurities; drawbacks of this method are the very limited sensitivity and 
resolution achieved.  
Noteworthy, most of sample preparations described above suffer from common disadvantages such as 
low shot-to-shot and spot-to-spot reproducibility, short sample life-time as well as high difference in 
sensitivity and tolerance toward impurities. In addition, the majority of these methods have not been 
successfully applied to automated spectra acquisition.  
In attempt to overcome some the limitations cited above, MALDI sample supports with pre-structured 
surface were developed (AnchorChipTM, Bruker Daltonics; and similar hydrophobic coated target 
samples supports) 167,168. These supports provide a pre-structured surface consisting of small 
hydrophilic islands (sample spot anchors), with different diameters (200, 400, 600 or 800 µm), 
surrounded by the strongly solvent-repellent surface of a Teflon-like material. The sample anchors hold 
the sample droplets, in place and direct sample deposition onto them during solvent evaporation. The 
CHCA matrix using the TL preparation method in combination with pre-structured sample supports was 
successfully applied to automated spectra acquisition for high throughput analysis. Notably, only 
previous time consuming and difficult to automate micro pre-purification steps 169. 
Therefore, a robust and highly sensitive sample preparation which allows reliable and automated 
MALDI-TOF MS and MS/MS spectra acquisition was developed. 
 
Matrix layer sample preparation method for proteomics 
studies (Publication I) 
DHB matrix Layer (ML) sample preparation 
The new matrix layer (ML) sample preparation method is based on DHB and capitalizes its 
advantageous features as matrix 170, which in combination with pre-structured MALDI sample 
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supports168 allows to automated MALDI-TOF-MS and tandem MS spectra acquisition. This method is 
simple, requires little preparation time and results in an improved MS data quality. The DHB ML sample 
preparation method was optimized for the acid used and the total amount of organic solvent applied. 
Thus, the DHB matrix was prepared at a concentration of 5g/l and dissolved in 0.1 % TFA 
(trifluoroacetic acid) aqueous solution containing 30% acetonitrile. Best reproducibility, high S/N and 
resolution, homogeneity of crystals as well as reduced ion suppression are obtained using this 
formulation.  
The DHB ML method involves that the matrix solution is deposited onto the MALDI target and allowed to 
dry. Subsequently, acidified analyte solution (generally, prepared in TFA) is deposited onto the dried 
matrix layer. Finally the preparation is re-crystallized "on-target" using a solution containing ethanol in 
0.1 % TFA (80/20, v/v). 
 
DHB ML performance for in-solution and in-gel protein digests 
The new DHB ML sample preparation enables high quality MALDI-TOF-MS and tandem MS automated 
spectra acquisition, due to an improved analyte/matrix distribution and high crystals surface 
homogeneity with small crystals covering the majority of the anchor spot surface. Indeed, an increased 
shot-to-shot and spot-to-spot reproducibility was evidence. Therefore, MALDI-TOF-MS spectra of equal 
quality (S/N and resolution) could be acquired from different positions of the sample spot surface. The 
laser fluence required to obtain ions was constant once the threshold was reached. Notably, crystals 
appearance and ion signals were unchanged after several laser shots at the same position. Indeed, in-
solution and in-gel protein tryptic digest samples prepared with the DHB ML using automated spectra 
acquisition were compared to DHB DD and CHCA TL methods. With the DHB ML increased number of 
peptides were detected, improved proteins sequence coverage and reduced mass error were obtained. 
Notably, analysis of variance (ANOVA) confirmed that the improvements observed from DHB ML are 
statistically relevant. Moreover, the new DHB ML method demonstrated an improved tolerance toward 
sample impurities (e.g., salts and buffers), eliminating the need for pre-purification of in-gel tryptic digest 
of proteins. Thus, the sample preparation is less complex and avoids the loss of informative peptides. 
Consequently, the DHB ML sample preparation method is well suited for a fully automated MALDI-MS 
and MS/MS spectra acquisition, leading to reliable and rapid analysis. 
Sensitivity 
The sensitivity and the dynamic range of detection are two determinant parameters to evaluate the 
reliability and robustness of a sample preparation for MALDI MS. The DHB ML sample preparation is 
very sensitive either in case of analysis of purified peptides and in complex mixture of peptides 
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originated from protein digests. Thus, a limit of detection (LOD) of 1 and 100 attomole was determined 
for single peptides and protein digests, respectively. Moreover, picomole amounts of peptide mixtures 
were readily analyzed without performance degradation. Thus, the dynamic range of the DHB ML 
preparation method is about 106.  
Phosphorylated protein analysis 
The physicochemical characteristics of the negatively charged phosphate groups influence the behavior 
of phosphopeptides during sample preparation and during the MALDI desorption/ionization process. 
Therefore, phosphorylated peptides are often detected with low efficiency or not at all in MALDI MS 
spectra. Notably, the DHB ML method prepared with the addition of phosphoric acid as matrix additive 
demonstrate an improved ionization of phosphopeptides in MS spectra. Moreover, the method allowed 
high quality MS/MS spectra for characterization of phosphopetides leading to determine the site of 
phosphorylation.  
Application to proteomics studies 
The improved performance and the robustness of the new developed DHB ML preparation method was 
definitively demonstrated by the application to the proteomic map of mouse lung research project. This 
project involved 2-DE separation followed by MALDI TOF/TOF MS identification and characterization of 
protein from mouse lung extracts. Here, the DHB ML allowed a protein identification success rate of 
88%. Noteworthy, based on the number identified protein and the peptide detected, the protein 
sequence coverage, the total number of MS/MS performed and the mascot score obtained, DHB ML 
demonstrate an improved performance by 44% when compared with CHCA TL method. 
Taken collectively, the DHB ML sample preparation demonstrated to be a valuable and robust method 
for MALDI-TOF MS and MS/MS analysis in proteomics studies. 
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ABSTRACT: 
The analytical performance of MALDI-MS is highly influenced by sample preparation and the choice of 
matrix. Here we present an improved MALDI-MS sample preparation method for peptide mass mapping 
and peptide analysis, based on the use of the 2,5-dihydroxybenzoic acid matrix and pre-structured 
sample supports, termed: Matrix Layer. This sample preparation is easy to use and results in a rapid 
automated MALDI-MS and MS/MS with high quality spectra acquisition. The between-spot variation was 
investigated using standard peptides and statistical treatment of data confirmed the improvement gained 
with the matrix layer method. Furthermore, the sample preparation method proved to be highly 
sensitive, in the lower-attomole range for peptides, and we improved the performance of MALDI-MS/MS 
for characterization of phosphopeptides as well. The method is versatile for the routine analysis of in-gel 
tryptic digests thereby allowing for an improved protein sequence coverage. Furthermore, reliable 
protein identification can be achieved without the need of desalting sample preparation. We 
demonstrate the performance and the robustness of our method using commercially available reference 
proteins and automated MS and MS/MS analyses of in-gel digests from lung tissue lysate proteins 
separated by 2-DE. 
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MALDI-TOF-MS is extensively applied to protein research. Since the pioneering work of Michael Karas 
and Franz Hillenkamp [1], an improved understanding of the MALDI ionization mechanisms and the 
development of different matrix substances has extended the use of MALDI-MS beyond proteomic 
studies. Initially, in MALDI-MS the analytes were embedded in a UV-absorbing matrix, notably 
tryptophan then nicotinic acid [2]. Thereafter, new matrices as well as new laser and mass analyzer 
technologies were developed [3, 4] allowing the analysis of (mostly) large bio-molecules in the low fmol 
range [5, 6]. More recently, MALDI-MS is applied to an analysis of small molecules, small peptides with 
masses below 1000 amu. as well as lipids and carbohydrates [7, 8]. Additional applications of MALDI 
MS include an imaging of blotted samples, gels or tissues [9, 10]. 
In proteomic studies, the combination of high resolution protein separation by two-dimensional gel 
electrophoresis (2DE) and MALDI-TOF-MS analysis has been proven to be in valuable for an 
identification of proteins and the characterization of post-translational modifications (PTM) [11-14]. 
In this regard, the choice of the matrix and the sample preparation method are of critical importance for 
a successful peptide mass mapping (PMM) analysis, for their influence on the ionization behavior, the 
formation of adducts, the stability (or fragmentation) of the analytes and, other practical implications in 
MALDI-MS analysis. 
Specifically, derivatives of benzoic acid, e.g., 2,5-dihydroxybenzoic acid (DHB) and of cinnamic acid, 
e.g., α-cyano-4-hydroxycinnamic acid (CHCA) are commonly used matrices in UV-MALDI. Notably, the 
DHB matrix is suited for the analysis of low molecular weight compounds, proteins and glycoproteins 
[15], whereas the CHCA matrix is frequently used for the analysis of peptides and small proteins [5]. 
In general an optimal sample preparation method should provide a broad mass range for detection of 
the analyte ions, high sensitivity and mass accuracy as well as reproducibility of sample/matrix crystal 
preparation to obtain mass spectra.  Several methods for sample preparation have been described, the 
most commonly used are: the dried droplet method (DD) [1], fast solvent evaporation, known as thin-
layer (TL) [16], sandwich preparations [17] and two-layer [18]. However, factors such as solvent 
composition, pH or temperature can influence the rates of matrix–analyte co-crystallization and thus the 
quality of the MALDI sample preparations [5, 19]. In addition, contaminants like buffers, salts and 
detergents brought in by the sample are further important factors influencing the quality of MALDI-MS 
analysis [20]. 
Here we present an improved DHB sample preparation method, termed: Matrix Layer (ML). The 
preparation capitalizes advantageous features of DHB as matrix and in combination with pre-structured 
MALDI sample supports [21, 22] allows to automated MALDI-TOF-MS and tandem MS spectra 
acquisition. This preparation is easy to use, requires little preparation time and results in an improved 
MS data quality. Furthermore, we demonstrate that our sample preparation enables high quality MALDI-
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TOF-MS and tandem MS automated spectra acquisition, due to an improved analyte/matrix distribution 
and high crystals surface homogeneity. Indeed, we evidence an increased shot-to-shot and spot-to-spot 
reproducibility leading to reliable and rapid automated MS analysis. In addition, the DHB ML preparation 
method demonstrates a sensitivity in the lower-attomole range. Our method shows and improved 
tolerance toward impurities (e.g., salts and buffers), eliminating the need for pre-purification of in-gel 
tryptic digests samples. Furthermore, we find that addition of o-phosphoric acid to DHB ML preparation 
to improve the performance of MALDI-TOF-MS/MS analysis as well as the characterization of 
phosphopeptides. Finally, an increased signal-to-noise ratio and resolution of peaks, a high protein 
sequence coverage and the high quality MS/MS obtained in the analysis of in-gel digests from lung 
tissue lysate proteins separated by 2-DE, demonstrate the usefulness of this method for proteomic 
studies. 
The new DHB Matrix Layer (DHB ML) sample preparation method was optimized for the acid used and 
the total amount of organic solvent applied. In our experience the best reproducibility, signal-to-noise 
ratio, homogeneity of crystals and reduced ion suppression are obtained when DHB is prepared in 0.1 
% TFA acidified solution containing 30% acetonitrile. We used DHB at a concentration of 5g/l, in order 
to achieve crystallization solely on the anchor surface but keeping an optimum of analyte-to-matrix ratio. 
Similar to the conventional CHCA TL preparation, for the DHB ML preparation method the matrix 
solution is depositited onto the MALDI target and allowed to dry. Subsequently, an acidified analyte 
solution is deposited onto the dried matrix layer. Finally the preparation is re-crystallized "on-target" 
using a solution containing ethanol/ 0.1 % TFA (80/20, v/v). 
In the inserts of Figure 1 photographs of sample preparations of BSA digests using the new DHB ML 
method and conventional DHB DD and CHCA TL methods (see Supporting Information, Materials and 
Methods) are depicted. The widely used CHCA TL preparation resulted in the formation of small crystals 
evenly distributed over the whole anchor surface [Figure 1 (b), insert]. The DHB DD preparation resulted 
in randomly distributed aggregates of large crystal needles pointing inward to the anchor center [Figure 
1 (a), insert]. On the contrary, the new DHB ML showed better crystal distribution with small crystals 
covering the majority of the anchor surface [Figure 1 (c), insert]. 
In the case of CHCA TL, analyte ions were obtained from the entire preparation surface. Nonetheless, 
ion signal intensity varied depending on the position on which the spectrum was acquired. With the 
conventional DHB DD preparation, spectra of more variable quality and a larger spot-to-spot variation of 
ions were yielded. The automated spectra acquisition was hampered because of the search for “sweet 
spots” from which signals of acceptable signal-to-noise ratio are obtained. Only few positions on the 
sample spot preparation, mainly on large crystals, resulted in good quality spectra. In addition, the laser 
fluence required to obtain spectra of reasonable quality varied strongly from the different positions on 
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the surface of the DHB DD preparation, which rendered an automated spectra acquisition impossible. 
This in agreement well with observations reported elsewhere [6, 30]. In contrast, the new DHB ML 
preparation resulted in good quality spectra, with favorable signal-to-noise ratio, resolution and intense 
ion signals. Notably, the crystal appearance and ion signals were unchanged after several shots at the 
same position. Therefore, MALDI-TOF-MS spectra of equal quality (signal-to-noise ratio and resolution) 
could be acquired from different positions of the sample surface. The laser fluence required to obtain 
ions was constant once the threshold was reached. Consequently, the new DHB ML sample preparation 
method is well suited for a fully automated MALDI-MS spectra acquisition analysis. 
To determine the significance of our observation, a standard peptides mixture composed of nine 
peptides with a mass range of 700 to 3500 m/z was used. Evaluations are based on 27 spots of the 
same peptide mixture prepared according to the three different matrix preparations described above. 
For each spot data derived from 400 laser shots were acquired using the same automatic acquisition 
parameters. The relative standard deviation (RSD) for the mass precision and the average of signal-to-
noise intensities were calculated. These results are presented in Table 1. 
For all observed peptides the mass precision was much better with the DHB ML preparation methode as 
compared to DHB DD. The RSDs of the mass precision were in the range 2,5-5,6% (for the mass range 
700-2500 m/z), except for somatostatin 28 were the RSD was. 22,1% . but with the  DHB DD method 
34,6%. 
Furthermore, with the DBH ML method the signal-to-noise ratio was improved as well (S/N up to 2300) 
especially in the low mass region (<1300 m/z) when compared to CHCA TL (S/N < 1700) method. 
To prove superiority of the DHB ML method an analysis of variance (ANOVA) was computed. We used 
the relative mass error of the single peptide expressed in ppm in the ANOVA test as target factor to 
assess the differences measured between the methods [Figure 2 (a)] (For further details on the 
statistics applied see supporting Information, Materials and methods). To address which of the 
components have the highest significance, a post-hoc Fisher last significance difference (LSD) multiple 
comparison was performed. The p <0,05 for the direct comparison of DHB ML with the other two 
method, confirm that the differences are significant (Supporting Information, Table S1). In addition, in 
Figure 2 [panel (b)] the mean value of measured relative mass error versus the single peptides for all 
method employed is plotted. The accuracy for the DHB ML method is significantly better (< 30 ppm) 
when compared with the other methods. 
The statistical analysis and the results are presented in table 1. We therefore confirm the DHB ML 
preparation to be significantly better even in an automated spectra acquisition mode. 
To document the advantageous features of the new DHB ML method, four tryptic digests of standard 
proteins were studied. Notably, BSA, ovalbumin and α-and β-casein were used to compare the DHB ML 
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with the conventional CHCA TL and DHB DD preparations. All experiments were performed at least 
three times. Each protein was reduced, alkylated, and thereafter digested with trypsin overnight. Two 
hundred fmol of the protein digests were prepared using the preparation methods above described. 
In Figure 1, the MALDI-TOF-MS spectra of BSA tryptic digests obtained by automated acquisition of the 
three preparations are given. The new DHB ML preparation [Figure 1 (c)] provided an improved signal-
to-noise ratio as compared with the DHB DD preparation [Figure 1 (a)]. In addition, a reduced chemical 
noise, reduced matrix signal and less ions suppression in the low mass region was observed as 
compared to CHCA TL preparation [Figure 1 (b)]. Noteworthy, the spectrum of the DHB ML preparation 
yielded the highest number of peptide signals, therefore leading to enhanced protein sequence 
coverage. In fact, a total of 52 BSA tryptic peptides were detected with the DHB ML preparation method 
allowing for a sequence coverage of 76%. In contrast, 33 BSA peptide detected with CHCA TL method 
allowed a sequence coverage of 57%, while the 45 peptides detected with the DHB DD method resulted 
in a sequence coverage of 68%. Notably, for all the analyzed protein digests, more peptides were 
detected with DHB ML than with CHCA TL and/or DHB DD preparations, resulting in higher sequence 
coverage (data not shown). 
The differences between DHB ML and DHB DD preparations in the peak resolution, signal-to-noise ratio 
and the number of peptide observed are probably caused by different analyte incorporation, thus 
resulting in different crystal structures of the two preparations. Most likely, the formation of smaller 
crystals obtained with the DHB ML preparation, is beneficial for an homogeneous incorporation of the 
sample over the whole preparation surface. Thus, a sufficient analyte-to-matrix ratio and an improved 
isolation between analyte molecules were obtained, which is required for an efficient desorption and 
consequently ionization process [31-33]. The mass data obtained differ not only quantitatives but also 
qualitatives in terms of different peptides observed, probably caused by the ionization process related to 
the kind of matrices. Notably, DHB leads to the formation of molecular ions with low internal energy, 
which remains intact during mass analysis. In contrast, CHCA leads to significant decomposition of 
peptide ions during the analysis [34, 35]. Here, we confirm previous observations demonstrating that the 
representation of complex analytes in MALDI MS spectra is dependent on the matrix, the solvent 
composition, and the properties of the analytes it self [31, 5]. 
MALDI is known to tolerate small amount of impurities and salt contaminants more readily than other 
MS ionization methods. However, the signal of peptide ions can still be suppressed by the presence of 
impurities and salts, such as those from in-gel digested samples. The use of micro-columns to desalt 
and concentrate the analyte prior to MALDI-MS analysis is a widely applied method to get rid of 
impurities from the sample [30, 36]. 
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In order to study the tolerance towards impurities of our newly developed DHB ML preparation method, 
we applied it to the analysis of different peptide mixtures obtained from in-gel digest of proteins. The 
same four standard proteins cited above were loaded on 1-D gel; the stained protein-bands were 
manually excised and subjected to in-gel digestion with trypsin. An aliquot of the digestion supernatant 
from each protein-band was prepared using the DHB ML method; same amounts were desalted and 
concentrated using ZipTip®-C18 reversed-phase micro-column and prepared according to DHB DD and 
CHCA TL preparation methods. The mass spectra obtained from 0.8 µl of supernatant from α-casein in-
gel digest, which corresponds to approximately 250 fmol are shown in Figure 3. It should be noticed that 
the crystals from DHB DD preparation after micro-column purification were particularly large. As 
previously reported, an automated MS spectra acquisition was not possible. However, from some 
positions of the DHB DD preparation, peptide signals with a good signal-to-noise ratio were manually 
acquired [Figure 3 (a)]. The spectrum of CHCA TL preparation is dominated by matrix cluster signals 
and shows a considerable reduced number of peptide ions [Figure 3 (b)]. In contrast, DHB ML 
preparation resulted in a more homogeneous crystal surface and the acquired spectrum resulted in 
signals of comparable signal-to-noise ratio [Figure 3 (c)]. Only in the central region of the preparation, a 
reduced crystal density was observed. However, the automated spectra acquisition was never 
hampered and it was always possible to acquire data of sufficient quality. Probably, salts and 
contaminants are concentrated to the central region of the preparation. This observation is supported by 
MS that spectra obtained from this region with significant more chemical noise. Moreover, a similar 
‘desalting’ effect has already been described for DHB preparations [4]. This ‘desalting’ effect seems to 
be less efficient for DHB DD preparation with the conditions applied herein. 
Notably, spectra of DHB DD and CHCA TL preparations were of less quality when prepared without the 
additional desalting and concentration procedure (data not shown). Nevertheless, an increased signal-
to-noise ratio for the peptide ions was observed in the spectra after sample cleanup, but a lower number 
of informative peptide ions were detected. Examination of the spectra from all analyzed protein-bands 
digest showed that the loss of peptides included signals corresponding to small hydrophilic and large 
hydrophobic peptides. Probably, they are not retained on the micro-column or cannot be eluted with the 
solution used. Noteworthy, a database search with peak list obtained from the spectrum of α-casein, 
prepared according to DHB ML method, identified the two variants α-casein-S1 and α-casein-S2 with 12 
and 15 peptides matched, respectively. With the conventional DHB DD preparation in combination with 
micro-column purification, only 8 detected peptides matched with α-casein-S1 and 12 in the case of α-
casein-S2. Poorly results were obtained when the CHCA TL preparation method coupled with micro-
column purification was used, i.e. 5 peptides were detected for α-casein-S1 and 5 for α-casein-S2. 
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Taken collectively, the DHB ML method is particularly useful for proteomic studies of complex protein 
samples with the presence of impurities from a gel-based separation step prior to mass spectrometric 
analysis. The preparation is less complex and no purification is required, which avoids the loss of 
informative peptides. Furthermore, the preparation results in a comparable signal-to-noise ratio. Finally, 
the data acquisition can be automated. 
The sensitivity of our DHB ML sample preparation method was studied using the peptide Glu1-
Fibrinopeptide B (GluFib). In Figure 4 (a) and (b) spectra obtained from a dilution series from 10 amol to 
1 amol of GluFib are depicted. A 0.8 µl volume of each dilution was prepared with the DHB ML 
preparation method and compared with the CHCA TL method. With 10 amol of the GluFib applied on 
the target, spectra acquisition was straightforward. Laser fluence just above the threshold produced 
spectra with reliable quality for every single shot. Loading an amount of 1 amol, with the DHB ML 
preparation method, the peptide signal was readily detectable. Comparable results were obtained with 
CHCA TL preparation method but peak intensity and signal-to-noise ratio of both preparations was 
different. Attempts to detect 0,5 amol of GluFib prepared with the DHB ML method were successful in 
roughly half of all measurements, whereas, the detection of the same amount of peptide failed with the 
CHCA TL method. The DHB DD preparation method was also included in the study but proved to be 
less sensitive (data not shown). 
In-solution tryptic digest of reduced and carbamidomethylated BSA was used for evaluating the 
sensitivity of our method for a peptide mixture. The loading on sample support of 100 fmol of the protein 
digest, resulted in intense signal of peptides with high signal-to-noise ratio. A total of 42 BSA peptides 
were detected and the sequence coverage was 63.3%. Similar sequence coverage was obtained for 10 
fmol of digest, where 39 BSA peptides were detected allowing for a sequence coverage of 57%. A slight 
decrease in the signal-to-noise ratio and loss of some peptide signals was observed between 10 and 5 
fmol. At 1 fmol of BSA digest 22 peptides were detected with a sequence coverage of 36.1% . Below 1 
fmol, e.g. at the 100 amol level, the spectra deteriorated dramatically, several peptide signals were lost 
and the signal-to-noise ratio decreased significantly [Figure 4 (c)]. However, a database search with 
peak list obtained from this spectrum still identified BSA with a score of 69 and 10 peptides matched 
allowing to a sequence coverage of 17,3%. In general, the sensitivity of the DHB ML preparation was 
slightly higher than the CHCA TL preparation. Attempts to detect 100 amol with DHB DD and CHCA TL 
methods failed [Figure 4 c (1) and (2)]. 
Here, we established the lower limit of the routine working range of the DHB ML method to be in the 
lower-attomole range. Moreover, picomole amounts of peptide mixtures were readily analyzed without 
performance degradation. Thus, the dynamic range of the DHB ML preparation method is at least 106. 
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Encouraged from our findings with the DHB ML method, we tested its performance when applied to 
MALDI tandem mass spectrometry. Two singly protonated peptides from the spectrum of α-casein in-gel 
digest showed in Figure 3,were selected as precursor ions for MALDI MS/MS analysis. Figure 5 (a) 
displays the MS/MS spectrum of the single protonated precursor ion at m/z 1098.60. The complete y- 
and b-ion series was readily obtained, a database search using the fragmentation data identified the 
peptide 204AMKPWIQPK212 from α-casein-S2 with an ion score of 53 .The fragmentation pattern of the 
single protonated precursor ion at m/z 1267.70, is shown in Figure 5 (b). An almost complete y- and b-
ion series corresponding to the α-casein-S1 peptide 106YLGYLEQLLR115 was identified with an ion score 
of 40. This confirms our initial identification of α-casein-S1 and α-casein-S2 in the PMM analysis of the 
in-gel digests and broadens the application of the DHB ML preparation method for MALDI tandem MS 
analysis as well. 
Furthermore, we were interested to apply our method for the detection and characterization of 
phosphorylated peptides. Notably, phosphorylated peptides are often detected with low efficiency or not 
at all, due to the physicochemical characteristics of the negatively charged phosphate groups, which 
influence the behavior of phosphopeptides during sample preparation and during the MALDI 
desorption/ionization process. Recent reports suggest the use of o-phosphoric acid as matrix additive to 
enhance the signal of phosphorylated peptides in complex mixture [19, 37]. Thus, we tested the 
performance of DHB ML preparation method by addition of phosphoric acid to the matrix and the re-
crystallization solutions. Best results were obtained at the concentration of 0.1% o-phosphoric acid 
which has no negative influence on the crystallization and on the hydrophobic coating of sample 
support. The bovine milk α-casein is phosphorylated stoichiometrically at serine residues. With the DHB 
ML preparation using TFA, only the peptide ion m/z 1951.95 was readily detectable [see figure 3 (c) ion 
label S1p). By use of the DHB ML preparation with addition of 0.1 % of o-phosphoric acid, the ions at 
m/z 1660.79, m/z 1927.69 and m/z 1951.95 were readily detected in the spectra of 400 fmol of in-
solution digestion of α-casein [Figure 6 (a)]. Thus these ions were selected and tandem MS/MS spectra 
were acquired. Figure 6 (b) and (c) display the MS/MS spectra of ions m/z 1660.79 and m/z 1951.95. 
The MS/MS spectra of these peptides were dominated by an [MH - 98]+ ion and [MH - 80]+ ion, which 
correspond to gas phase β-elimination of a H3PO4 and loss of HPO3 groups, respectively. Note, the 
facile loss of H3PO4 and HPO3 did not prevent the formation of the amino acid sequence ions. Thus, the 
nearly complete series of y- ions was easily detected, corresponding to the α-casein peptide 
121VPQLEIVPN(pS)AEER134 at m/z 1660.79 which was identified with an ion score of 94. The ion at m/z 
1951.95 was identified with an ion score of 48 as the peptide 119YKVPQLEIVPN(pS)AEER134. 
Furthermore, the MS/MS fragmentation pattern of both peptides reveled the position of the phosphate 
moiety on serine 130. Figure 6 (d) displays the MALDI-MS/MS spectrum of the ion m/z 1927.69. In this 
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case two abundant ion signals, at [MH - 98]+ and [MH - 196]+, corresponding to neutral loss of two 
H3PO4 were detected downstream of the parent ion signal. Thus, two phosphorylated amino acids in the 
peptide are present. In fact, a database search using the fragmentation data assigned the ion m/z 
1927.69 to the phosphopeptide 58DIG(pS)E(pS)TDQAMEDIK73 with an ion score of 42. Notably, the y- 
and b- ion series allowed clearly to identify the two phosphorylated residues as serine 61 and 63, 
excluding the threonine in position 64. Similar results were obtained for phosphorylated peptides of the 
other analyzed proteins (data not shown). These results confirm the compatibility of our DHB ML sample 
preparation method with the addition of o-phosphoric acid for the analysis of phosphorylated peptides to 
characterize the phoshporylation sites. 
To demonstrate the performance and the robustness of our new DHB ML preparation method in a 
proteomic research project, we analyzed in-gel digests from 2-DE gel separated proteins of mouse lung 
lysate. Arbitrary, a set of 66 protein spots were excised from different parts of  200 µg proteins loaded 
2-DE mini-gel (pH gradient 3-11 non linear), followed by in-gel digestion with trypsin and the resulting 
spectra were analyzed. The 66 excised protein spots (Figure 7) were classified in three groups 
according to their intensity: weak (W: 26spots), medium (M: 22 spots), and strong (S: 18 spots) as 
denoted in Table S2 (Supporting information). An amount of 1 µl of the digestion supernatant from each 
spot was prepared according to DHB ML method and loaded onto the pre-structured MALDI sample 
support. MALDI-MS spectra acquisition and tandem MS precursor ions selection and acquisition was 
done in automated mode (see Supporting Information, Material and Methods). Figure 8 depicts 
representative peptide mass maps of the identified protein in the spot 44 using the two different sample 
preparation methods. In both cases, the protein could be identified as Selenium-binding protein 1. 
Notably, the CHCA TL method gave sequence coverage of 24% with 10 peptide matched and a Mascot 
score of 94 [Figure 8 (a)]. The sequence coverage with the DHB ML method was 70% with 32 peptide 
matched and a Mascot score of 233 [Figure 8 (b)]. In addition, only with the DHB ML method three ions 
could be automatically selected for MS/MS spectra acquisition with high ion scores, thus confirming the 
robustness of the DHB ML method for MALDI tandem MS analysis [Figure 8 (c), (d), (e)]. 
The result of the comparison showed that the DHB ML preparation method was in general superior, 
when compared to the CHA TL method in terms of improved number of peptides identified, sequence 
coverage and Mascot score (Figure 9). The DHB ML method gave an average sequence coverage of 
42%, while the classical CHCA TL method average sequence coverage of 32, respectively (Figure 9). 
Furthermore, a total of 71 MS/MS spectra were successfully acquired with DHB ML method, compared 
to only 31 with the CHCA TL method. Overall, an improved performance by 44% was determined, 
furthermore, some peptides were detected uniquely with one or the other preparations. 
Appendix Chapter I 48 
Taken collectively, with the DHB ML preparation method 58 of 66 mouse protein spots analyzed were 
identified by database search as compared to 56 with the CHCA TL method. By iterative database 
searching of the data obtained with the DHB ML method a mixture of proteins could be analyzed for the 
protein spots: 13, 17 and 58. Using the CHCA TL method only the spot 58 a mixture could be analyzed. 
For the spot 31, assigned as medium, the identification was confirmed by MS/MS. Medium- and strong-
intensity spots were identified with a success rate of 100%, while spots with weak intensity were 
identified with a success rate of 69%. Note, this corresponds to an overall success rate of 88%. 
Combined with reasonable high amino acid sequence coverage and the high sensitivity demonstrated, 
DHB ML sample preparation method is a viable and robust alternative to standard matrix preparation 
protocols. 
The DHB ML method presented here has several advantages in terms of facile preparation, feasibility 
for automated data acquisition. With this method a decrease in chemical noise and  a high tolerance 
toward impurities avoided the loss of informative peptides leading to higher proteins sequence coverage 
as compared with conventional sample preparation methods. With this matrix sample preparation, the 
signal-to-noise ratio and resolution for the ion signals over the entire preparation surface is improved, 
most likely due to the formation of smaller crystals which are homogeneously distributed over the whole 
spot surface. The high mass accuracy, the increased number of peptides ions detected, the higher 
sequence coverage and the enhanced tandem MS performance proven the reliability and robustness of 
the DHB ML method. 
When prepared using o-phosphoric acid as additive, our DHB ML preparation method can efficiently be 
applied for an identification of phosphorylated proteins and the characterization of the phosphorylation 
site. 
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Table 1 
 
Spot to Spot Variation 
    
PEPTIDES CHCA TL DHB DD DHB ML 
Bradykinin (1-7)    
m/z average(Da) 757,439 757,345 757,350 
m/z STDEV (%) 1,8% 4,2% 2,5% 
S/N average 77,7 1157,5 1342,9 
Angiotensin II    
m/z average(Da) 1046,586 1046,505 1046,503 
m/z STDEV (%) 2,4% 5,1% 2,5% 
S/N average 1691,6 2316,8 2346,3 
Angiotensin I    
m/z average(Da) 1296,736 1296,667 1296,658 
m/z STDEV (%) 2,8% 6,4% 2,6% 
S/N average 544,2 1018,7 1222,7 
Substance P    
m/z average(Da) 1347,789 1347,720 1347,713 
m/z STDEV (%) 2,8% 6,8% 2,8% 
S/N average 2071,4 770,2 1345,8 
Bombesin    
m/z average(Da) 1619,880 1619,815 1619,811 
m/z STDEV (%) 3,2% 8,2% 3,2% 
S/N average 2264,9 685,8 1256,8 
Rinein Substrate    
m/z average(Da) 1758,990 1758,940 1758,925 
m/z STDEV (%) 3,5% 9,2% 3,3% 
S/N average 1035,7 775,3 758,5 
ACTH Clip (1-17)    
m/z average(Da) 2093,153 2093,092 2093,082 
m/z STDEV (%) 4,2% 10,3% 4,1% 
S/N average 932,3 877,9 762,7 
ACTH Clip (18-39)    
m/z average(Da) 2465,279 2465,200 2465,192 
m/z STDEV (%) 4,7% 12,0% 5,6% 
S/N average 1650,3 1170,8 642,4 
Somatostatin (28)    
m/z average(Da) 3147,586 3147,576 3147,479 
m/z STDEV (%) 6,5% 34,6% 22,1% 
S/N average 182,5 80,3 169,8  
 
Table 1 
Spot to spot variation using DHB ML and DHB DD CHCA TL methods for the obtained molecular 
masses [M+H]+ in spectra of 500 laser shots, acquired using the same automatic acquisition 
parameters, at 27 different sample spots with nine standard peptides. 
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Figures 
Figure 1 
 
 
 
Figure 1. DHB ML preparation method. 
MALDI-TOF mass spectra obtained from a BSA tryptic digest. A 200 fmol amount of the digest was 
prepared with (a) CHCA TL, (b) DHB DD, and (c) DHB ML. 
Stars indicate signals matching tryptic peptides of BSA.  
With DHB DD method 45 peaks matched with BSA allow for sequence coverage of 68%. With CHCA 
method 33 peaks matched and a sequence coverage of 57%: Using the DHB ML method the peaks 
matched were 53 allowing for a sequence coverage of 76%.  
The inserts display images of the relative preparation methods. 
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Figure 2 
 
 
 
Figure 2. Statistical analysis of spot-to-spot variation. 
(a) The relative mass error of the single peptide expressed in ppm was used as target factor to compare 
methods. We use the software STATISTICA to perform the ANOVA analysis. F(0,05;2;691) = 28,14. 
Fcritic (0,05;2;691) = 3,01. Critic values of F when Alpha= 0,05, degree of freedom between= 2, degree of 
freedom within= 691. 
(b) The DHB ML, the CHCA TL and DHB DD were compared on the basis of the mean of relative mass 
error. The accuracy of the DHB ML method is significantly improved when compared to the CHCA TL 
and DHB DD (Relative mass error <30pmm). 
Vertical bars indicate standard error. For detailed peptide masses see Supporting Information, Materials 
and Methods. 
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Figure 3 
 
 
 
Figure 3. MALDI-TOF mass spectra obtained from a α-casein in-gel tryptic digest. 
A 250 fmol amount of the digest was prepared with (a) the DHB DD and (b) the CHCA TL method and 
included a desalting and concentration step using micro-columns (see text), (c) the DHB ML preparation 
method without sample purification. 
The tryptic peptide ions of α-casein-S1 and α-casein-S2 are indicated with S1 and S2 respectively. 
Commonly observed matrix and trypsin auto-digest signals are indicated by M and T, respectively. 
The ion peak S1p in panel (c) m/z 1951.95, indicate the only poshorylated peptide ion detectable with 
DHB ML preparation using TFA. 
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Figure 4 
 
 
 
Figure 4. Sensitivity of the DHB ML sample preparation method. 
MALDI-TOF mass spectra of a dilution series of the peptide Glu1Fibrinopeptide B (monoisotopic 
m/z1570.59) using DHB ML (a) and CHCA TL (b). A 0.8 µl volume of sample, in 25% ACN, 0.1% TFA, 
was used for each sample. 
(c) MALDI-TOF mass spectra of BSA tryptic digest. A 100 amol amount of the digest was prepared with 
(1) the DHB DD, (2) CHCA TL and (3) DHB ML method. 
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Figure 5 
 
 
 
Figure 5. Peptide sequencing by MALDI-MS/MS with the DHB ML sample preparation. 
MALDI-TOF/TOF mass spectra of singly protonated peptide ions from α-casein. (a) The single 
protonated precursor ion at m/z 1098.60 and the y- and b-ion series could be assigned to the peptide 
204AMKPWIQPK212 of α-casein-S2 with an ion score of 53. 
(b) The fragmentation pattern of the single protonated precursor ion at m/z 1267.70 revealed the 
complete y- and b-ion series of the α-casein-S1 peptide 106YLGYLEQLLR115 and was identified with an 
ion score of 40. 
The y-H2O- and b-H2O-ions are not labeled for simplicity. 
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Figure 6 
 
Appendix Chapter I 56 
 
 
Figure 6. Enhanced desorption/ionization efficiency of phosphorylated molecular ions by addition of o-
phosphoric acid (PA) in the DHB ML preparation solutions(matrix and re-crystallization solution). 
Application of o-phosphoric acid (PA) as matrix additive enabled recovery of both singly and multiply 
phosphorylated species in a tryptic digest of α-casein. 
(a) Detailed view of the region m/z 1600–2000 of tryptic MALDI-TOF peptide mass map of 400 fmol α-
casein tryptic digest prepared with the DHB ML method using 0.1% PA. Only the phosphorylated 
molecular ions are indicated. 
 Note, in the spectrum of α-casein in-gel digest DHB ML prepared with TFA only the ion m/z 1951.95 
was detectable [see Figure 2 (c), molecular ion m/z 1951.95 labeled as S1p]. 
Phosphopeptides sequencing by MALDI-MS/MS. 
(b) and (c) MALDI-TOF-MS/MS of singly protonated phosphopeptide ions from α-casein-S1. The 
monophosphorylated peptides displayed a near complete series of y-ions confirming the sites of 
modification. Multiple ion signals from mainly y-H2O but also b- and b-H2O have not been labeled for 
simplicity. The phosphopeptide precursor ion signal [M+H]+ m/z 1660.79 and m/z 1951.95 [labeled as y-
14 in (b) and as y-16 in (c), respectively], were accompanied by intense -98 Da satellite ion signals due 
to β-elimination of phosphoric acid from phosphoserine (S130) (    ). 
(d) MALDI-TOF-MS/MS of double protonated phosphopeptide ion from α-casein-S1. The 
phosphopeptide precursor ion signal [M+H]+ m/z 1927.69 (labeled as y-16), was accompanied by two 
intense -98 Da ion signals due to successive β-elimination of phosphoric acid from the two 
phosphoserine (   ). The doubly phosphorylated peptide displayed a complete series of y-ions leading to 
assign the phosphorylation to the two serine in the sequence (S61 and S63). The, y-H2O- and b-H2O-
ions are not labeled for simplicity. 
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Figure 7 
 
 
 
Figure 7. 2D-gel separation of mouse lung proteins visualized with colloidal Coomassie Brilliant Blue G-
250. 
The separation was performed with pH 3-11 IPG strips, 70 X 50 mm second dimension SDS-PAGE gel 
12% total acrylamide. A total 66 protein spots with molecular masses between 15and 100 kDa were 
prepared using the DHB ML method and loaded onto pre-structured sample support. A total of 58 
protein spot could be identified with PMM. For 3 protein spots of the 58, a mixture of two proteins each 
was found. A total of 71 tandem MS spectra were from the automated system selected and performed 
to confirm the identifications. 
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Figure 8 
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Figure 8. MALDI-TOF-MS peptide mass maps and MS/MS of in-gel digest of spot 44 separated by 2D 
gel electrophoresis (Figure 6) illustrating that the DHB ML sample preparation method on pre-structured 
sample support improve sequence coverage and the MS/MS performance. 
(a) MALDI-TOF-MS peptide mass map obtained with traditional CHCA TL preparation method. A total of 
10 peptides could be assigned to Selenium-binding protein 1, which corresponds to an protein 
sequence coverage of 24% and a MASCOT score of 94. 
(b) MALDI-TOF-MS Peptide mass map using DHB ML preparation method. A protein sequence 
coverage of 70% could be obtained, which corresponded to 32 identified peptides with a MASCOT 
score of 233. 
Peptide sequencing by MALDI-TOF-MS/MS of Selenium-binding protein 1, spot 44. 
(c) MALDI-TOF-MS/MS of single protonated ions m/z 1149.60, y-ion series allowed to assign to the 
peptide 228IFVWDWQR235 of Selenium-binding protein 1 with an ion score of 33. 
(d) MALDI-TOF-MS/MS of single protonated ions m/z 1212.64, the peptide 53SPQYSQVIHR62 of the 
same protein, was identified with an ion score of 28. 
(e) MALDI-TOF-MS/MS of single protonated ions m/z 1689.83. The fragmentation pattern revealed the 
complete y- and b-ion series of the peptide 212DGFNPAHVEAGLYGSR227 of Selenium-binding protein 1 
and was identified with an ion score of 98. 
The y-H2O- and b-H2O-ions are not labeled for simplicity. 
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Figure 9 
 
 
 
Figure 9. A Comparison of the DHB ML and the CHCA TL methods using in-gel digested proteins from 
lung tissue lysate. In general, the DHB ML method improved the sequence coverage (a), the number of 
identified peptides (b), and Mascot score (c). The DHB ML and the CHCA TL protocols yielded an 
average of protein sequence coverage of 42% and 32%, respectively. 
* = second protein identified for the spot. 
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Chapter II 
Development of a new method for 
detection and molecular characterization 
of DNA alkylating agents by MALDI-TOF 
mass spectrometry 
PAH-DNA adducts 
All organisms are exogenously exposed to varying amounts of a broad range of foreign substances, 
generally defined xenobiotica. Although most of the xenobiotica are innocuous compounds of natural 
source, some chemicals demonstrated to have carcinogenic or mutagenic properties in experimental 
systems.  
The modern research on chemical carcinogenesis began with the isolation of benzo[a]pyrene (B[a]P) 
from coal tar in 1930 by Cook and colleagues, and the subsequent demonstration that B[a]P initiates 
tumors when repeatedly painted on mouse skin 171. Cook and colleagues presented the first proof that 
polycyclic aromatic hydrocarbons (PAH) are capable to induce cancer, a milestone of the modern study 
on chemical carcinogenesis. 
The PAH are a group of highly lypophilic organic compounds containing two or more condensed 
benzene rings representing a wide range of molecular size and structural complexity (Figure 12). PAH 
are primarily formed by the incomplete combustion of organic materials, although they can also be 
generated following the preparation of food that has been charred or grilled 172,173. Common sources of 
PAH carcinogenic to humans include automobile exhaust emissions, tobacco smoke, and coal tar 173-
175. The Monographs Program on the Evaluation of Carcinogenic Risks to Humans of the International 
Agency for Research on Cancer (IARC) publishes authoritative carcinogenic risk assessments 9. The 
IARC Monographs identify chemicals, mixtures, occupational exposures, physical and biological agents, 
lifestyle and environmental factors that can increase the risk of human cancer. Nearly all of these risks 
were first identified through observational epidemiology, and then verified by supplementary studies in 
animals and other experimental systems. Therefore, tested chemicals have been classified into 5 
groups based on their potential to cause cancer in humans. To date, these evaluations have identified a 
total of 107 agents, mixtures and exposures that are classified in group 1: “carcinogenic to humans”. 
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Figure 12. Chemical structures of some polycyclic aromatic hydrocarbons (PAHs). From ref. 176. 
 
The B[a]P is included in this group 1 and most PAH are included in the first three group of risk 
classification. Numerous animal studies involving dermal, intraperitoneal, and intratracheal routes of 
exposure as well as exposure through the diet have confirmed the potent carcinogenic properties of 
PAH 13,177. The impact of PAH on human health has been a great topic of concern due to their universal 
presence in environmental pollution and certain occupational settings 12,174,178,179. Evidence linking PAH 
to the induction of carcinogenesis in humans points to an increased risk of lung, skin, and bladder 
cancer following environmental and occupational exposure 10. 
While PAH are generally not carcinogenic per se, metabolic activation leads to intermediates that might 
react with nucleic acid and protein leading to DNA, RNA and proteins adducts. Most of the DNA adducts 
formed in the genome are normally removed by the DNA repair mechanisms. However, unrepaired DNA 
adducts can potentially lead to genetic mutation when the genome is replicated. Presently, there are 
three principal metabolic pathways for PAHs that have been proposed and established with 
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experimental evidence. A pathway proposed more than 30 years ago suggests the activation of PAH by 
the formation of radical cations by removal of one electron from the π electron system of the molecule 
through one-electron oxidation catalyzed by P450 peroxidase 180. Radical cations are electrophilic 
capable of interacting with nucleophilic centers in cellular macromolecules 181,182. DNA adducts formed 
through PAH radical cation are unstable leading to spontaneous depurination which would result in 
formation of apurinic sites as the major type of DNA damage 183,184. In the late 1980s a pathway of PAH 
activation that involves the formation of o-quinones catalyzed by dihydrodiol dehydrogenases has been 
postulated 185,186. Evidence has revealed that PAH-o-quinones are highly reactive Michael acceptors 
which can form both stable and depurinating DNA adducts 187. Notably, the theory of bay region 
dihydrodiol epoxide (DE), well established through studies over the past half century, is widely accepted 
by scientists in this field as the dominant mechanism of PAH metabolic activation 188-190. This 
mechanism involves three enzyme-mediated reactions as (Figure 13).  
 
 
Figure 13. Metabolic activation of B[a]P and the formation of B[a]PDE-dG. From ref.191.  
 
Firstly, the oxidation of a double bond on the PAH catalyzed by P450 enzymes (CYP), i. e. CYP1A1 and 
CYP1B1, to form unstable arene oxides. Secondly, the hydrolysis of the arene oxides by microsomal 
epoxide hydrolase (EH) to trans dihydrodiols. Finally, a second CYP catalyzed oxidation at the double 
bond adjacent to the diol function to generate a vicinal DE. This pathway can lead to sterically hindered 
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“bay” or “fjord” region DE. The bay and/or fjord region DE are electrophiles capable of binding to DNA 
while some of the DE stereoisomers of PAHs are found to be ultimate carcinogens 192,193. 
Two pairs of enantiomeric DE may result from the reaction, although the ultimate carcinogen-DNA 
adducts that are observed appear to indicate high stereoselectivity.  
 
These DE metabolites may covalently bind via a cis or trans addition of the exocyclic amino groups of 
purines and pyrimidines. However, the ability of adducts to bind to DNA and persist to form mutations 
may depend on the conformation of the adduct, the DNA sequence and the efficiency of repair enzymes 
in identify the lesion 194. Notably, some DNA adducts derived from B[a]P can be repaired by a nucleotide 
excision repair pathway 195,196. 
Since the first report of the quantization of a DNA adduct in 1969 197, an extensive amount of analytical 
work has been done to establish the relevance of DNA adducts as important biomarkers for cancer 
development. While some compounds such as aminobiphenyl have been closely associated with the 
onset of cigarette smoking-induced cancer 11,198, the complexity of environmental exposure mechanisms 
complicates the establishment of a direct causal link of compound such as PAH. Notably, B[a]P has 
been shown to cause nonrandom mutational hotspots in the p53 tumor suppressor gene and ras proto-
oncogene resulting in predominantly G:C to T:A transversions 199,200. 
PAH-DNA adducts detection and characterization 
Methods 
A number of methods have been developed for the detection of PAH-derived DNA adducts, which are 
dictated by the inherent chemical and physical properties of these molecules. These methods can be 
distinguished in indirect and direct methods. With indirect method the detection of PAH is made on the 
compounds released from the DNA following acid hydrolysis 201. The direct method allow the detection 
of PAH bond to DNA or nucleotides. Therefore, the direct methods were preferred because in most 
cases they permitted the determination of the part of DNA involved in the adduction event. These 
methods include high performance liquid chromatography (HPLC) separation technique coupled to 
fluorescence detection, or NMR, circular dichroism, UV/visible fluorescence spectroscopy, synchronous 
fluorescence spectroscopy and gas chromatography 202-207. The production of antibodies recognizing 
PAH-DNA adducts has led to the development of also immunoaffinity and immunological based 
methods 203,208. The most common method used for the sensitive detection of DNA adducts is the 32P-
postlabeling assay.Nonetheless, methods based on mass spectrometry were recently developed. The 
main advantage of MS based methods is that it not only provides information on the molecular mass of 
the DNA adducts, but can also generate structurally significant information for its characterization. In the 
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following paragraphs recent advances of methods for the detection and structural characterization are 
discussed in detail together with the advancement added by the work of this doctoral thesis.  
32P-postlabeling assay 
32P-Postlabeling analysis has been widely used for the detection of a variety of DNA adducts induced by 
endogenous and exogenous mutagens or carcinogens 209-213. The principal stages of the 
32Ppostlabeling assay are the digestion of DNA to nucleoside 3'-monophosphates with micrococcus 
nuclease and calf spleen phosphodiesterase II. This is followed by an enrichment step to enhance the 
sensitivity, which involved extraction of the aromatic/hydrophobic adducts into butanol as a means of 
separating them from the un-adducted normal nucleotides. The extracted adducted nucleotides are 5'-
labeled with 32P-orthophosphate from [γ- 32P]-ATP by the T4 polynucleotide kinase catalyzed reaction. 
Finally, chromatographic and/or electrophoretic separations of the labeled species are performed 
followed by their detection and quantitation. Indeed, the [32P]-5'-labeled nucleotides adducts are 
commonly separated by multidimensional thin-layer chromatography (TLC) on polyethyleneimine (PEI)-
cellulose plates using several different buffer conditions 210,211. Alternatively, the use of non-denaturing 
polyacrylamide gel electrophoresis (PAGE) has been adapted 214. The adducts were detected using 
autoradiography or by storage phosphor imaging coupled with scanning densitometry to quantify the 
radioactivity on the chromatograms 215,216. This method is widely used due to the small amounts of the 
DNA required and its high sensitivity, i.e. one adduct per 106-108 non-adducted nucleotides (5µg DNA) 
can be detected 210,211. However, the method require the handling of hazardous radioactive phosphorus, 
and is laborious with significant inter- and intra-laboratory variations 213. The major drawbacks of the 
32P-postlabeling assay are that the chemical nature and molecular structure of the adducing agent can 
not be determined, and co-chromatography studies with DNA adducts reference materials resulted in 
erroneous information as recently reported 217. 
ESI tandem MS based methods 
Recently, methods for the detection of PAH-DNA adducts based on the use of LC coupled with ESI-MS 
were developed. The general strategy (Figure 14) used in these approaches is based on the enzymatic 
digestion of the adducted DNA to single nucleotides/nucleosides. A subsequent solid phase extraction 
(SPE) as pre-purification step is used prior to HPLC separations using several detection systems (e. g. 
fluorescence, UV). Finally, the adducts are characterized by ESI-MS using a number of different tandem 
MS fragmentation techniques 191. Moreover, direct reaction products of purified bioactivated form of 
PAH with DNA or single deoxy-nucleotides were used as standard reference compounds. 
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Figure 14. General procedure used for detection of PAHDE-deoxynucleotides adducts in DNA Samples using LC-
MS/MS. dN= generic 2’-deoxynucleoside. Adapted from ref. 191 
 
LC-MS/MS methods using ESI ionization and SRM have been reported for the detection, 
characterization and quantification of several PAH-2′-deoxyguanosine (dG) adducts of the dietary 
mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 218 and for B[a]P 191. The adducts 
were initially characterized in calf thymus DNA modified in-vitro with bioactivated form of PAH. 
Moreover, the adducts were detected in the colon and liver of animals treated with PAH. After, 
enzymatic digestion of the DNA samples to 2’-deoxynucleosides, and SPE purification to remove 
unmodified 2’-deoxynucleosides the analysis was followed by LC-ESI-MS/MS with triple quadrupole 
(TQ) operated in the SRM scan mode. In this mode, the precursorions (the protonated adducts 
molecular ion [M + H]+) are selectively transmitted by the first quadrupole mass analyzer (Q1) and are 
subjected to CID in the second quadrupole (Q2). These collision conditions generally result in the loss of 
deoxyribose [M+H-116]+ to form the protonated base adduct ion [BH2]+, which are selectively 
transmitted through the third quadrupole (Q3). In these repots limits of detection about 3 adducts per 
108 2’-deoxynucleosides were determined by measurements based on isotope dilution with internal 
standards. However, the full product ion scan mode, used in these LC-ESI-MS/MS analysis, can not be 
employed for the characterization of unknown DNA adducts at trace level, because of the slow scan rate 
and the low sensitivity in such scan mode. Alternatively, the analysis rely on the characteristic retention 
time, but searches based on SRM, do not permit de novo identification of DNA adducts. In addition, the 
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needs of stable isotope internal standards further limit the wide applicability of the methods. Notably, 
despite the implementation with multi-stage scan events (MSn), which can eliminate isobaric 
interferences, with these approaches only the adducts on deoxyguanosine were detected 191,218. 
Moreover, Wang et. al. reported the use of nanoflow liquid chromatography coupled to ESI-hybrid 
quadrupole-TOF MS using CID fragmentation for the detection of DNA adducts from lung and urine of 
mice expose of asphalt fume and in-vitro 219-221. Notably, Gaskell et. al. reported along with the main 
base adducts the identification and characterization of phosphodiester adducts as minor product formed 
following reaction of B[a]PDE with 2'-deoxynucleotides in-vitro 222. In addition, applications of capillary 
zone electrophoresis-ESI-MS were also described, leading to detect B[a]PDE of 2'-deoxyguanosine 
together with adducts formed with 2'-deoxyadenosine and 2'-deoxycytidine 223,224. A particular approach 
reported by Feng and colleagues implemented the LC-MS/MS with diode array and fluorescence 
detection . In this way they were able to separate the four stereoisomeric anti-BPDE-dG and two 
interfering anti-BPDE tetrols by taking advantage of their distinct fluorescence quenching 225,226.  
It should be noted that relevant improvements were reported with these approaches, such as the 
detection of many different adducts and the feasibility of a molecular characterization of some of them. 
However, the major drawbacks of these approaches are the need of large quantities of starting material 
and time consuming pre-purification steps as well as HPLC separation procedures required.  
MALDI MS  
There few reports on the application of MALDI MS for the analysis of DNA adducts, mostly limited to 
targeted analysis. Some of these reports should be considered as feasibility studies of the application of 
MALDI MS for DNA adducts analysis 227. Stemmler et. al. reported the use of MALDI-FTICR MS to test 
several different matrices for the structural characterization of synthesized PAH-deoxynuxcleotides 
adduct 228. Chiarelli and colleagues reported the use of MALDI for the analysis of arylamine adducts 229 
and for the structural differentiation of diastereoisomers of PAH-deoxyadenosine adducts 230. In several 
investigations the analysis was performed on oligonucleotide rather then single nucleotide adducts 231-
234, probably due to the lack of reliable matrices and sample preparation methods for an analysis in the 
low mass range (<1000 Da). Recently, the detection of B[a]PDE and the dietary mutagen PhIP -
deoxyguanosine adducts by MALDI with CID fragmentation has been also reported 235,236.  
However, these repots were unable to demonstrate applicability to wide range of compound. Moreover, 
the analysis relied on the detection of the molecular ion and just few characteristic fragments. In 
addition, large amounts of sample were needed, and in most cases the matrix interfered with a reliable 
detection do to matrix cluster formation. 
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Therefore, efforts were invested to develop a new robust and sensitive method for the detection and 
characterization of PAH-DNA by MALDI-TOF MS. 
 
A MALDI-TOF MS based method for the rapid detection and 
molecular characterization of DNA Alkylating Agents 
(Publication II)  
This study aimed of the development of a rapid and sensitive method for the detection, identification and 
molecular characterization of PAH-DNA adducts by MALDI-TOF-MS 
The strategy relied in the synthesis of standards molecules of metabolic activated forms (dihydrodiol 
epoxide, DE) of PAH-DNA adducts to be used as model analytes. The synthesized PAHDE-DNA 
adducts were used to develop a wide applicable analytical method. Moreover, their mass spectra were 
exploited to generate a repository of references MS and tandem MS spectra to be used for the 
identification and characterization of unknown adducts.  
Initially, single nucleotides and nucleosides were reacted with several PAHDE. Therefore, adducts were 
synthesized by direct reaction of the four 2’-deoxynucleosides and the four 2’-deoxynucleosides-3’-
monophosphates with anti-7,8 Dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (B[a]PDE), 
anti-11,12-dihydroxi-13,14-epoxy-9,10,11,12.tetrahydrobenzo[a,l]pyrene (B[al]PDE), anti-
11,12,dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrobenzo[g]chrysene (B[g]ChDE), anti-3,4-dihydroxy-
1,2-Epoxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene (B[c]PhDE) and with anti-9,10-dihydroxy-11,12-
epoxy-9,10,11,12-tetrahydrobenzo[c]chrysene (B[c]ChDE) (the general abbreviation of PAHDE for these 
PAH activated form will be used herein).  
The subsequent step was to develop a reliable MALDI matrix sample preparation for analysis of such 
molecules. Several matrix and sample preparations were compared on basis of production of ions, 
signal reproducibility, degree of analyte fragmentation and sensitivity. The DHB ML (publication I) 
“doped” with ammonium phosphate demonstrated to be the method of choice for an analysis of PAHDE 
and PAHDE-DNA adducts by MALDI-TOF MS.  
However, to obtain high quality MALDI-MS spectra sample purity is of great importance. Therefore, 
several enrichment methods were tested using commercial available solid phase extraction (SPE) 
cartridges devices with different sorbent bed materials. These devices demonstrated large differences in 
performance depending on the resin used as well as needed large amount and volume (milliliters) of 
sample. In some cases, adsorption of the analytes on the device components was evidenced. The N-
vinylpyrrolidone/divinylbenzene (hydrophilic-lypophilic balance, HLB) copolymer sorbent demonstrated 
to be valuable enabling increased recovery and enhanced loading capacity as compared to other resins. 
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In addition, we implemented the HLB sorbent and developed self-assembled disposable micro-columns 
(HLB-µ-SPE, see experimental section in publication II) to meet the sample amount and the volume 
(micro liters) used for MALDI-MS sample preparation. The micro-columns were prepared in pipette tip, 
thus, micro to nano grams amount in micro liters volumes of sample could be handled.  
An additional issue is that the PAHDE-DNA adducts have masses under 1000 Da, thus, in the low mass 
range (LMR). Unfortunately, for MALDI-TOF MS in the LMR there were no available instrument settings 
for spectra acquisition and, most importantly, methods for spectra calibration.  
Development of a calibration method 
For applications in MALDI-TOF MS the availability of methods for calibrate the spectra is mandatory for 
accurate measurements. Commercially available calibration mixtures are designed for MALDI spectra 
calibration in the mid-mass range (from 700 to 4000 Da). For this reason, some investigators reported 
the use of purified mixture of analyte-related compound as calibrators 237,238. Unfortunately, not always 
purified molecules are available and these should be prepared new each application. To provide a 
reliable wide application a peptide based calibration mixture was developed. The calibration mixture will 
be used for the external calibration of spectra in the LMR. The calibration mixture is composed of 8 
peptides with masses between 147 Da and 913 Da. Notably, the mixture was optimized to in order to be 
compatible of combination with a commercial calibration mixture for the mid-mass range (Peptide 
calibration standard II, Part-No. #222570, Bruker Daltonics, Bremen, Germany). Indeed, the Peptide 
calibration standard II covers a range between 750-3400 Da, whereas, the new developed calibration 
mixture covers a range of 140- 910 Da. Therefore, the combined calibration mixture allows the 
calibration of MALDI MS spectra form the low to the mid-mass range (from 100 to 4000 Da). 
Figure 15 shows a typical MALDI-TOF mass spectrum of the peptides calibration mixture in the mass 
range 10-1200 m/z, prepared using the DHB ML sample preparation. The spectrum shows a notable 
absence of matrix cluster ions and few weak cationized ions which allows to a simple interpretation and 
optimal calibration. 
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Figure 15. Typical positive ion MALDI-TOF mass spectrum of the developed calibration mixture acquired on an 
Ultraflex II mass spectrometer (Bruker Daltonics). X= peptide from the commercial peptide mixture which fallow in 
this mass range.  
 
Reference spectra  
The reaction mixtures of the four 2’-deoxynucleosides and the four 2’-deoxynucleosides-3’-
monophosphates were subjected to HLB-µ-SPE sample cleanup (see experimental section). Then, 
aliquots of the purified analytes were loaded on MALDI target with the DHB ML sample preparation 
protocol described above. Using the calibration mixture developed for external calibration, a mass 
accuracy below 20 ppm over the whole mass range (10–1200 m/z) was obtained. Notably the accuracy 
was <10 ppm for the molecular ions ([M+H]+) at a resolution of >5000 (FWHM). Based on dilution series 
of a 32 µM stock solution of purified B[a]PDE-2’-deoxyguanosine-3’-monophosphate (dGp) a limit of 
detection (LOD) <100 fmol loaded on target (65 pg, S/N> 3) was determined. 
The MALDI-TOF MS spectra of PAHDE-DNA adducts together with the molecular ion ([M+H]+) provide 
typical mass-signature specific for the alkylating molecule and the nucleotide involved in the alkylation 
reaction. Such fingerprints can thus be defined as DNA-adduct mass fingerprint (DMF). Based on the 
DMF, the [M+H]+ and specific ions were selected for MALDI-TOF-CID-MS/MS measurements to obtain 
definitive structural diagnostic fragment ions, i.e DNA-adducts fragment fingerprint (DFF). Therefore, the 
DMF and DFF of synthesized PAH-DNA adducts were acquired to be use as reference MS and tandem 
MS spectra.  
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Determination of PAHDE-DNA adducts in calf thymus DNA 
The robustness and reliability of the developed methodology was demonstrated by the application for 
the analysis of adducts formed with calf thymus DNA upon reaction with B[a]PDE and B[c]ChDE. Based 
on the full MALDI-TOF mass spectrum, a simple comparison with the reference DMF allowed 
specification of the molecular ion and characteristic fragment ions of the B[a]PDE-DNA adducts. Readily 
molecular ions and characteristic fragment for deoxynucleotides and deoxynucleosides at the same time 
were detected. The MALDI-TOF and –CID-MS/MS spectra yielded characteristic fragmentation patterns 
that allow identification of deoxyguanosine, deoxyadenosine and deoxycytidine DNA adducts. The 
spectra are simple to interpret and there is a notable absence of cationized sample and matrix ions. 
Notably, additional adducts as dinucleotide could be detected, identified and characterized by MALDI 
tandem MS.  
Overall the method is sensitive and nanogramms of hydrolyzed DNA are sufficient for the identification 
and characterization of adducts. 
When compared with the 32P-postlabeling assay a distinct advantage of the method is the unambiguous 
identification of DNA adducts and the possibility to identify the chemical nature of the alkylating agent. 
Moreover, the developed method allowed the simultaneous and unambiguous detection and 
identification of deoxynucleotide and deoxynucleosides and dinucleotides PAHDE adducts at the same 
time, leading to a more comprehensive analysis. In addition, the analysis time is drastically reduced and 
a dedicated radioactivity laboratory is not required. 
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ABSTRACT 
Metabolic activation of polycyclic aromatic hydrocarbons (PAH) may cause DNA adduct formation. 
While these are commonly detected by the 32P-postlabeling assay, this method is not informative on the 
chemical nature of the alkylating agent. Here we report a simple and reliable method that employs 
MALDI-TOF-MS with 2,5-dihydroxybenzoic acid (DHB) matrix layer (ML) sample preparations for the 
detection and structural characterization of PAH-DNA adducts. The method involves the enzymatic 
digestion of DNA to 2’-deoxynucleotides followed by solid phase extraction to remove salt and other 
contaminants prior to MALDI-MS analysis. By collision induced dissociation (CID) structurally relevant 
fragments are obtained to permit characterization of the alkylating molecules and the adducted 
nucleotide. Next to guanosine, adenosine and cytidine adducts formed from reactions with (±)-anti-
benzo[a]pyrene-7,8-diol-9,10-epoxide (B[a]PDE) are identified at a sensitivity of <100 fmol and a mass 
accuracy of <10ppm. Studies with (±)-anti-benzo[c]chrysene-9,10-diol-11,12-epoxide (B[c]ChDE) further 
document the versatility and usefulness of the method. When compared with the 32P-postlabeling assay 
MALDI-MS only indentified deoxycytidine as well nucleoside and dinucleotides adducts. Therefore, this 
sensitive method enables molecular specification and characterization of adducted nucleotides and of 
the alkylating agent, and thus, provides comprehensive information that is beyond the 32P-postlabeling 
assay. 
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Introduction 
Polycyclic aromatic hydrocarbons (PAH) are ubiquitous environmental pollutants and are primarily 
formed by incomplete combustion of organic matter, such as automobile exhaust emissions, tobacco 
smoke, coal tar, but are also generated by cooking of food that has been charred or grilled. While PAH 
are not carcinogenic per se, metabolic activation leads to intermediates that might react with nucleic 
acid and proteins leading to DNA, RNA and protein adducts. Estimates suggest up to 50 000 DNA 
damage events per day. While DNA repair enzymes remove DNA adducts efficiently, non-repaired 
lesion may cause mutations to initiate malignant transformations1.Thus, exposure to PAH has been 
linked to lung, skin, and bladder cancer2-4. Furthermore, in molecular epidemiological studies DNA 
adducts are used to evidence exposure to hazardous chemicals and to estimate risks in particular work 
places or environments5;6. Notably, PAH are activated by three major mechanisms involving either one-
electron oxidation to form intermediate radical cations, a reactive o-quinone and the oxidation to 
dihydrodiol epoxide (DE) intermediates7. The DE formation requires an initial metabolic activation of 
PAH, which is efficiently catalyzed by the combined action of cytochrome P450 1A1 and 1B1 resulting in 
the oxidation of a double bond to yield an epoxide. The epoxide is then converted to trans dihydrodiol by 
microsomal epoxide hydrolase, which undergoes biotransformation by cytochrome P450 
monooxygenase resulting in an oxidation at the adjacent double bond to generate the ultimate reactive 
DE species8. Such metabolic activation may lead to sterically hindered bay or fjord PAHDE, which are 
electrophiles, that covalently react by cis or trans addition with the exocyclic amino group of the DNA 
bases. Studies on PAH metabolism, DNA binding, mutagenicity and cell transformation assay 
demonstrated that PAH such as benzo[a]pyrene (B[a]P), chrysene, Benzo[c]chrysene (B[c]Ch), 
benzo[c]phenantrene (B[c]Ph), 5-methylchrysene, dibenzo[a,l]pyrene are activated by this pathway7;9 
and  react with amino groups of the purine bases as preferential alkylating sites10. Typical targets in 
DNA are the N2 exocyclic amino group of guanine, the N6 of adenine and to a lesser extend the N4 
exocyclic amino group of cytosine11.The molecular structure of PAH is an important determinant of their 
biological activities12, as the metabolically activated epoxides located either in a bay or fiord region 
display different carcinogenic properties. For instance the tumorigenic activity of fjord region PAHDE is 
remarkably higher then of the structurally related bay region PAHDE7;13. While guanine residues are the 
principal site of reaction for PAHDE derived from planar hydrocarbons such as B[a]P14, adenine 
residues are targeted as well or more effectively than guanine residues when the reactive metabolite is 
derived from a nonplanar hydrocarbon such as B[c]Ph15. 
Much research has been invested for an identification of PAH-DNA adducts and included HPLC 
separation techniques coupled with ultraviolet, or NMR, circular dichroism (CD), UV/visible, 
fluorescence spectroscopy and immunoassays16-19. However, the most common method used for the 
 Appendix Chapter II 81 
sensitive detection of DNA adducts is the 32P-postlabeling assay. This method involves the reduction of 
genomic DNA to single deoxynucleosides-3’-monophosphate by enzymatic hydrolysis. Then, the 
enzymatic transfer of radiolabeled phosphate groups from [32P] ATP to nucleotides, followed by the 
multidimensional thin layer chromatography (TLC) allows the separation and detection of modified 
nucleotides. This method is widely used, in part, due to the small amounts of the DNA required and its 
high sensitivity, i.e. one adduct per 106-108 non-adducted nucleotides (5µg DNA)20;21 can be detected, 
but the method is laborious with significant inter- and intra-laboratory variations22. Unfortunately, the 
chemical nature and molecular structure of the alkylating agent can not be analyzed by this method and 
co-chromatographic studies with DNA adduct reference materials resulted in erroneous information as 
recently reported23. There is need for a method of high sensitivity that permits chemical identification 
and characterization of the DNA adducts at the same time. In this regard, mass spectrometry (MS) 
based methods were developed for the study of PAH-DNA adducts, and are based on liquid 
chromatography (LC), capillary LC or capillary electrophoresis (CE) coupled to Electrospray ionization 
(ESI) tandem mass spectrometry (MS/MS)24-26. For example, LC-ESI/MS/MS has been used for the 
structural characterization of B[a]P-derived DNA adducts formed upon the reaction of B[a]PDE with 
naked DNA, or cell lines and tissue extract of mice that have been exposed to alkylating agents27-29. 
Nonetheless, these methodologies have some limitations, e.g. large amounts of sample requirement, 
extensive liquid–liquid extraction, time consuming HPLC or chromatographic purification, as well as 
expensive instrumentation. Furthermore, the full product ion scan mode, used in LC-ESI-triple 
quadrupole-MS/MS analysis, can not be employed for the characterization of unknown DNA adducts at 
trace level, because of the slow scan rate and the low sensitivity in such scan mode. Alternatively, an 
analysis rely on the characteristic retention time, but searches based on selected reaction monitoring 
(SRM), do not permit de novo identification of DNA adducts30. Taking all this into account, the 
availability of a sensitive, accurate and reliable methodology for the molecular characterization would be 
of great interest. To this end, MALDI-TOF-MS, as introduced by Karas and Hillenkamp in 198731, has 
rapidly become a valuable technique for the analysis of a wide range of molecules with sensitivities in 
the attomole range32;33. 
We therefore report the development of a robust and simple method for the detection and 
characterization of PAHDE-DNA adducts based on MALDI-MS. We employ micro solid phase extraction 
(µ-SPE) to remove efficiently salt and other contaminants of the PAHDE-DNA reaction products. Then 
MALDI-MS spectra are recorded to obtain DNA-adduct mass fingerprint (DMF). Subsequent, MS/MS-
CID of selected DMF ions produce diagnostic fragments that permit an identification and molecular 
characterization of PAHDE and the nucleotide involved in the alkylation, i.e. DNA-adducts fragment 
fingerprint (DFF). The usefulness of the method is afforded by characterization of adducts formed in 
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vitro with calf thymus DNA upon reaction with several different PAHDE. Finally, the MALDI-MS method 
is also compared with the 32P-postlabeling assay in regards to sensitivity and specificity. 
 
Experimental section 
Safety considerations 
Caution: B[a]PDE and B[c]ChDE are potential mutagenic and carcinogenic agents and must be 
handled with care. Protective clothing must be worn. Appropriate safety procedures should be followed 
when working with this compound and for discard waste materials. 
 
Chemicals and reagents. Acetonitrile, methanol and Water LC-MS grade were from JT Baker 
(Griesheim, Germany). T4 Polynucleotide kinase was from USB Corporation (Cleveland, OH). 
Phosphodiesterase II from bovine spleen (SPDE), micrococcal nuclease from Staphylococcus aureus 
(MN) and all other chemicals were of high-purity grade purchased from Sigma Chemical Co. (St. Louis, 
MO).  
Synthesis of PAH-diol-epoxides. The (±)-anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (B[a]PDE) was synthesized according to the protocol given by Yagi et al.34 
The (±)-anti-9,10-dihydroxy-11,12-epoxy-9,10,11,12-tetahydrobenzo[c]chrysene (B[c]ChDE) was 
synthesized as described by Amin et al.9 
Reactions of 2’-deoxynucleosides and 2’-deoxynucleosides-3’-monophosphate with PAHDE. 
Adducts were synthesized by direct reaction of the four 2’-deoxynucleosides and the four 2’-
deoxynucleosides-3’-monophosphates (500 µg, 1 mg/ml dissolved in water) with B[a]PDE and with 
B[c]ChDE (125 µg; 1 mg/ml dissolved in tetrahydrofuran) for 18 h at 37°C in the dark. Standard 
solutions were generated by purification of reaction products as described below. The concentrations 
were determined by UV spectroscopy performed on a LAMBDA 40 spectrophotometer (Perkin Elmer 
,Waltham, MA) using known extinction coefficients35;36 
Synthesis of PAHDE modified calf thymus DNA and enzymatic hydrolysis. The calf thymus DNA 
adducts of individual PAHDE were synthesized as described by Amin et al.18. Details are given in the SI.  
Micro-scale solid phase extraction (µ-SPE) for sample Purification. Purification of B[a]PDE-
nucleosides, -nucleotides adduct and DNA hydrolysates was accomplished by hydrophobic interaction 
liquid chromatography using N-vinylpyrrolidone/divinylbenzene (hydrophilic-lypophilic balance, HLB) 
sorbent on self-assembled micro solid phase extraction (HLB-µ-SPE) disposable columns (for details 
see SI). Typically, 4 pmol of B[a]PDE-nucleosides, -nucleotides or 12.5 ng of DNA hydrolysates were 
the amount loaded onto the MALDI target. Note, representative results of at least three independent 
experiments are presented herein. 
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DNA-adduct determination by the 32P-postlabeling assay. The 32P-postlabeling was carried out as 
described by Gupta et al. 37 with modification given by Halter et al.38. Details are given in the SI.  
Mass spectroscopic analysis. MALDI-MS experiments were performed on an Ultraflex II MALDI-
TOF/TOF mass spectrometer equipped with a SmartBeam™ laser and a LIFT-MS/MS facility. Typically, 
600 spectra over a 10–1200 m/z mass range, acquired at 100Hz, were summed and externally 
calibrated using a standard mixture composed 9 peptides. (instrumentation and software from Bruker 
Daltonics, Bremen, Germany). For details see SI. 
DHB matrix layer, MALDI matrix preparation protocol. DHB matrix layer (ML) sample preparation on 
AnchorChip™ sample support (Bruker Daltonics) was performed as described by Garaguso & Borlak32, 
with slight modifications. The DHB was prepared at a concentration of 5 g/l in 0.1 % TFA solution 
containing 30 % acetonitrile and 1 g/l of ammonium phosphate monobasic. The matrix solution, 0.5 µl, 
was deposited onto the MALDI target and allowed to dry. Subsequently, the analyte solution was 
deposited onto the dried matrix layer formed.  
 
Results  
MALDI-MS analysis of the B[a]PDE-2’-deoxynucleosides reaction products. 
The reaction mixtures of the four 2’-deoxynucleosides and the four 2’-deoxynucleosides-3’-
monophosphates were subjected to HLB-µ-SPE sample cleanup (see experimental section). Then, 
aliquots of the purified analytes were loaded on MALDI target with the DHB ML sample preparation 
protocol described above. The calculated and measured masses are given in Table S-1, and the ion 
assignments are consistent with the elemental compositions of the fragment ions depicted in Scheme 1. 
A mass accuracy below 20 ppm over the whole mass range (10–1200 m/z) was obtained and was <10 
ppm for the molecular ions ([M+H]+) at a resolution of >5000. Based on dilution series of a 32 µM stock 
solution of purified B[a]PDE-2’-deoxyguanosine-3’-monophosphate (dGp) a limit of detection (LOD) 
<100 fmol loaded on target (65 pg, S/N> 3) was determined.  
The purified reaction products of B[a]PDE-2’-deoxyguanosine (dG) and dGp yielded abundant 
protonated molecular ions ([M+H]+) at m/z 570 and m/z 650, respectively (Figure 1A, B, and S-1A, S-
2A). Only weak cationized molecular ions [M+Na]+ and [M+K]+ were present. The aglycon fragment ion 
([BH2]+) at m/z 454 is the result of the cleavage of the glycosidic bond with transfer of one hydrogen 
from the sugar to the base (see scheme 1). The facile loss of the neutral deoxyribose, is a characteristic 
mass-signature26;29;39;40. The next intense ion signal at m/z 303 corresponds to the B[a]PDE triol 
([PAH]+) while the ions at m/z 285 and m/z 257 correspond to a subsequent neutral losses of H2O 
([PAH-H2O]+) and CO ([PAH-H2O-CO]+) from the [PAH]+ ion, all of which are specific of the alkylating 
molecule. Furthermore, specific alkylated nucleotide ions are present, i.e. the 2’-deoxyguanosine 
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([dG+H]+) ion at m/z 268 and guanine ([G+H]+) ion at m/z 152 (Figure 1A and S-1A), whereas the ion at 
m/z 348 ([dGp+H]+) is specific for the 2’-deoxyguanosine-3’-monophosphate (Figure 1B and S-2A). 
While B[a]PDE-2’-deoxyadenosine (dA) and -2’-deoxyadenosine-3’-monophosphate (dAp) abundant 
protonated molecular ions at m/z 554 and m/z 634 are observed (Figure S-1B and S-2B); whereas the 
alkylated nucleotide resulted in intense signals: at m/z 252 that corresponds to [dA+H]+, and the ion at 
m/z 332 that corresponds to [dAp+H]+. Moreover, in both spectra specific ions for the alkylating 
molecule are detected together with the adenosine [A+H]+ ion at m/z 136. The protonated molecular 
ions [M+H]+ of B[a]PDE-2’-deoxycytidine (dC) and 2’-deoxycytidine-3’-monophosphate (dCp) reactions 
yielded weaker signals (Figure S-1C, S-2C) possible due to an instability of B[a]PDE-2’-deoxycytidine 
adducts that undergo extensive hydrolysis to B[a]P tetrols (m/z 320). In addition, the aglycon [BH2]+ is 
detected as weak sodiated ([BH2+Na]+) ion at m/z 436 in both spectra, while an increased abundance of 
the B[a]P tetrols ions and its extensive fragmentation to [PAH]+, [PAH-H2O]+ and [PAH-H2O-CO]+ is 
observed in both spectra. Presumably, differences in electrophilicity and steric constraints of the dC and 
dCp compared to other deoxynucleosides may account for a low reaction efficiency and increased 
instability as suggested by ohers11;26;41. However, no adducts were detected in the reaction mixture with 
2’-deoxythymidine (dT) and 2’-deoxythymidine-3’monophosphate (dTp). 
MS/MS-CID analysis for characterization of B[a]PDE-2’-deoxynucleosides reaction products. The 
MS/MS-CID measurements involved the molecular ions [M+H]+ at m/z 570 and m/z 650 for B[a]PDE-
2’deoxyguanosine adducts (Figure 1C, D and S-3A, S-4A), at m/z 554 and m/z 634 for B[a]PDE-
2’deoxyadenosine adducts, and at m/z 530 and m/z 610 for B[a]PDE-2’deoxycytidine adducts (Figure S-
3 and S-4). Product ions corresponding to the characteristic aglycon fragment ([BH2]+) at m/z 454 for dG 
and dGp, at m/z 438 for dA and dAp, at m/z 414 for dC and dCp were readily detected. Here, the 
[dN+H]+, [dNp+H]+ and [N+H]+ ions of the respective B[a]PDE reactions are observed that allowed the 
characterization of the nucleotides involved in the alkylation reaction. The ion at m/z 268 ([dG+H]+) and 
at m/z 152 ([G+H]+) characterize the dG (Figure 1C). Likewise the ion at m/z 348 ([dGp+H]+) and at m/z 
152 ([G+H]+) characterize the dGp (Figure 1D). With 2’-deoxyadenosine, the fragments ions at m/z 252 
([dA+H]+) and m/z 136 ([A+H]+) characterize the dA (Figure S-3B), whereas the ions at m/z 332 
([dAp+H]+) and m/z 136 ([A+H]+) characterize the dAp (Figure S-4B). Notably, from 2’deoxycytidine 
[M+H]+ ions MS/MS-CID spectra of the same quality were obtained see Figure S-3C with the 
characteristic ions at m/z 112 ([C+H]+) and m/z 228 ([dC+H]+). Furthermore, the ions at m/z 112 
([C+H]+) and m/z 308 ([dC+H]+) characterize the dCp (Figure S-4C). Importantly, all spectra yielded the 
ions [PAH]+ at m/z 303, [PAH-H2O]+ at m/z 285 and [PAH-H2O-CO]+ at m/z 257 that allowed the 
characterization of the B[a]PDE alkylating molecule.  
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Aglycon fragmentation. The MS/MS-CID of the [BH2]+ fragment (Figure 1E) resulted firstly in loss of 
H2O ([BH2-H2O]+), a strong PAH triol fragment ion ([PAH]+) together with the production of protonated 
base ion ([G+H]+). Subsequent isolation and MS/MS-CID fragmentation of the [BH2-H2O]+ ion at m/z 436 
(Figure 1F) show two additional losses of H2O [BH2-2H2O]+ and [BH2-3H2O]+, the [PAH]+ ion and its 
fragments to yield an abundant protonated base ion [G+H]+ which dominated the spectrum. 
PAH Triol Fragments. The MS/MS-CID of the [PAH]+ at m/z 303 (Figure 1G) resulted in two dominant 
fragments at m/z 285 ([PAH-H2O]+) and m/z 257 ([PAH-H2O-CO]+). An additional loss of water yielded 
the [PAH-2H2O-CO]+ ion at m/z 239. 
Determination of B[a]PDE adducts in Calf thymus DNA hydrolysates by MALDI-MS. B[a]PDE was 
reacted with calf thymus DNA and hydrolyzed as described in the experimental section. One aliquot 
corresponding to 1.5 µg of DNA was subjected to HLB-µ-SPE purification and about 12.5 ng of 
adducted DNA were loaded onto the MALDI sample support using the DHB ML protocol. The ion at m/z 
570 corresponds to the [M+H]+ of B[a]PDE-dG, the ion at m/z 650 corresponds to the [M+H]+ of 
B[a]PDE-dGp, while the [M+H]+ ion at m/z 554 characterizes B[a]PDE-dA (Figure 2A). Next to the 
[M+H]+, the aglycon ([BH2]+) at m/z 454 and at m/z 438, the protonated deoxynucleoside ions ([dN+H]+) 
at m/z 268 and at m/z 252, the deoxynucleoside-monophosphate ions ([dNp+H]+) at m/z 332 and at m/z 
348, the protonated nucleobase fragment ions ([N+H]+) at m/z 136 and at m/z 152 of the B[a]PDE 
adducts are detected. The signals of the positively charged B[a]PDE triol fragment at m/z 303 and its 
fragments are also present. Subsequently, MS/MS-CID experiments in the positive mode are employed 
to confirm the identification and structural characterization of the DNA adducts (Figure 2B, C). It should 
be noted that the weak ion for the B[a]PDE-dGp could be fragmented in one of three MS/MS-CID 
experiments (data not shown). Of further interest are some ions detected at m/z 819, m/z 843 and m/z 
859 labeled as α, β and γ, respectively (Figure 2A). Their selection and subsequent MS/MS-CID 
fragmentation disclose the presence of incomplete hydrolysis products. Thus, the MS/MS-CID of the ion 
at m/z 843 (Figure 2D) yield a characteristic mass-signature allowing an identification of the alkylated 
dinucleotide B[a]PDE-dAp-dC. The ions at m/z 112 ([C+H]+) and at m/z 210 ([dC-H2O+H]+) indicate the 
presence of dC , while ions at m/z 136 ([A+H]+) and m/z 332 ([dAp+H]+) indicate the presence of dAp. 
The presence of B[a]PDE is confirmed at m/z 303 (PAH]+) and its characteristic fragment ions. The ion 
at m/z 541 is the base peak in the spectrum and correspond to the loss of B[a]PDE (-302) from the 
[M+H]+, with a subsequent loss of cytosine at m/z 430. The ion at m/z 634 (B[a]PDE-dAp) reveal the 
identity of the alkylated nucleotide, which is confirmed by the presence of the [BH2]+ ion at m/z 438 and 
by the ion at m/z 732 resulting from the loss of a cytosine (-111) of the [M+H]+. Moreover, the absence 
of a B[a]PDE-dC aglycon ion [BH2]+ at m/z 414 and a B[a]PDE-dCp ion at m/z 610 defines the site of 
adduction of the dAp. Likewise, MS/MS-CID spectra are obtained from the ion at m/z 819 leading to 
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unambiguous identification and characterization of the dinucleotide B[a]PDE-dCp-dC (Figure 2E). An 
intense ion at m/z 112 ([C+H]+) and at m/z 308 ([dCp+H]+) define the presence of deoxycytidine. The 
ions at m/z 610 (B[a]PDE-dCp) and the aglycon ion at m/z 414 characterize the alkylation event, while 
the ion at m/z 708 represents the loss of a cytosine (-111) from the [M+H]+. The ion at m/z 517 
corresponds to the loss of B[a]PDE (-302) from the [M+H]+ and a subsequent loss of cytosine at m/z 
406, are further informative ions in this spectrum. The MS/MS-CID of the weak ion at m/z 859 produced 
poor spectra.  
Determination of B[a]PDE adducts in calf thymus DNA by the 32P-postlabeling assay. Ten µg of 
B[a]PDE-DNA hydrolysates that were also used for MALDI-MS studies were enriched by butanol 
extraction. Eventually an equivalent of 2 ng of 32P-Postlabeled DNA was applied to multidimensional 
TLC (Figure 2A inset). Here, one intense spot corresponding to B[a]PDE-deoxyguanosine and a faint 
spot tentatively assigned to the B[a]PDE-deoxyadenosine adduct, were detected, giving rise to a relative 
adduct level (RAL) of ~25 adducts per 106 deoxynucleotides and ~2 adducts per 106 deoxynucleotides 
for B[a]PDE-deoxyguanosine and B[a]PDE-deoxyadenosine, respectively.  
Determination of B[c]ChDE adducts in Calf thymus DNA hydrolysates by MALDI-MS 
To further demonstrate the reliability of the MALDI-MS based methodology, DNA adducts derived from 
reaction with (±)-anti-benzo[c]chrysene-9,10-diol-11,12-epoxide (B[c]ChDE), a metabolic activation 
product of benzo[c]chrysene, were studied. In Scheme 2 the major predicted fragment and the 
fragmentation pathways of B[c]ChDE-DNA adduct are depicted. Thus, one aliquot of hydrolysate that 
corresponds to 1.5 µg of DNA was subjected to HLB-µ-SPE and a volume corresponding to 12.5 ng of 
modified DNA was loaded onto the MALDI sample support. The ion at m/z 596 corresponds to the 
[M+H]+ of B[c]ChDE-dG, the ion at m/z 580 is the [M+H]+ of B[c]ChDE-dA and the ion at m/z 556 
corresponds to the [M+H]+ of B[c]ChDE-dC, all of which were readily detected (Figure 3A). In addition, 
MALDI-TOF analysis yielded signals of the 2’-deoxynucleoside-3’-monophosphate adducts: the 
B[c]ChDE-dGp at m/z 676, the B[c]ChDE-dAp at m/z 660 and the B[c]ChDE-dCp at m/z 636. Next to the 
[M+H]+, unique mass-signature ions for the B[c]ChDE and the alkylated nucleoside were also detected. 
Here, the characteristic [BH2]+ ions at m/z 480 for B[c]ChDE-dG, at m/z 464 for B[c]ChDE-dA and at m/z 
440 for B[c]ChDE-dC are noted. The protonated deoxynucleoside ions ([dN+H]+), at m/z 268 and at m/z 
252, the deoxynucleoside-monophosphate fragment ([dNp+H]+) at m/z 332 and 348 and the protonated 
nucleobase fragment ([N+H]+) at m/z 112, 136 and 152 are also detected. For the B[c]ChDE triol 
([PAH]+) at m/z 329 mainly loss of H2O, the [PAH-H2O]+ ion at m/z 311 are observed. Subsequently, 
MS/MS-CID experiments in the positive mode were carried out to obtaine fragmentation spectra of 
B[c]ChDE-dG, B[c]ChDE-dA, B[c]ChDE-dC (Figure 3B-D), B[c]ChDE-dGp and of B[c]ChDE-dAp (Figure 
3E and F). Typically, the B[c]ChDE triol [PAH]+ yielded a weak ion at m/z 329, an intense fragment ion 
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[PAH-H2O]+ at m/z 311 as well as [PAH-2H2O]+ at m/z 293. Moreover, consecutive loss of CO and water 
from the ion at m/z 311 produce [PAH-H2O-CO]+ at m/z 283 and [PAH-2H2O-CO]+ at m/z 265. (Figure 
3B inset and Scheme 2). This characteristic fragmentation pattern could be further evidenced in MS/MS-
CID esperiments and together with the [M+H]+ and the aglycon [BH2]+ all the structural characteristic 
specific ions are present in each spectrum in agreement with the elemental compositions of the 
fragment ions depicted in Scheme 2. An identification and molecular characterization of the DNA 
adducts could thus be definitively confirmed. Moreover, the MS/MS-CID spectrum of B[c]ChDE-dC 
[M+H]+ ion at m/z 556 yield, next to its specific fragments, additional ions at m/z 136 and at m/z 480 that 
correspond with high probability to the [N+H]+ of dA and the aglycon ion [BH22]+ of B[c]ChDE-dG, 
respectively. We propose that the isobaric fragment at m/z 556.1478 derived from a dinucleotide (see 
below) could not be efficiently discriminated by the ion-selector in the fragmentation process. We 
additionally observed ions at m/z 845, m/z 869, m/z 884 and m/z 893, which are labeled α, β, γ and δ in 
Figure 3A, respectively. The molecular ion at m/z 893 allowed an identification of the B[c]ChDE-dAp-dA 
dinucleotide (Figure 4A). The ion at m/z 660 (B[c]ChDE-dAp) reveal the identity of the alkylated 
nucleotide, which is confirmed by the presence of the aglycon [BH2]+ at m/z 464 and by the ion at m/z 
758 derived from the loss of adenine (-135) of the [M+H]+. The CID spectrum yielded the specific ions 
for the deoxyadenosine: the ions at m/z 136 ([A+H]+), at m/z 252 ([dA+H]+) and m/z 332 ([dAp+H]+), 
whereas the ion at m/z 565 corresponded to the loss of B[c]ChDE (-328) from the [M+H]+. The selection 
and subsequent MS/MS-CID fragmentation of the [M+H]+ ion at m/z 869 led to an identification of the 
dinucleotide B[c]ChDE-dAp-dC (Figure 4C). Thus, ions at m/z 112 ([C+H]+) and at m/z 210 ([dC-
H2O+H]+) identify the dC, while ions at m/z 136 ([A+H]+) and 332 ([dAp+H]+) identify the dAp as the 
nucleotide components. The specific ion at m/z 660 (B[c]ChDE-dAp) reveal the identify of the alkylated 
nucleotide which is confirmed by the [BH2]+ ion at m/z 464 and by the ion at m/z 758 which resulted from 
the loss of cytosine (-111) of the [M+H]+. Moreover, the ion at m/z 541 corresponded to the loss of 
B[c]ChDE (-328) from the [M+H]+ with subsequent loss of cytosine (-111) at m/z 430. The MS/MS-CID 
spectrum of the ion at m/z 845 identified the dinucleotide B[c]ChDE-dCp-dC (Figure 4D).The ion at m/z 
636 (B[c]ChDE-dCp) revealed the identity of the alkylated nucleotide which is confirmed by the 
presence of the [BH2]+ at m/z 440 and by the ion at m/z 734 derived from loss of cytosine (-111) of the 
[M+H]+. Further specific ion for the nucleotide components includes the ions at m/z 112 ([C+H]+) and a 
weak [dCp+H]+ ion at m/z 308. Regarding the ion at m/z 884 (Figure 4B) the incomplete fragmentation 
pattern of the CID spectrum leads us to tentatively assigne fragment ions. Thus, the ion at m/z 660, the 
ion at m/z 464 (as its aglycon [BH2]+) together with ions at m/z 136 ([A+H]+) and m/z 332 ([dAp+H]+) 
define the presence of B[c]ChDE-dAp, while the ion at m/z 758 could be due to the loss of thymine (-
126) from the [M+H]+ (if B[c]ChDE-dAp-dT). Noteworthy, the ion at m/z 556 is isobaric to the B[c]ChDE-
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dC (at m/z 556.2078) but could correspond to the loss of B[c]ChDE (-328) from the [M+H]+. However, 
selection and fragmentation lead to the spectrum depicted in Figure 3D.  
Determination of B[c]ChDE adducts in calf thymus DNA by the 32P-postlabeling assay. Ten µg of 
B[c]ChDE-DNA hydrolysates that was also used for MALDI-MS analysis were enriched by butanol 
extraction followed by 32P-postlabeling with 2 ng of adducted DNA hydrolysate being applied to 
multidimensional TLC (see inset in Figure 3A). Here, two radioactive intense spots corresponding to 
B[c]PhDE-deoxyguanosine and B[c]PhDE-deoxyadenosine adducts and a third very faint spot 
tentatively assigned as B[c]PhDE-deoxycytidine adduct were detected. The RAL was determined as 
~59 adduct per 106 deoxynucleotides for B[c]PhDE-deoxyguanosine, ~18 adduct per 106 
deoxynucleotides for B[c]PhDE-deoxyadenosine and ~3 adduct per 107 deoxynucleotides for B[c]PhDE-
deoxycytidine. 
 
Discussion 
This study aimed for the development of a rapid and sensitive method for the detection, identification 
and characterization of PAHDE-DNA adducts by MALDI-TOF-MS and the following experimental 
conditions need to be considered. Firstly, to facilitate the acquisition of MALDI-MS and MS/MS-CID 
mass spectra, the matrix sample preparation should produce consistent, reproducible and long-lasting 
analyte signals. This is achieved by the homogeneous distribution of the matrix-analyte crystals on the 
sample support. Secondly, the matrix should produce a limited number of identifiable matrix peaks, and 
should not be affected by the presence of salts, buffers, and other common sample components, which 
could results in matrix clusters formation and ion suppression. Thirdly, the matrix influences the extent 
of desorption/ionization-induced fragmentation of analytes 42. Notable, the 3-hydroxypicolinc acid (HPA) 
matrix proved useful for the analysis of oligonucleotides43, while α-cyano-4-hydroxycinnamic acid 
(CHCA) and 2,5-dihydroxybenzoic acid (DHB) worked well for the analysis of proteins and peptides32;44. 
For an analysis of PAHDE-DNA adducts these matrices exhibited different characteristics with respect 
to appearance of the crystals, the production of matrix ions, signal reproducibility, and the degree of 
analyte fragmentation (data not shown). We found the DHB prepared by the matrix layer (ML) method32 
to be the matrix of choice for an analysis of PAHDE and PAHDE-DNA adducts. An improved 
homogeneity of the matrix crystals, enhanced sensitivity and reduced cationized matrix and analyte 
molecular ions by the addition of ammonium phosphate as matrix “dopant” was observed. Furthermore, 
the DHB ML sample preparation delivered consistent signals for hundreds of laser shots at one location 
to facilitate the acquisition of MALDI-MS and MS/MS-CID spectra. Likewise, the MALDI signals are 
long-lived, and a single sample can easily be used for extensive MS/MS-CID experiments. In addition, 
the purity of the sample is of great importance with DNA hydrolysates containing huge amounts of 
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unreacted nucleotides, buffers and enzymes which could hinder the matrix crystallization, the 
reproducibility of the spectra and provoke ion suppression effects to impair the MALDI-MS analysis. 
Samples were therefore subjected to solid phase extraction for purification/enrichment that either 
consisted of silica-based C18, polymer-based styrene/divinylbenzene (SDB) or N-
vinylpyrrolidone/divinylbenzene (hydrophilic-lypophilic balance, HLB) bed materials. While many reports 
described the use of one of these resins alone or in combination for the purification/enrichment of 
PAHDE-DNA adducts25;26;29, the HLB copolymer sorbent proofed valuable enabling increased recovery 
and enhanced loading capacity as compared to other resins. Therefore, we implemented the HLB 
sorbent and developed self-assembled disposable micro columns (HLB-µ-SPE, see experimental 
section) to meet the sample amount and the volume used for MALDI-MS sample preparation. 
As shown in Table S-1 the reaction products of B[a]PDE with the four 2’-deoxynucleosides and the four 
2’-deoxynucleosides-3’-monophosphates purified by HLB-µ-SPE and were measured with a mass 
accuracy of <10 ppm at a resolution of >5000, and a sensitivity of >100 fmol loaded on target.  
The molecular ions ([M+H]+) corresponded to the monoalkylated B[a]PDE adducts of dG, [M+H]+ at m/z 
570; dGp, [M+H]+ at m/z 650; dA, [M+H]+ at m/z 554; dAp, [M+H]+ at m/z 634; dC, [M+H]+ at m/z 530; 
dCp, [M+H]+ at m/z 610. In the reaction mixture with 2’-deoxythymidine (dT) and 2’-deoxythymidine-
3’monophosphate (dTp), no adducts were detected presumably due to low alkylation efficiency. This is 
consistent with previous reports using similar condition but other ionization techniques26. Noteworthy, 
cationazed ([M+Na]+ or [M+K]+) molecular ions were weak or absent, which is a particular advantage for 
the interpretation of spectra. The MALDI-TOF spectra of PAHDE-DNA adducts together with the 
molecular ion ([M+H]+) provide typical mass-signature specific for the alkylating molecule and the 
nucleotide involved in the alkylation reaction. Indeed, next to the [M+H]+, the aglycon fragment ([BH2]+), 
the protonated 2’-deoxynucleoside ([dN+H]+) or the 2’-deoxynucleoside-3’-monophosphate fragments 
([dNp+H]+), the protonated nucleobase ([N+H]+) together with signals of the positively charged B[a]PDE 
triol fragment ([PAH]+) are the observed mass-signature (Figure 1A, B and S-1, S-2). Such fingerprints 
can thus be defined as DNA-adduct mass fingerprint (DMF). Based on the DMF, the [M+H]+ and specific 
ions were selected for MS/MS-CID measurements to obtain definitive structural diagnostic fragment ions 
(Figure 1 C, D and S-3, S-4 ), i.e DNA-adducts fragment fingerprint (DFF). In Scheme 1 the major 
fragment and the fragmentation pathways are depicted. Several different investigations reported the 
detection of the aglycon ion [BH2]+, as major ion product for the characterization of DNA 
adducts28;29;39;40;45;46.The new developed method allowed further fragmentation of this and other DFF 
ions component on the same target spot. Thus, MS/MS-CID fragmentation of the [BH2]+ and the [PAH]+ 
ions were achieved leading to additional diagnostic fragment ions which enabled improved 
characterization. Indeed, fragmentation of the protonated adducted base ([BH2]+) produced [G+H]+ and 
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involves hydrogen transfer from PAH triol. This, would explain the positive charged [PAH]+ fragment. 
Moreover, the fragmentation of the [PAH]+ produced the fragments [PAH-H2O]+, [PAH-H2O-CO]+ and 
[PAH-2H2O-CO]+ which are specific and characteristic of the PAH triol moiety. All together these 
information allow the identity of the PAH and the number and type of ring substituent to be defined. In 
fact, these diagnostic fragments were used to structurally differentiate diastereoisomers of PAH and 
PAH-DNA adducts42;47;48. Therefore, both the DMF and DFF permitted an identification and 
characterization of B[a]PDE adducts formed with the four 2’-deoxynucleosides and the four 2’-
deoxynucleosides 3’-monophosphates (see Figure 1 and S-1-S-4 ). 
Consequently, we applied this methodology for analysis of adducts formed with calf thymus DNA upon 
reaction with B[a]PDE. Based on the full MALDI-TOF mass spectrum, a simple comparison with the 
reference DMF allowed specification of the molecular ion and characteristic fragment ions of the 
B[a]PDE-DNA adducts. Readily molecular ions and characteristic fragment for deoxynucleotides and 
deoxynucleosides were detected. The B[a]PDE-dG at m/z 570, B[a]PDE-dGp at m/z 650 and B[a]PDE-
dA at m/z 554, B[a]PDE-dCp at m/z 610 DNA adducts were the main adducted molecules detected  with 
calf thymus DNA. Notably, the latter adduct could be identified as a dinucleotide component. Some of 
the commercially available SPDEs, used in the DNA hydrolysis, contain 3’-phospatase activity49. This 
may explain why the B[a]PDE-DNA adduct hydrolysates contained both the alkylated nucleotides and 
nucleosides. We exclude the possibility that these PAHDE-2’-deoxynucleosides are fragmentation 
products from the equivalent 3’-monophosphate as we never observed such a fragmentation in MS or 
MS/MS-CID reference spectra. Further adducts were identified as dinucleotide resulting from incomplete 
DNA hydrolysis. i.e. the ions corresponding to the B[a]PDE-dCp-dC and the B[a]PDE-dAp-dC 
dinucleotides. Moreover, the MALDI-MS/MS-CID analysis allowed the specification and characterization 
of the alkylation event as the B[a]PDE-dCp and B[a]PDE-dAp adducts, respectively. In one report and 
next to B[a]PDE-dGp ions at higher m/z were observed. However, the investigators were unable to 
determinate the identity and to characterize further adducts, despite the elaborate SPE enrichment prior 
to CE-coupled ESI-MS25. Incomplete DNA hydrolysis products are probably formed because the 
alkylated nucleotides are not efficiently recognized from MN and/or SPDE due to sterically unfavorable 
interactions of their modified structure. Nonetheless, the efficiency of MN/SPDE enzymatic hydrolysis 
could be improved by a preceding DNA hydrolysis step with DNA-ase I or Benzonase® endonucleases 
which release 5’-phosphate oligonucleotides. Importantly, the digestion protocol used in this study is 
widely used for 32P-postlabeling assay. Noteworthy, cationazed ([M+Na]+ or [M+K]+) molecular ions 
were weak or absent. Thus sufficient cleanup of analytes was achieved. In previous report using 
standard solutions of adducts the cationazed form ions were the base peaks in the spectra rendering an 
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interpretation challenging. In contrast the here reported HLB-µ-SPE purification/enrichment protocol is 
simple and robust. 
We also compare findings obtained by MALDI-MS with the 32P-postlabeling assay. Here, two radioactive 
spot were detected corresponding to B[a]PDE-deoxyguanosine and the B[a]PDE-deoxyadenosine 
adducts. Importantly, dinucleotides which are also substrate of the T4 polynucleotide kinase were not 
detected. Hence, a comparison of the two methodologies clearly demonstrates that only MALDI-MS 
provided molecular specification to characterize the nucleotide and the alkylating agent involved. 
Additionally, the B[a]PDE-dCp adduct was identified by MALDI-MS. Thus, MALDI-MS provided 
comprehensive information such as the detection and identification of deoxynucleotides and 
deoxynicleosides and dinucleotides adducts. That was not detected by the 32P-postlabeling assay.  
The reliability of our MALDI-MS based methodology is further demonstrated by the detection, 
identification and characterization of the adducts derived from reaction of calf thymus DNA with (±)-anti-
benzo[c]chrysene-9,10-diol-11,12-epoxide (B[c]ChDE). The B[c]ChDE, is an intruding PAH since is 
characterized by the presence of a bay and a fjord region within the same molecule (see Scheme 2). 
The location of the epoxide in the sterically-hindered fjord region determines its high carcinogenic 
activity 9. With the 32P-postlabeling assay only three radioactive spot were detected corresponding to 
B[c]ChDE-deoxyguanosine, -deoxyadenosine and deoxycytidine adducts. Applying the newly developed 
method we were able to readily identify a total of six B[c]ChDE-DNA adduct as 2’-nucleosides and 2’-
nucleosides-3’monophosphate: the B[c]ChDE-dG at m/z 596, the B[c]ChDE-dGp at m/z 676, the 
B[c]ChDE-dA at m/z 580, the B[c]ChDE-dAp at m/z 660, the B[c]ChDE-dC at m/z 556 and the 
B[c]ChDE-dCp at m/z 636. In addition, three dinucleotides adducts were also detected: the B[c]ChDE-
dAp-dA, the B[c]ChDE-dAp-dC and the B[c]ChDE-dCp-dC. MS/MS-CID fragmentation confirmed the 
identificaty and allowed the molecular characterization of the nucleotides and nucleosides with 
B[c]ChDE as the alkylating molecule. Again, a comparison of the two methodologies confirm that only 
MALDI-MS led to a comprehensive analysis and provided molecular specification for an identification 
and characterization of the adducts formed. In regard to the sensitivity, B[a]PDE-deoxycytidine was 
detected by the 32P-postlabeling with a RAL of ~3 adduct per 107 deoxynucleotides. Consequently, the 
MALDI-TOF-MS method has at list a similar sensitivity. 
Conclusions  
A rapid MALDI-TOF-MS based method has been developed, and applied for the sensitive detection, 
identification and characterization of prototypic PAH-DNA adducts derived from B[a]PDE and B[c]ChDE 
that were reacted with calf thymus DNA. We evidence that MALDI-TOF and MS/MS-CID spectra yielded 
characteristic fragmentation patterns that allow identification of deoxyguanosine, deoxyadenosine and 
deoxycytidine DNA adducts. The spectra are simple to interpret and there is a notable absence of 
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cationized sample and matrix ions. Overall the method is sensitive, and nanogramms of hydrolyzed 
DNA are sufficient for the identification and characterization of the adducts. When compared with the 
32P-postlabeling assay a distinct advantage of the method is the unambiguous identification of DNA 
adducts and the possibility to identify the chemical nature of the alkylating agent. Moreover, our method 
allowed the simultaneous and unambiguous detection and identification of deoxynucleotide and 
deoxynucleosides PAHDE adducts at the same time. In addition, the analysis time is drastically reduced 
and a dedicated radioactivity laboratory is not required. In the long term, a database of DNA-adducts 
mass fingerprints and fragmentation pattern of reactions products of several different PAH with 
nucleotides and nucleoside will be developed for an automated detection of DNA-adducts. 
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Scheme 1 
 
 
 
 
Scheme 1. Proposed MALDI-MS/MS-CID fragmentation pathway of B[a]PDE-2’-deoxynucleosides and 
B[a]PDE-2’-deoxynucleosides 3’-phosphate. G: guanine, A: adenine; C: cytosine  
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Scheme 2 
 
 
 
 
Scheme 2. Proposed MALDI-MS/MS-CID fragmentation pathway of B[c]ChDE-2’-deoxynucleosides and 
B[c]ChDE-2’-deoxynucleosides 3’-monophosphate. G: guanine, A: adenine; C: cytosine . 
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Figure 1. MALDI-TOF-MS and MS/MS-CID reference spectra of B[a]PDE adducts. 
Typical positive ion MALDI-TOF mass spectra of B[a]PDE-dG (A) and B[a]PDE-dGp (B). [*= 
matrix ions]. Positive ion MALDI-MS/MS-CID mass spectra of the molecular ions [M+H]+: at 
m/z 570 of the B[a]PDE-dG in A (C), at m/z 650 of the B[a]PDE-dGp (D) in B. Positive ion MALDI-
MS/MS-CID reference spectra of specific relevant fragment ions: aglycon [BH2]+ at m/z 454 (E); 
[BH2-H2O]+ at m/z 436 (F) and B[a]PDE triol [PAH]+ at m/z 303 (G) of the B[a]PDE-dG in A. The peak 
annotations are detailed in scheme 1.  
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Figure 2. Analysis of B[a]PDE-DNA adducts by MALDI-MS and the 32P-postlabeling assay. Typical 
positive ion MALDI-TOF mass spectrum of adducts formed upon reaction of B[a]PDE with calf thymus 
DNA (A). α, β and γ are incomplete hydrolysis products (see below). [*= matrix ions]. Typical storage 
phosphor image obtained following two dimensional TLC; 1 indicates B[a]PDE-dG adduct; 2 indicates 
the tentatively assigned B[a]PDE-dA adduct; x denotes the origin (A, inset ).  
Positive ion MALDI-MS/MS-CID mass spectra of the [M+H]+ ions of the DNA adducts present in DNA 
hydrolysate. Product ion spectra of the B[a]PDE-dG adduct at m/z 570 (B) and the B[a]PDE-dA adduct 
at m/z 554 (C) of the hydrolysates in A. The peak annotations are detailed in Scheme 1.  
Positive ion MALDI-MS/MS-CID spectra of incomplete hydrolysis products detected in the B[a]PDE-
DNA hydrolysates labeled β and α in A. Product ion spectra obtained from the molecular ions [M+H]+: at 
m/z 843, identified as B[a]PDE-dAp-dC (D); at m/z 819, identified as B[a]PDE-dCp-dC (E).  
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Figure 3. Analysis of B[c]ChDE-DNA adducts by MALDI-MS and the 32P-postlabeling assay. 
Typical positive ion MALDI-TOF mass spectrum of adducts formed upon reaction of B[c]ChDE with calf 
thymus DNA (A). α , β, γ and δ are incomplete hydrolysis products. [*= matrix ions ]. Typical storage 
phosphor image obtained following two dimensional TLC; 1 indicates B[c]ChDE-dG adduct; 2 indicates 
B[c]ChDE-dA adduct; 3 indicates the tentatively assigned B[a]PDE-dC adduct; x denotes the origin (A, 
inset ). Positive ion MALDI-MS/MS-CID mass spectra of the [M+H]+ ions of DNA adducts present in 
DNA hydrolysate. Product ion spectra of the B[c]ChDE-dG adduct at m/z 596 (B), the B[c]ChDE-dA 
adduct at m/z 580 (C), the B[c]ChDE-dC adduct at m/z 556 (D), the B[c]ChDE-dGp at m/z 676 (E) and 
the B[c]ChDE-dAp adduct at m/z 660 (F) of the hydrolysates in A. Expanded region of B for details of 
the B[c]ChDE triol ion [PAH]+ characteristic mass-signature (B, inset ). The peak annotations are 
detailed in Scheme 2.  
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Figure 4 
 
 
 
 
Figure 4. MALDI-MS/MS-CID spectra of incomplete hydrolysis products detected in of B[c]ChDE-
DNA hydrolysates. Positive ion MALDI-MS/MS-CID mass spectra of the dinucleotides [M+H]+ present 
the DNA hydrolysates labeled δ, γ, β and α in Figure 3A. The [M+H]+ ions: at m/z 893, identified as 
B[c]ChDE-dAp-dA (A); at m/z 884 (B); at m/z 869, identified as B[c]ChDE-dAp-dC (C); at m/z 845, 
identified as B[c]ChDE-dCp-dC (D)  
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Chapter III 
Development of methods for 
phosphoproteins identification and 
phosphorylation site determination 
Reversible protein phosphorylation 
The term “protein post-translational modification” (PTM) describes protein processing by cleavage or 
covalent attachment of chemical groups to a protein. These modifications increase tremendously the 
diversity and heterogeneity of gene products and the way in which they are regulated. Over 300 types of 
modifications are known 239. Protein reversible phosphorylation is one of the most studied cellular 
mechanisms to regulate protein functions. The process was discovered by the pioneering studies 
undertaken by the Nobel Prizwinner Krebs and Fisher to elucidate the complex hormonal regulation of 
skeletal muscle glycogen phosphorylase. They could determine the mechanism by which the inactive 
phosphorylase b was converted to phosphorylase a as the result of an enzyme-catalyzed 
phosphorylation-dephosphorylation reaction 240,241.  
Reversible protein phosphorylation is a ubiquitous mechanism for the control of signal transduction 
networks that regulate diverse biological processes including response to extracellular stimuli, DNA 
damage and cell growth and division. Changes in protein phosphorylation affect the structure and 
activity of proteins regulating nearly all aspects of cell life including metabolic processes, DNA 
replication, gene expression, and the cell cycle. The phosphorylation statuses of proteins in a cell is 
controlled and modulated in a highly dynamic way by two different classes of enzymes: protein kinases 
which catalyze the transfer of phosphoryl groups from a high-energy compound to a nucleophilic 
acceptor on an amino acid side-chain of proteins, and protein phosphatases which catalyze water-
driven hydrolysis of phosphoester bonds (Figure 16). The importance of these two classes of enzymes 
is also supported by their high number of genes in the genome, constituting approximately 2% of the 
proteins encoded by the human genome 242,243.  
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Figure 16. Protein phosphorylation is triggered by a stimulus inside or outside the cell. The protein kinase enzyme 
transfers the phospho-group from adenosine triphosphate (ADP+P =ATP) to the protein. Attaching the phospho-
group to the protein will change its conformation and thus changes its activity. A protein phosphatase de-
phosphorylates the protein and reversing its conformation. 
 
It was estimated that the human genome codes for more than 500 protein kinases, the third most 
populous gene family, and 100 phosphatases 244. The activities of protein kinases and phosphatases 
are subject to control both by extracellular stimuli and intracellular mechanisms and the molecular basis 
of this control is complex and varied.  
Four types of phosphorylation are known which affect different amino acids. Indeed, the O-phosphates 
(O-phosphomonoesters) are formed by phosphorylation of hydroxyamino acids such as serine (S), 
threonine (T) and tyrosine (Y), residues. The N-, S- and acyl-phosphorylation are far less widespread 
and occur mostly on histidine and lysine (N-phosphates, phosphoamidates), cysteine (S-
phosphothioesters) and aspartic and glutamic acid residues (acyl-phosphates, phosphate anhydrides). 
The predominant class of proteins phosphorylation in mammalian cells are O-phosphates which occur 
on Y, T and S residues with an estimated relative abundances of 1.8%, 11.8%, and 86.4%, respectively 
245. Moreover, there is a higher gain in signals involving tyrosine phosphorylation because it is less 
abundant and more tightly regulated 246.  
Protein (de)phosphorylation can change the protein’s enzyme activity, the cellular location, increase 
protein–protein interactions and target proteins for degradation, all of which induce cascade 
amplification variances of many essential cell processes such as signal transduction, cell differentiation, 
proliferation, metabolic maintenance, cell division, and apoptosis. Whereupon, regulation changes of the 
tightly controlled balance between phosphorylation and de-phosphorylation may lead to serious 
pathological conditions. Abnormalities in this complex (de)phosphorylation process have been shown to 
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be related to many diseases and cancer 21,32,247. Therefore, identifying phosphorylation sites related to 
diseases might help to understand the origin, progression and hopefully the termination of these 
diseases. In addition, the protein kinases activity, regulated through phosphorylation in turn, plays a 
important role in cancer and it has been well described to be involved in development of malignancies 
32-34. The analysis of the entire cellular phosphoprotein panel, the so-called phosphoproteome, the 
understanding of regulatory roles and where and when protein phosphorylation takes place has become 
of pivotal importance in tissue injury and in particular in cancer studies. Knowledge of these molecular 
details will provide a framework for the development of novel therapies for the early detection and 
treatment of cancer. Because of this, there is considerable interest on developing methodologies to 
identify phosphorylated proteins and characterize its phosphorylation state in the contest of 
tissues/organ systems.  
Protein phosphorylation analysis 
Despite a growing knowledge of many phosphorylation consensus sequences, it is possible to predict 
whether a site could be substrate for a kinase but we cannot predict when a site will be phosphorylated. 
Thus, the experimental determination of sites of phosphorylation is an important task. The human 
proteome contains more than 100,000 phosphorylation sites 248,249. It is estimated that one out of every 
three proteins is phosphorylated at some point in its life cycle 250. Notably, phosphorylation leads to 
heterogeneity. Most phosphoproteins undergo phosphorylation on more than one residue, which means 
that all the molecules of a given protein are not identically phosphorylated. Another characteristic of 
phosphorylation is the ratio of phosphorylated to non-phosphorylated protein present in the cell 251. 
Some protein residues may be always quantitatively phosphorylated, while others may only be 
transiently phosphorylated. The abundance of phosphorylated forms of a protein can be as low as 1-2% 
of the total amount of that protein 252. Phosphorylation is highly dynamic and intensely regulated, and 
phosphorylation cycles may take place on a very short timescale. Therefore, the complexity of 
phosphorylation in terms of regulation, dynamics, abundance and stoichiometry render the analysis of 
phosphoproteins and the resulting phosphopeptides difficult. Various strategies for protein 
phosphorylation detection have been developed throughout the years. The combination of more 
different methods could lead to very articulated strategies. D’ Ambrosio and colleagues 253 recently 
presented a survey of the different strategies for phosphoprotein enrichment which are summarized by 
the diagram in Figure 17. After sample pre-treatment to freeze the phosphorylation state of the proteins, 
detection of the phosphoprotein usually is the first step towards an identification. Consequently, sample 
purification/enrichment has become an essential step for the characterization of protein phosphorylation 
events, as it offers a reduction in complexity of the sample. Eventually, the phosphorylation sites are 
identified and characterized by Edman degradation or MS-based methods.  
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Figure 17. Different techniques for the enrichment and analysis of phosphorlylated proteins based on MS 
procedures. From ref. 253. 
 
Some of the most commonly used purification, identification and characterization methods are 
discussed below. At the end of each section the contributions which this doctoral thesis has brought in 
the field are described. 
Phosphorylated protein detection and identification 
Phosphoprotein sample treatment 
Tissue/Cell lysis frees all the phosphatases and the proteases from normal cellular regulation, thus 
affecting quickly and substantially the phosphoproteins stoichiometry and number. The phosphatases 
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dephosphorylate and proteases digest low copy number signaling proteins. Therefore, an essential part 
of sample preparation for phosphoprotein analysis from intact tissue/cells is to freeze the 
phosphorylation state of protein in the sample. This can be achieved by inhibiting the enzymatic activity 
of phosphatases, kinases and proteases after cell lysis. By far the most common means of inhibiting 
phosphatases in phosphoproteomic studies is through the use of commercially available inhibitors. 
While vanadium oxides such as pervanadate and orthovanadate are used to inhibit all protein tyrosine 
phosphatases (PTPs). The three most common serine/threonine phosphatases family, protein 
phosphatase 1 (PP1), PP2A and PP2B are efficiently inhibited by calyculin A (for PP1 and PP2A) and 
deltamethrin (PP2B) 254. Therefore, inadvertent activities can be inhibited by adding commercial 
available “cocktail“of phosphatase, kinase and protease inhibitors which could lead to increase up to 
40% the number of phosphoproteins identified 255. Moreover, microwaves 256 and rapid heating 257 of 
samples have been also used for inactivating kinases and phosphatases. 
Radioactive Labeling of Phosphoproteins 
The radioactive labeling of phosphorylated proteins with 32P has been for a long time the method of 
choice to study protein phosphorylation due to its sensitivity and selectivity. Usually, for in-vivo labeling 
the 32P ortho-phosphate can be added to a cell culture, the endogenous kinases of the cells will 
incorporate radioactive phosphate groups in the phosphoproteins. Alternatively, in vitro labeling 
experiments are performed by applying radioactive γ-ATP using with specific kinase(s) that incorporate 
the radioactive phosphate to its specific amino acid and/or substrates. These procedures are followed 
by the extraction and electrophoretic separation (SDS-PAGE) or (2-DE) of proteins. The detection of 
phosphorylation is then performed using scintillation counting, by autoradiography or PhosphorImager 
systems 258. The 32P-labeling used not only to detect phosphorylation but also to identify the peptide and 
ultimately the phosphorylated amino acid. This can be achieved by Edman sequencing and/or by mass 
spectrometry 259,260. Even though 32P-labeling is still the most sensitive approach for the detection of 
phosphorylation it has several drawbacks. Firstly, 32P is a radioactive compound must be handled in 
restricted dedicated laboratory under controlled and stringent safety rules. Secondly, the incorporation 
of radioactive phosphorus may considerably alter the in vivo state of the cells as shown in comparative 
studies 261. Noteworthy, the radioactive labeling can not be applied to in-vivo studies of phosphoproteins 
in tissues.  
Direct Staining of Phosphoprotein 
Fluorescent-based dye systems, which selectively stain phosphorylated proteins and peptides 
independently of the kind of phosphorylated residues has been recently introduced 262-264. These dyes 
rely on the recognition principle of inorganic phosphate receptors developed by chemists 265,266. The 
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structure of the commercially available Pro-Q stain (Molecular Probes) is a proprietary patents but it is 
likely to be similar to the published structures. These dyes allow detection of phosphorylated proteins 
and the subsequent visualization of the total protein content (i.e. by coomassie staining) in the same gel. 
In addition, these stains are compatible with enzymatic in-gel digestion and MS 267. However, the 
sensitivity of staining depends on the number of phosphorylated residues present in the protein. About 
16 ng for pepsin (1 phosphorylated residue) and 2 ng for alpha-casein (8 phosphorylated residues) were 
the detection limits 268. Although it is quite sensitive, it is not sufficient for comprehensive analysis of the 
phosphoproteome. Additional disadvantages are the failure to differentiate between the three 
phosphorylated residues and the lower sensitivity when compared to 32P-labeling and antibody based 
approaches. Moreover, it should be noted that O-sulfonation can also contribute to the staining, albeit 
apparently to a lesser extent 263. 
Detection of Phosphoproteins Employing Phosphatases 
Phosphatase treatment on phosphorylated proteins results in hydrolysis of phosphate groups, which 
changes the net charge and molecular weight of the proteins. Consequently, phosphatase treatment 
changes the migration behavior of phosphorylated proteins during electrophoretic separation (such as 
SDS-PAGE or 2-DE). These changes have been exploited to discriminate phosphorylated from 
unphosphorylated proteins. The starting sample is divided in two aliquots, one of which is treated with 
phosphatase. Subsequently, both aliquots are 2-DE separated and the proteins properly stained. 
Phosphorylated proteins are consequently detected by comparison of the 2-DE protein patterns, 
exploiting the shift to more basic position in the gel due to loss of phosphate groups. Thus, detected 
phosphoproteins are identified by MS. The specific enzymatic activity of λ-phosphatase (λ-PPase), 
combined with the high resolution power of 2-DE and MS has led to the identification of some novel 
phosphoproteins in cultured rat fibroblasts 269. Some drawbacks of this technique are that the 
recognition by comparison of phosphorylated/dephosphorylated forms in complex 2-DE patterns is very 
difficult and could lead to misinterpretations, due to the high level of complexity generated. The method 
can not distinguish where and which kind of residues are the sites of phosphorylation in the protein. In 
fact, phosphatase treatment is used as general proof of phosphorylation 267. In addition, phosphatases 
are inhibited by orthovanadate and other component used to maintain the integrity of phosphorylation 
used in sample preparation. Finally, large amount of sample are required (one analysis before and one 
after phosphatase treatment).  
Edman Sequencing 
The development of this technique by Pehr Edman in which the amino acid sequence of a protein could 
be elucidated led to a breakthrough in biotechnology. Edman sequencing relies on the sequential 
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degradation of the amino acids at the N-terminus of a polypeptide chain, which is coupled to a solid 
phase. Under mildly alkaline conditions the Phenylisothiocyanate (PTC) is reacted with N-terminal 
amino group of the coupled peptide. Then, under acidic conditions, the phenylthiocarbamoyl derivative 
formed is cleaved as a thiazolinone derivative, selectively extracted into an organic solvent and treated 
with acid to form the more stable phenylthiohydantoin (PTH) amino acid derivative. The resulting amino 
acid derivatives are analysed using HPLC and the procedure repeated again. Thus, stepwise 
sequenced by comparing the elution profile of each the sample with standard amino acid derivatives 
each rum. If a phosphopeptide sample is marked with 32P, phosphorylation site pinpointing can be 
achieved by concomitant measurement of 32P activity. The major drawbacks are that no more than the 
first 10-15 residues of the peptides can be sequenced and the proteins have to be purified in advance. 
Most importantly, each single sequence need several hours, therefore, this technique can not be 
implemented in high throughput analysis. 
Antibodies and specific domain capture molecules  
Antibodies directed against phosphor-serine, -threonine, and -tyrosine have been used to generally 
enrich for proteins phosphorylated at the respective residues in immunoprecipitation experiments. It 
should be noted that the ability of global antibodies directed against phoshorylated resdiues is not 
always related to the similar efficiency in precipitate phosphorylated proteins 270. This might be due to 
the better accessibility of the phosphate group located on tyrosine or because of the lower complexity of 
the structural nature of the threonine and serine antigens compared to tyrosine. In addition, antibodies 
remaining in the sample can complicate downstream analysis 271,272.  
Following phosphorylation site identification, specific antibodies can be exploited for a more focused 
approach. Indeed, antibodies directed against regions surrounding a phosphorylated residue, are 
usually quite selective and can be effectively be used to enrich for a phosphoprotein of interest. The 
major drawbacks of this approach are that the exact residue has to be known and that the generation of 
these antibodies is expensive and time consuming. 
In addition to antibodies there are several different protein specific domains which are capable of 
binding phosphorylated proteins and peptides. While SH2 (Src Homology 2) and PTB (phosphotyrosine 
binding) domains recognize predominantly tyrosine phosphorylation, 14-3-3 proteins as well as WW 
domains bind to proteins phosphorylated on serine and threonine, and FHA (forkhead associated) 
domains show a preference towards threonine phosphorylation 273-275. In principle all of these domains 
or the respective proteins can be used for the enrichment of different sorts of phosphorylated peptides. 
Moreover, immobilized 14-3-3 proteins have been used for the purification of serine/threonine 
phosphorylated proteins 276,277. As described, each of these domains/proteins only recognizes a subset 
of the total pool of phosphorylated proteins and experimental setups relying on these domains are 
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therefore not as widely applicable as methods relying on more general affinity mechanisms. However, a 
combination of a more general affinity chromatography followed by different more restrictive approaches 
could however, further facilitate the analysis of the phosphoproteome. 
Prediction programs and Phosphoprotein databases 
As the last years have seen an exponential increase in the number of identified phosphorylation sites, 
several groups have expended enormous efforts to curate and compile these data into on-line 
resources. Much of the high quality data, including some high-content data, are curated in UniProt 278, 
which is probably the best way to make the data available to the wider biological community. In addition, 
more specific compendiums are available and each provides specific types of tools (e.g., predictors, 
network/pathway viewers) and/or information (e.g., analytical context in which peptides were identified, 
quantitative profiles of phosphorylation dynamics after agonist stimulation). There are several 
phosphorylation site prediction programs available, which rely on different algorithms to elucidate the 
probability of phosphorylation on specific amino acids for any given protein. Some of these are 
implemented to search for motifs within proteins that are likely to be phosphorylated by specific Ser/Thr- 
or Tyr-kinases protein kinases or bind to specific domains. The NetPhos 2.0 server 
(http://www.cbs.dtu.dk/services/NetPhos/) 279 and the Scansite 2.0 (http://scansite.mit.edu) 280 belong to 
this predictors. However, because of the enormous complexity of the cellular proteome, prediction 
programs could lead to false positive results and their output has to be handled with care.  
Also, several databases have been constructed, which contain data on experimentally verified 
phosphorylation sites. The PhosphoSitePlus® (PSP) (http://www.phosphosite.org/) 281, the Phosida 282 
and Phospho.ELM 9.0 (http://phospho.elm.eu.org/) 283 contain information from literature experimental 
and manually cured data not only on phosphorylation but also on other protein PTMs. As all these 
databases are growing they are becoming more and more useful for the researcher and they will 
probably play an important role in the future for serving as encyclopaedias of phosphorylation sites and 
for the development of more sophisticated prediction programs. 
A 2-DE and western blotting based approach to detect and 
identify phosphoproteins in tissue extracts (Publication III) 
In recent years antibodies that selectively recognize phosphorylated protein residues have become 
available 270,284-286, making the use of antibodies a versatile and comprehensive strategy for the analysis 
of the protein phosphorylation. Unfortunately, some of these antibodies efficiently recognize 
phosphorylated proteins in western-blot applications but were ineffective to precipitate phosphoproteins 
270. 
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Despite considerable effort to develop new separation methods for proteomics studies, 2-DE, introduced 
more than 25 years ago, remains one of the most efficient technique for separating the thousands of 
proteins expressed in a eukaryotic cell 287 including protein variants produced by the co- or post-
translational processing 288,289. Furthermore, in combination with MALDI-MS is commonly and efficiently 
used for large scale protein analysis and for proteome and phosphoproteome studies. 
Here, a rapid and simple strategy to identify phosphorylated proteins in the contest of a tissue was 
developed. For this purpose, the lung phosphoproteome profiles of C57BL6 mouse strain was analyzed 
using several well characterized specific monoclonal antibodies (MAb) which recognize 
phosphoproteins. For the detection of serine phosphorylated proteins a set of 5 different anti-
phoshoserine (pSset) and the MPM-2 MAbs were used. Moreover, a set of 4 different monoclonal anti-
phoshotyrosine (pYset) and the 4G10 MAbs were used for the detection of tyrosine phosphorylated 
proteins. Notably, to screening for and to identify phosphorylated lung proteins a combination of five 
different techniques and technologies were employed (Figure 18) : (1) 2-DE, (2) 2-DE-western blotting 
with antibodies anti-phosphorylated proteins; (3) computer assisted image analysis and processing; (4) 
MALDI-TOF Tandem mass spectrometry (MS) with automated spectra acquisition and analysis. 
Therefore, 250 µg of tissue lysate proteins were separated on 2-DE and stained with Colloidal 
Coomassie G-250 and the gel image was acquired (2-DE-cCBB). In parallel, 40 µg of total protein 
extract were separated by 2-DE and subsequently transferred onto PVDF membrane for incubation with 
antibodies directed against phosphorylated proteins and developed (pAb). With a marker pen, 
landmarks points (Crosses in Figure) were set around the membranes and the image of phosphorylated 
proteins acquired (WB-pAb). Subsequently, the total proteins on the same membrane were revealed by 
cCCB-post staining and the image recorded (WB-CBB). Using the added landmark points, these two 
images were superimposed and combined by the image analysis software to create a virtual image 
showing the phosphoproteins and the total proteins together (WB-virtual). Several protein spots from 
this image, which are in common with the cCBB-2-DE image, were selected and as additional 
landmarks used to superimpose the WB-CCB image to the 2-DE-cCBB image to decipher 
phosphorylated proteins on the gel. The highlighted protein spots were then excised from the gel using 
spot cutter, subjected to in-gel digestion using trypsin, and the proteins identified using MALDI-TOF-
MS/MS. Moreover, to increase the sequence coverage and for a more comprehensive analysis, the 
trypsin digested protein spots were analyzed using two sample preparations: the CHCA thin layer (TL) 
and DHB matrix layer (ML), while MS/MS data were used to reliable confirm identified proteins.  
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Figure 18. Schematic representation of the combined 2-DE-westr blotting approach. 
 
With this approach 160 unique proteins were identified. The identified putative phosphoproteins were 
additionally characterized using bioinformatics which allowed the assignment of number and position of 
potential phosphorylation sites, the search for kinases and phosphorylation-dependent binding motifs, 
and the classification of the phosphoproteins with respect to their Gene Ontology (GO) annotations. In 
addition, database searches were used to provide the exact position of the known phosphorylated sites 
on the based on the available literature. Thus, out of 160 proteins analyzed 106 (66.2%) are already 
validated phosphoproteins based on the available literature, 26 proteins (16.2%) were predicted in 
mouse but validated as phosphoproteins either in human or in rat and 30 (18.8%) are only predicted to 
be phosphorylated and to enharbour a kinase docking domain. The MAbs used demonstrated different 
specificity in the recognition of phosphorylated proteins. Thus, by the combination of several anti 
phopsphoprotein MAb with different specificity a more comprehensive characterization of 
phosphoproteins is achieved. Moreover, broaden cellular distribution and molecular function retrieved 
from the functional annotation for the identified proteins, provides further evidence of the versatile 
character of the developed assay.  
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Protein Phosphorylation site determination 
Phosphopeptide Enrichment 
Phosphopeptide enrichment is still a necessary step for most phosphoproteins due to suppression 
effects from the large amount of non-phosphopeptides. In a large scale phosphorylation studies, the 
general strategy relied on the use of direct phosphopeptide enrichment methods after trypsin digestion 
of the proteins. In this case, intermediate phosphoprotein enrichments are avoided. However, most 
strategies applied to phosphoprotein enrichment can apply to phosphopeptide enrichment as well. Much 
more effort has been put into phosphopeptide enrichment method improvement and innovation, some of 
the most popular methods will be covered herein. 
Chemical derivatization methods  
Two main approaches have been presented that make use of chemical derivatization strategies for the 
enrichment of phosphorylated proteins and peptides. One method consists in β-elimination and Michael 
addition chemistry where a nucleophile which is suitable for selective enrichment is used to replace the 
phosphate group of phosphorylated amino acid. However, this method can only be applied to p-Ser/p-
Thr residues, because p-Tyr does not undergo β-elimination. 290-293. In addition, unwanted side reactions 
which can lead replacement of O-glycosides, sulfonated residues as well as hydroxyl groups on serine 
and threonine are the limitations of this approach 294.  
The alternative is a strategy involving temporary carbodiimide coupling of the phosphate residues of p-
Ser/p-Thre/p-Tyr to a solid phase, followed by washing steps to remove nonphosphorylated species 
295,296. This strategy has the distinct advantage of including phosphotyrosine in the analysis and that no 
side reactions are reported so far. Unfortunately, it involves several modification steps which increase 
the likelihood of sample loss.  
Immobilized metal affinity chromatography (IMAC) 
Immobilised Metal Affinity Chromatography (IMAC) is the most widely method used for phosphopeptide 
enrichment. This technique was initially developed by Porath et al. 297 for purification of His-tagged 
proteins. The method is based on electrostatic interactions of a negatively charged amino acid residue 
to a positively charged metal that is immobilized on a metal chelator matrix such as iminodiacetic acid 
(IDA), nitriloacetic acid (NTA) or Tris-(carboxymethyl)-ethylendiamine (TED) chelators. Since a 
phosphate group has a stronger net negative charge than any other amino acid residue, phosphorylated 
proteins/peptides are better retained on the matrix than their nonphosphorylated counterparts 294. Iron 
and gallium are the used metals for the enrichment of phosphorylated species 298,299. Despite the wide 
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application, the major disadvantage of IMAC based methods is a strong non-specific interaction with 
other negative groups such as side chain carboxylic acids from aspartate and glutamate residues 300,301. 
To circumvent the unspecific binding, peptides can be methylesterified using HCl-saturated, dried 
methanol to convert glutamic and aspartic acid residues into their non-charged methyl esters 302. 
Unfortunately, the harsh conditions used (pH 0-1) leading to side reactions such as deamination of 
glutamines and asparagines 303. Moreover, incomplete esterification and site reaction render 
methylesterification especially unsuitable for complex protein mixtures in large scale phosphoproteome-
wide analysis.  
Metal Oxide Affinity Chromatography (MOAC) with titania and 
zirconia 
Recently, it was shown that metal oxides can also be used for the enrichment of phosphorylated 
peptides. In these studies affinity chromatography based on titania (titanium dioxide) 304,305 or zirconia 
(zirconium oxide) 306 was used. Online coupling of a titania pre-column and an anion exchange or 
reversed phase column in an HPLC setup has been shown to be useful in the selective analysis of 
phosphorylated peptides derived from proteolytic digests. Identification of the phosphopeptides was 
achieved by monitoring the UV 307 trace or by using a mass spectrometer 308. Similarly, Fe3O4/TiO2 
core shell particles were used to specifically isolate and detect phosphopeptides 308. Unspecific binding, 
which is also reported when using titania, can be reduced by methylesterification 308,309 and the use of 
appropriate incubation buffers [132]. However, the use of a special incubation buffer is preferable 
because of the side reactions occurring during methylesterification.  
Phosphopeptide identification 
Molecular Mass Shift and Phosphatase Treatment 
With the molecular mass shift method, spectra of the protein tryptic digest were acquired, usually with 
MALDI-TOF-MS, and then the peptides mass detected values were compared with theoretically 
expected values. A molecular mass shift by single or multiples of +80 Da (HPO3 = 80 Da) indicates a 
phosphopeptide 310. Unfortunately, this method has many drawbacks. First: can be applied only to single 
protein analysis. Second: it is difficult to obtain MS signal of all the peptides of a protein the tryptic 
digest. Third: detection of phosphopeptides is worse because of the usual low stoichiometry and weak 
ionization of phosphopeptides as well as signal suppression from non-phosphopeptides.  
The use phosphatases combined with MALDI-TOF-MS has been an improvement of this method. 
Indeed, by comparing spectra of protein tryptic digests with and without phosphatase treatment, a 
characterisitic shift of one multiple of -80 Da in molecular mass indicates phosphopeptides due to the 
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cleavage of HPO3 from the phosphopeptides by phosphatases 311. Although this approach can be more 
widely applied, it suffers of the drawbacks related to the decreased MS ionization and low stoichiometry 
of phosphopeptides. 
Phosphopeptide fragmentation by tandem mass spectrometry 
As discussed earlier (chapter I), peptide fragmentation occurs through charge directed dissociation, 
where the amide nitrogen becomes protonated and thus weakens the amide bond making the 
fragmentation of the peptide possible. In addition, depending on the instrument type used there is a 
variety of different fragmentation signatures typical for phosphopeptides, which can be used for the 
detection of phosphorylation and/or for the determination of phosphorylation sites. Every fragmentation 
technique leads to different fragmentation patterns, some of them leaving the phosphorylation intact, 
while others evoke the detachment of the phosphate group during the fragmentation process (see 
introduction/tandem MS). 
However, the bond between the peptide and the phospho-group is labile which makes it favorable for 
fragmentation. Therefore, phospho-group detaches from the peptide easily generating an intense 
neutral loss ion of 98 Da or 80 Da lower than the measured peptide. These neutral losses represents 
the losses of H3PO4 (98 Da) and HPO3 (80Da). The loss of 98 Da is observed from the pSer and pThr 
where as the loss of 80 Da is mostly observed from pTyr (and to some extent from pSer and pThr) 312. 
Different mechanisms for neutral loss from pSer and pThr have been proposed 312,313 differing in the 
model for removal of the hydrogen by the departing phosphate group. The charge-remote loss of H3PO4 
(98 Da), know as β-elimination, suggests that the hydrogen originates from the α-carbon 312, whereas 
the charge-directed loss theory proposes that the hydrogen is the mobile proton 314. Notably, a neutral 
loss from pTyr produces the loss of HPO3 (80 Da) 312. The H3PO4 cannot be lost since the bond 
between the carbon in aromatic ring and the oxygen in the phospho-group is stronger than the 
corresponding bond in pSer and pThr due to stabilization by the aromatic ring. The bond in the 
phosphogroup between oxygen and phosphate is weaker so the loss of HPO3 occurs instead of H3PO4 
315. These characteristic fragmentations were exploited using a number of tandem MS methods for the 
detection and characterization of phosphorylated peptides 60,316-319. In particular, Steen et al. 320 
developed a MS/MS precursor ion scan method for detection of Tyr phosphorylated peptides where they 
used immonium ion of pTyr. In this method the MS instrument is set to scan 216.043 m/z (immonium ion 
of tyrosine, 136 Da and phosphogroup, 80 Da = 216 Da) which has been reported to be a characteristic 
fragment ion for pTyr containing peptides. 
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Identification and characterization of phosphopeptides by 
MALDI-TOF/TOF MS (Publication III) 
Most phosphoproteome studies are based on optimized in-vitro cell culture studies. In order to identify 
de novo phosphoproteins in tissue extracts a new method based on MALDI-TOF MS/MS was 
developed. Indeed, using DHB ML as sample preparation in combination with MOAC-TiO2 enrichment 
the peptide phosporylation sites were identified and characterized. 
For a molecular characterization of the phosphorylation sites, fifty micrograms of lung extracted proteins 
were separated by SDS-PAGE and the gel cut in 15 regions. The phosphpeptides of the digested 
proteins from each region were enriched using a specific developed disposable micro-column and 
protocol based on MOAC-TiO2 (µ-MOAC-TiO2). Eventually, the enriched samples were analyzed by 
MALDI-TOF-MS and each peptide signal present in the MS spectrum was subjected to MS/MS 
fragmentation. It should be noted that the DHB ML delivered an improved homogeneity of the sample 
preparation when the matrix is “doped” with diammonium hydrogen phosphate. Notably, the yielded 
spectra contained the characteristic neutral loss of ions at -98 and -80 from the molecular ion as result 
of β-elimination of H3PO4. Moreover, the high quality of spectra enabled detection of copious signal from 
the peptide back bone (y- and b- series) leading to an unambiguously characterization of the 
phosphorylation site(s) and in some cases even close to the complete peptide sequence. In addition, 
peptide ions of masses of > 2000 Da were detected to yield highly informative and structurally relevant 
fragment ions. Therefore, with this approach 17 proteins of and 19 phosphorylated peptides were 
identified and characterized by MALDI-TOF-MS/MS.  
While TiO2 have been widely described for the efficient enrichment of phosphorylated peptides 321 none 
of the presented works demonstrated the implementation with MALDI-TOF tandem MS for the specific 
characterization of phosphorylation sites. The ML sample preparation in combination with µ-MOAC-TiO2 
enrichment allows the successful fragmentation and characterization of novel phosphorylation sites. 
Indeed, the fragmentation pattern of the peptide at 1526.60 m/z (Figure 19) was identified as the peptide 
R.KAPESQEDEEER.A of the advanced glycosylation end product-specific receptor protein 
(RAGE_MOUSE). The fragmentation pattern allows not only an unambiguous identification of the 
peptide through the detection of the full y- and b- ion series but the presence of specific fragment such 
as characteristic neutral loss and internal fragment ions lead to determine the Ser 377 as the site of 
phosphorylation. Noteworthy, this protein is described as phosphorylated on threonine 271 but not as 
phosphorylated on serine (377) in mouse lung. 
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Figure 19. MALDI-TOF MS/MS of phosphopeptides.  
The efficient fragmentation of phosphorylated peptide by MALDI-TOF-MS/MS lead to characterization of Ser 377 as a 
novel phosphorylation site of RAGE_MOUSE protein.   
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ABSTRACT 
Reversible protein phosphorylation is an essential mechanism in the regulation of diverse biological 
process, but is frequently altered in disease. Furthermore, in order to identify de novo phosphoproteins 
in tissue extracts new methods are in need as most phosphoproteome studies are based on optimized 
in-vitro cell culture studies. Here, we describe a rapid and reliable method for the detection of 
phosphoproteins in tissue extract based on an immunoblotting strategy that recognize phosphorylated 
proteins in 2-DE and subsequent identification by MALDI-TOF-MS/MS. This method was applied to lung 
tissue of mice and resulted in an identification of 160 unique phosphoproteins. Notably, after TiO2 
enrichment of pulmonary protein extracts 17 additional phosphoproteins and 20 phosphorylation sites 
could be characterized. By use of this method, we report an identification of a phosphorylation site of an 
advanced glycosylation end product-specific receptor. So far this protein was unknown to be 
phosphorylated in lung tissue of mice. Overall the developed methodology allowed efficient and rapid 
screening of phosphorylated proteins and can be employed as a general experimental strategy for an 
identification of phosphoproteins of tissue extracts. 
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Introduction 
Reversible protein phosphorylation is a major cellular mechanism in the regulation of protein function 
but such post-translational modifications are accomplished by the activities of protein kinases and 
reversed by phosphatases in a highly dynamic manner. It was estimated that the mammalian genome 
codes for more than 500 protein kinases and the proteome contains more than 100 000 phosphorylation 
sites 1. The predominant class of protein phosphorylation in eukaryotic cells are O-phosphates and 
modifications occur on serine (S), threonine (T) and tyrosine (Y) residues, with an estimated relative 
abundances of 86.4% 11.8% and 1.8%, respectively 2. Notably, phosphorylation may change activity of 
proteins to cause translocation, protein–protein interactions or to target proteins for degradation, thereby 
modulating cellular processes such as signal transduction, cell differentiation, proliferation, metabolic 
maintenance, cell division, as well as programmed cell death 3. It is well established that perturbations 
of the tightly controlled balance between phosphorylation and de-phosphorylation is associated with 
numerous pathological conditions and thus are the subject of targeted therapies, most notably in the 
treatment of cancers where hyperactivity of protein kinases is frequently observed 4-7. To this effect it is 
highly desirable to study an entire phosphoproteome, the low abundance of phosphoproteins and the 
stoichiometry of protein phosphorylation, however, hinder routine phosphoproteome investigations. 
There is therefore considerable interest in the development of facile methodologies to identify 
phosphorylated proteins and to asses the phosphorylation state in tissues and organs, but such studies 
remain demanding and challenging. Indeed, studies with tissues and particularly those of low organ 
weight, such as lung are complicated by the limited availability of biological material. Consequently, only 
a small number of investigations report the pulmonary proteome and are primarily based on studies with 
cell lines 8-10 or nasal/bronchoalveolar lavage 11-13. Importantly, in biomedical research mouse models of 
disease are frequently employed in the study of molecular mechanisms, yet the mapping of 
components, regulatory events and substrates in signaling pathways, remain a challenge. Furthermore, 
research on phosphoproteins benefitted from the availability of antibodies that selectively recognize 
phosphorylated amino acid residues 14-17, thus enabling a more broad search of phosphoproteins 18 but 
some may proof to be ineffective in the precipitation of phosphoproteins 14. In this regard, a variety of 
experimental strategy for the enrichment and detection of phosphorylated proteins have been 
developed. Nonetheless, none of these approach can be regarded as fit for all-proposes with the 
mapping and characterization of phosphoproteins requiring a combination of different methods and 
experimental strategies 19. Specifically, Metal oxide affinity chromatography (MOAC) with titanium 
dioxide (TiO2) has been proposed for the selective enrichment of phosphopeptides prior to MS 20;21. This 
technique is based on the selective interaction of phosphopeptides with porous TiO2 microspheres 
(titanspheres) via bidentate binding at the TiO2 surface and is employed in combination with. MALDI-MS 
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for the detection of phosphopetides, Nonetheless, the characterization of de novo identified 
phosphoproteins is generally persued by HPLC coupled to ESI-MS/MS.  
Finally, despite considerable advancement in the separation of complex protein mixtures, two-
dimensional electrophoresis (2-DE), introduced more than 25 years ago, remains an efficient technique 
for the study of thousands of proteins expressed in eukaryotic cells 22 including protein variants 
produced by pre-and post-translational processing 23;24. Indeed, protocols have been developed to 
combine 2-DE with MALDI-MS for proteome and phosphoproteome mapping studies. 
Here we describe a rapid and simple assay to identify phosphorylated proteins from tissues and report 
the lung phosphoproteome of the C57BL6 mouse strain. The procedure involves separation of protein 
extracts by 2-DE and Western immunoblotting (WB). Subsequently, proteins are identified by MALDI-
TOF-MS/MS. Furthermore, lung proteins extracts are separated by SDS-PAGE and after in-gel 
digestion phosphopeptides are enriched with TiO2-MOAC micro columns,  whereas, the phosphorylation 
sites are characterized by MALDI-TOF-MS/MS. The identified phosphoprotein candidates are further 
characterized by bioinformatics. This allowes the assignment of number and position of potential 
phosphorylation sites, the search for kinases and phosphorylation-dependent binding motifs, and the 
classification of the phosphoproteins with respect to their Gene Ontology (GO) annotations. Finally, in 
depth database searches provide information on the exact position of known phosphorylated sites. 
Overall, we demonstrate that 2-DE Western immunoblotting combined with MALDI-TOF-MS can be 
efficiently used to search for novel phosphorylated proteins. As an example we report the  
characterization of a phosphorylation site of the advanced glycosylation end product-specific receptor, 
which so far was not reported as a phosphorylated protein in mouse lung tissue. 
Material and methods 
Animal care 
The C57BL/6 mice were maintained under specific pathogen free conditions. Mice were anesthetized 
with CO2 and sacrificed. After surgical removal the lung was washed with PBS containing protease and 
phosphatases inhibitors until free of blood. A total of n= 6 animals were studied. Further details are 
given in the SI 
Materials  
The α-cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxybenzoic acid (DHB) and MALDI pre-
structured sample support (AnchorChip™ 384/600) were from Bruker Daltonics (Bremen, Germany). 
Sequencing grade modified trypsin was from Promega Co. (Madison, WI). Protease inhibitor kit III and 
Phosphatase inhibitor kit II were purchased from Merck (Darmstadt, Germany). The 4G10 and MPM-2 
monoclonal antibodies were from Millipore (Billerica, MA), all other antibodies were from ALEXIS (Enzo, 
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Lörrach, Germany). The IPG pH 3-11 strips and buffer were from GE health Care (München, Germany). 
All other chemical and reagent were of the highest grade commercially available.  
Proteins extraction  
The whole lung tissues were washed two times with wash buffer (20mM Tris-HCl, pH 7.4) containing 
phosphatase inhibitors and protease inhibitor. The tissue was disrupted with an ultrasound sonicator in 
lysis buffer (0,5%SDS, 100mM DTT in 20 mMTris-HCl, pH 7.4) containing phosphatase inhibitors 
(diluted 1:100) and protease inhibitors (diluted 1:100). Subsequently, the proteins were precipitated with 
TCA/Acetone. After centrifugation at 20,000xg for 20 min at 4°C, the pellet was re-suspended in buffer 
reswelling buffer (8 M Urea, 2 M Thiourea, 2% CHAPS, 2% ASB 14, 65 mM DTT, 5% IPG Buffer pH 3-
11). The protein concentration was determined by the Bradford assay. 
High-resolution 2-DE 
Two hundred fifty micrograms of total tissue protein extracts were separated with 2-DE and gels were 
stained by colloidal Coomassie Brilliant Blue G-250 (cCBB) method as described previously 25. 
SDS-PAGE 
The proteins were loaded on polyacrylamide gels [stacking: 4%T, 2.6%C (Bis); resolving: 12%T, 2.6%C 
(Bis), 2% SDS] and run in a Mini-PROTEAN III, (Bio-Rad, Hercules, CA) according to the manufacturer 
recommendations and stained by cCBB. 
In-gel digestion of proteins 
Protein-bands were cut out from SDS-PAGE gels using a scalpel. Protein-spots from 2-DE gel were cut 
using EXQuest™ spot cutter (Bio-Rad, Hercules, CA). In-gel digestion was performed according to 
standard protocols 26 with minor modifications. The Protein-bands and protein-spots were rehydrated in 
30 µl and 16 µl of a digestion buffer containing 50 mM NH4HCO3 and 10 ng/µl of trypsin, respectively. 
The digestion was allowed to proceed at 37°C for 4 hours then blocked with a 0.5% TFA solution.  
TiO2 enrichment of phosphopetides 
The purification/enrichment of phosphorylated peptides was accomplished by metal oxide affinity 
chromatography (MOAC) with TiO2 beads on self-assembled disposable micro column (µ-MOAC-TiO2). 
Details are given in SI. 
MALDI matrix sample preparation protocols  
DHB matrix layer (ML) and CHCA thin-layer (TL) sample preparations on AnchorChip™ were carried 
out as described by Garaguso & Borlak 27. Details are given in SI.  
Mass spectrometric analysis 
MALDI-TOF-MS experiments were performed on an Ultraflex II MALDI-TOF/TOF mass spectrometer 
equipped with a SmartBeam™ laser and a LIFT-MS/MS facility. Typically, 400 spectra over a 600–4000 
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m/z mass range, acquired at 100Hz, were summed and externally calibrated using a standard mixture 
composed 7 peptides (instrumentation and software from Bruker Daltonics). For details see SI. 
Proteins Identification 
Automated MALDI-MS spectra acquisition, tandem MS/MS spectra selection and acquisition as well as 
protein identification were carried out with the Proteinscape software (Bruker daltomics), using 
SwissProt protein database and the Mascot (v. 2.0, Matrix sciences; UK) software 28. Sequence 
database searches were performed using the following search parameters for MS and MS/MS data: all 
entries; mass tolerance: 100 ppm for parent ion; 0.9 Da for fragments, one missed cleavage site; 
cysteine residues modified with acrylamide, whereas methionine oxidation as partial modification. 
Western blot analysis 
After run, 2-DE analytical gel proteins were electro-blotted onto PVDF membrane. The blotted 
membranes were first incubated with each set of anti-phosphoproteins specific monoclonal antibody 
(MAb), and then with horseradish peroxidase-goat anti-mouse conjugate polyclonal antibodies. 
Eventually, the protein-antibody complexes were visualized with OPTI-4-CN kit (Biorad). Details are 
given in SI.  
Image acquisition and analysis 
The images were acquired using an Expression 10000 XL scanner (Epson, Germany) and images were 
analyzed with PDQuest v 8.0.1 (Biorad). Additional details are given in SI. 
Prediction and classification of phosphoproteins and phosphorylation sites  
The NetPhos 2.0 server (http://www.cbs.dtu.dk/services/NetPhos/) 29 was used to predict the number 
and position of potential protein phosphorylation sites. Furthermore database searches within 
PhosphoSitePlus® (PSP) (http://www.phosphosite.org/) 30, Phospho.ELM 9.0 
(http://phospho.elm.eu.org/) 31 and UniProt (http://www.uniprot.org/) 32were carried out to gain 
information about the exact position of known phosphorylated sites. Scansite 2.0 
(http://scansite.mit.edu) 33 was used to predict potential Ser/Thr- or Tyr-kinases that could be 
responsible for the phosphorylation. Here, motive searches of specific amino acid sequence of 
phosphorylated protein helped to identify kinases possibly responsible for the phosphorylation. Finally, 
gene ontology (GO) lists were downloaded using the protein information resource (PIR) 
(http://pir.georgetown.edu/) 34.  Each protein was classified with respect to its cellular component and 
molecular function using GO annotation.  
A combined 2-DE-Western blotting approach  
To screening for and to identify phosphorylated lung proteins a combination of five different techniques 
and technologies were employed. Notably: (1) 2-DE, (2) 2-DE-western blotting with antibodies anti-
phosphorylated proteins; (3) computer assisted image analysis and processing; (4) MALDI-TOF 
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Tandem mass spectrometry (MS) with automated spectra acquisition and analysis. These technologies 
have been put together as depicted in Figure 1. A detailed description of the procedure is given in 
Supporting information (SI).  
 
Results and Discussion 
Representative 2-DE maps of tissue lysates together with the immunoblots are shown in SI Figure S1. 
On average 450±30 protein spots per gel were visualized by colloidal CCB staining (cCCB) at a pI 
range of 3-11. The identified proteins and relative information are reported in Table S1 in SI 
2-DE phosphoprotein analysis of lung lysates  
Successful research into protein phosphorylation requires both a selective separation and enrichment 
procedure, and a reliable method for the detection, identification and characterization of 
phosphoproteins. When phosphorylated proteins are detected by antibodies, it is important to note that 
each antibody (Ab) has its own unique properties regarding sensitivity and specificity. In addition, 
factors such as background from contaminating proteins and nonspecific reactivity of the antibodies 
toward unrelated proteins could influence the performance as well. In the present study, the employed 
monoclonal antibodies (MAb) were previously reported for their usefulness in the enrichment of 
phosphorylated proteins that was followed by MS identification, therefore, confirming the specificity and 
selectivity 14of the MAb. Table S2 of the SI informs on the properties and the combination of antibodies 
used for the search of pulmonary phosphoproteins. Notably, the various MAb were produced with 
slightly different antigens, that might influence the specificity and binding behavior of the Ab. Next to 
immunodetection of phosphoproteins their identification by MS and subsequent submission of identified 
sequences to software predictor and database search of already known literature information confirm 
the reliability of the identified phopshorylated proteins. Consequently, detection of phoshpoproteins with 
specific Ab and their identification by high performance MALDI-TOF-MS/MS is a simple and fast 
method. Moreover, to increase the sequence coverage and for a more comprehensive analysis, the 
trypsin digested protein spots are analyzed using two sample preparations: the CHCA thin layer (TL) 
and DHB matrix layer (ML), while MS/MS data are used to reliable confirm identified proteins. Once 
identified, bioinformatics is used to predict the potential protein phosphorylation sites and database 
searches provide information about the exact position of known phosphorylated sites. Next to the 
immunoblotting of phosphoproteins of lung tissue, extracted proteins are also separated by SDS-PAGE, 
and after in-gel digestion phosphopeptides are enriched with self-made TiO2 micro column. Here, the 
phosphorylation sites are identified and characterized by MALDI-TOF-MS/MS. 
Detection and identification of phosphorylated proteins with anti phoshoserine antibodies  
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For the detection of serine phosphorylated proteins a set of 5 different anti-phoshoserine (pSset) and 
the MPM-2 MAbs are used(SI, Table S2). After development on the PVDF membranes (Figure S1) with 
the pSset of monoclonal antibodies the corresponding spots are excised from the 2-DE-cCBB, in-gel 
digested with trypsin to yield 149 unique proteins (SI, Table S1). In Figure 2 an example of the 
specificity of the pSset of MAbs is given. Three distinct spots detected in the WB with the pSset MAbs 
also have two corresponding spots in the 2-DE-cCBB. Importantly, with of the CHCA TL sample matrix 
preparation only the heterogeneous nuclear ribonucleoproteins A2/B1 (O88569) is identified and 
confirmed by MS/MS. However, when the digests of the same spots are analyzed by the DHB ML 
sample preparation Glyceraldehyde-3-phosphate dehydrogenase (P16858) is additionally identified and 
confirmed by MS/MS. Therefore, a careful comparison of the spot in the developed immunoblot in the 2-
DE-cCBB stained gel and the visual inspection of region in which the spots appeared confirm co-
migration of both proteins as adjacent spots. Notably, the MS and MS/MS spectra are acquired in an 
automated procedure Consequently, the use of two different MALDI sample preparation methods in 
combination enabled more reliable identification of phosphoproteins. Furthermore, the pSset of MAbs 
identified a large number of kinases such as: the SRC kinase (P05480), inhibitor of nuclear factor 
kappa-B kinase subunit beta (O88351), integrin-linked protein kinase (O55222), serine-protein kinase 
ATM (Q62388) mitogen-activated protein kinase 3 (Q63844). With the MPM-2 MAb 43 unique proteins 
are identified (SI, Table S1) from the positive spots on the WB membrane which have an equivalent in 
the 2-DE-cCBB gel. Despite the reduced number of proteins detected with the MPM-2 MAb 6 unique 
proteins are identified which are not detected by the pSmix Abs, possible due to slight differences in 
specificity. One of these proteins is the heat shock protein HSP 90-alpha (HS90A). This chaperone is 
essential for proper protein folding, stabilization, and trafficking of an expanding list of proteins, but 
appears to be critical for a variety of signal transduction pathways through interaction with a wide range 
of transcription factors and protein kinases. Moreover, inhibition of HS90A activity is being pursued for 
the treatment of various kinds of cancer and particularly lung cancer 35;36. Moreover, the use of the 
software Scansite predicted HS90A as a substrate for Fgr Kinase, Src Kinase, Lck Kinase, Akt Kinase, 
Casein Kinase 2 and Erk D-domain. In addition, database search as with Phospho.ELM and 
PhosphoSitePlus confirmed the phosphorylation of serine, threonine and tyrosine in mouse and human 
based on other experimental data.  
Detection and identification of phosphorylated proteins with anti phoshotyrosine antibodies 
For the detection of tyrosine phosphorylated proteins a set of 4 different monoclonal anti phoshotyrosine 
(pYset) and the 4G10 MAbs are used (SI, Table S2). With the pYmix MAbs (SI, Figure S1) the positive 
spots on the membrane are excised and digested from the 2-DE-cCBB to enable an identification of 54 
unique proteins. The 4G10 is a well characterized MAb and recognizes phospho-tyrosine residues in 
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proteins as well as in peptides and does not cross-react with phospho-serine or phospho-threonine 
peptides or proteins. A comparison of the Western blots show that pYmix detected the greater number 
of protein spots, whereas 4G10 exhibited a similar reactivity but with fewer protein spots. With the 4G10 
MAb (SI, Figure S1) 40 phosphoproteins are identified of which 6 are uniquely recognized by this MAb.  
Bioinformatics analysis of phosphoproteins 
Functional annotation of identified phosphoproteins was carried out by categorizing the proteins into 
different groups based on GO terms. Figures 3 a and b depict a pie-chart distribution of the identified 
proteins cataloged according to the cellular component or molecular function (SI, Table S3). Out of the 
160 total phosphoproteins identified in total their distribution was assigned to 21.2% in the cytoplasm, 
17.9% in the nucleus, 11.9% in the mitochondra, 16.6% in the cytoskeleton, 15.2% in the plasma 
membrane and 7.3% as extracellular. Such a distribution provides further evidence of the versatile 
character of the developed assay in the search for novel phosphoproteins. The molecular functions of 
the 160 annotated proteins are consistent with the roles that phosphoproteins play in biological 
processes including protein binding (22.2%), nucleotide binding (15.7%), catalytic activity (9.8%), 
enzyme regulation activity (8.5%), enzyme binding (5.9%), and signal transduction activity (6.5%). Since 
phosphorylation is known to extensively control biological functions and activities, it is not surprising that 
the functions of most of the identified phosphoproteins are related to the functions of lung.  
The PhosphoSitePlus®, Phospho.ELM 9.0 and the UniProt database search were used to provide the 
exact position of the known phosphorylation sites based on the available literature. Furthermore, the 
putative phosphorylation sites of each protein with different software packages were analyzed. With 
Netphos 2.0, an output score of 0.5 is used as cutoff to ensure that the site is a bona fide 
phosphorylation site. Notably, for all of the 160 identified proteins several phosphorylation sites are 
predicted. Each phosphoprotein is further searched within Scansite 2.0, with high and medium 
stringency, to predict the kinase and phosphorylation-dependent binding motifs. Potential binding sites 
for the Erk D-domain, PDK1 Binding, DNA PK, ATM kinase and casein kinase are most commonly 
predicted; casein kinase 1 and 2, PKC epsilon and zeta sites are also frequently found. Thus, out of 160 
proteins analyzed 106 (66.2%) are already validated phosphoproteins based on the available literature, 
26 proteins (16.2%) were predicted in mouse but validated as phosphoproteins either in human or in rat 
and 30 (18.8%) are only predicted to be phosphorylated and to enharbour a kinase docking domain (SI, 
Table S1). Therefore a total of 130 (81.25%) were validated phosphoproteins and described   
De novo identification of proteins and characterization of phosphoryation site by MALDI-TOF-
MS/MS  
Several reports describe the use of titania in metal oxide affinity chromatography (MOAC-TiO2) for the 
successful enrichment of phosphorylated peptides. We find most of these protocols not useful for our 
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sample preparation due to the elevated concentration of DHB in the elution solution and the increased 
backpressure obtained 20. Therefore, we developed a disposable micro-column (µ-MOAC-TiO2) in 
which inert glass microfiber is used as frit and the composition of the elution solution is modified as 
reported in SI. To further characterize the position of the phosphorylation site, trypsin digests of positive 
spots are enriched by µ-MOAC-TiO2 and subsequently applied to the pre-structured sample support for 
MS analysis. Then MALDI-TOF-MS spectra were searched for the presence of phosphorylated peptide 
signals. None of the digested proteins gave acceptable signals of phosphorylated peptides (data not 
shown). Considering the low stoichiometry of phosphoporylation the total amount of peptides in the 2-
DE spots digests is simple insufficient for an identification of phosphopetides. Therefore, tissue 
extracted proteins separated by SDS-PAGE were enriched as follow: fifty micrograms of lung extracted 
proteins are loaded on SDS-PAGE and the lane is cut into 15 regions. The digested proteins from each 
region are enriched using µ-MOAC-TiO2 and analyzed by MALDI-TOF-MS. Each peptide signal present 
in the MS spectrum is subjected to MS/MS fragmentation. With this approach 17 additional proteins of 
and 19 phosphorylated peptides were identified and characterized by MALDI-TOF-MS/MS. Here, 14 
peptides contain a single pSer residue, 3 peptides contain two and 1 peptide contian 3 pSer residues. 
Moreover, one protein with a single pSer residue also contains pThre residue as reported in Table 1. 
The yielded spectra contained the characteristic neutral loss of ions at -98 and -80 from the molecular 
ion as result of β-elimination of H3PO4. The high quality of spectra enabled detection of copious signal 
from the peptide back bone (y- and b- series) leading to an unambiguously characterization of the 
phosphorylation site(s) and in some cases even close to the complete peptide sequence. In addition, 
peptide ions of masses of > 2000 Da were detected to yield highly informative and structurally relevant 
fragment ions as shown in Figure 4A for the peptide R.TPEELDDSDFETEDFDVR.S of alpha-1 catenin 
(P26231). In Figure 4 B the MALDI-TOF-MS/MS positive spectrum of peptide m/z 1526.5210 
corresponds to the peptide R.KAPESQEDEEER.A of the advanced glycosylation end product-specific 
receptor protein (RAGE_MOUSE). The fragmentation pattern allows not only an unambiguous 
identification of the peptide through the main fragmentation signal but the identification of the Ser 377 as 
the definitive phosphorylation site. Noteworthy, this protein is described as phosphorylated on threonine 
271 but not as phosphorylated on serine (377) in mouse lung. While TiO2 have been widely described 
for the efficient enrichment of phosphorylated peptide peptides none of the presented works 
demonstrated the feasibility of such enrichment for MALDI-MS for the specific characterization of 
phosphorylation sites. Indeed, the copious neutral loss in MS/MS spectra shadows the signal of the 
backbone peptide. With the CHCA TL sample preparation a reduced number of phosphrylated peptides, 
copious matrix clusters, and increased fragmentation renders the spectra impossible for data analysis 
(data not shown). However, the DHB ML sample preparation delivered an improved homogeneity and 
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increased backbone peptide fragments signal in MS/MS experiments when the matrix was doped with 
diammonium hydrogen phosphate. Therefore, the ML sample preparation in combination with µ-MOAC-
TiO2 enrichment allows the successful fragmentation and characterization of novel phosphorylation 
sites.  
Overall, two different approaches were used in the search of phosphoproteins. The first approach is 
based on immunoblots with anti-phosphorylated proteins MAbs, while the second approach is based on 
enrichment with TiO2. The immunoblot procedure does not always define all the possible residues 
subjected to posttranslational modifications of the investigated protein. Indeed, as depicted in Figure 5, 
the phosphoserine specific MAbs pSset recognize Aldehyde dehydrogenase (P47738) and Selenium-
binding protein 1 (P17563), but the 4G10, MPM-2 and pYset MAbs detectes only one of these proteins. 
Notably, these two proteins are phosphorylated at different sites as reported elsewhere. Thus, by use of 
several anti phopsphoprotein Ab with different specificity a more comprehensive characterization of 
phosphoproteins is achieved. Furthermore, the identified proteins enharbour a kinases binding motif as 
determined by bioinformatics. Here, 66 % of all the detected proteins have been reported to be 
phosphorylated at such sites in other organisms (Human and/or rat) and with MALDI-TOF-MS/MS the 
phosphorylation site can be identified, as evidenced in the present study. 
In regards to the sensitivity of the developed assay this is defined by the staining system of 2-DE. In 
other words, for a protein to be characterized, it must be visible on the gel. However, visibility is a 
necessary but not always a sufficient criterion. In several cases, MS failed to unambiguously assign a 
name to a poorly visible spot in the 2-DE-cCBB gel. Therefore, the staining system truly limits the 
sensitivity of the assay. 
Conclusions  
In conclusion an antibody based rapid screening method for detection and de novo identification of 
phosphoprotein is reported and this procedure is applied to lung tissue for an identification of pulmonary 
phosphoproteins. The facile use of MALDI-TOF-MS/MS for the characterization of phosphopetides is 
therefore demonstrated. The assay can readily be applied to any tissue for the search of 
phosphoprotein and to obtain information about on/off states with regard to protein phosphorylation. In 
the same way it is possible to study the effects of drug treatment with kinase inhibitors on the 
phosphoproteome. The proposed assay provides the capability to qualify protein phosphorylation status 
on a systematic scale and, therefore, can be employed in biomedical research.  
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Table 1  
 
 
Table 1. Identified phosphopeptides by MALDI tandem MS using DHB ML sample preparation. 
Phosphopeptides identified by MALDI-TOF-MS/MS from 50 µg of protein extracted from mouse lung and separated by SDS-PAGE.  
S= phosphorylated serine determined by MALDI TOF-MS/MS. M= oxidized methionine 
Protein Entry Name Accession Sequence Start end Meas. mass 
Ion 
Score 
Miss MW 
Angiotensin-converting enzyme  P09470  R.GPQFGSEVELR.H  1300-1310 1298.57765 63 0 151.888 
 Calnexin precursor  P35564  K.AEEDEILNRSPR.N  573-584 1508.67402 39 1 67.733 
Advanced glycosylation end product-specific receptor Q62151  R.KAPESQEDEEER.A  373-384  1526.60058 60 1 43.068 
 Nascent polypeptide-associated complex alpha  P70670  R.SVTDPAMAPRTAK.N  588-600  1600.58786 20 1 221.603 
Matrix-remodeling-associated protein 7  Q9CZH7  R.VAEPEESEAEEPAAEGR.Q 73-89  1879.75921 82 0 19.516 
Tensin  gi|226437589  R.SQSFPDVEPQLPQAPTR.G  790-806  1976.91134 56 0 203.317 
 Arginase-1   Q61176  -.MSSKPKSLEIIGAPFSK.G  1-17 2075.89248 35 0 34.999 
60S acidic ribosomal protein  P99027  K.KEESEESDDDMGFGLFD.-  99-115 2125.68687 40 1 11.651 
60S acidic ribosomal protein P1 P47955  K.KEESEESEDDMGFGLFD.-  98-114 2139.70251 40 1 11.610 
 Myosin phosphatase Rho-interacting protein  P97434  R.AEEQLPPLLSPPSPSTPHSR.R  280-299 2220.06959 27 0 117.357 
 Alpha-1 catenin P26231  R.TPEELDDSDFETEDFDVR.S  634-651 2238.85983 127 0 100.896 
Membrane-associated progesterone receptor O55022  K.EGEEPTVYSDDEEPKDETAR.K  173-192  2375.93983 112 1 21.692 
 60S acidic ribosomal protein P0 P14869  K.AEAKEESEESDEDMGFGLFD.- 298 - 317  2410.81924 45 1 34.408 
 Septin-2 P42208  K.IYHLPDAESDEDEDFKEQTR.L  210-229 2517.04527 115 0 41.783 
EH domain-containing protein Q8BH64  R.GPDEAIEDGEEGSEDDAEWVVTK.D  426-448  2557.01375 112 1 50.135 
Elongation factor 1-delta P57776  K.GATPAEDDEDKDIDLFGSDEEEEDKEAAR.L  145-173  3276.32225 144 2 31.916 
Serum deprivation-response protein Q63918   R.GNNSAVGSNADLTIEEDEEEEPVALQQAQQVR.Y  356-387 3520.57109 135 0 46.806 
   R.RGNNSAVGSNADLTIEEDEEEEPVALQQAQQVR.Y  355-387  3676.67219 105 1  
   K.SSPFKVSPLSFGR.K  287-299 1488.72465 53 1  
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Figures 
Figure 1 
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Figure 1. Description of the combined 2-DE-WB approach  
Two hundred microgramms of tissue lysate proteins were separated on 2-DE and stained with Colloidal 
Coomassie G-250 and acquired as an image (2-DE-cCBB). In parallel 40 µg of total protein extract are 
separated by 2-DE and subsequently transferred onto PVDF membrane for incubation with antibodies 
directed against phosphorylated proteins and developed (pAb). With a marker pen, landmarks points 
(Crosses in Figure) are set around the membrane and the image of phosphorylated proteins is acquired 
(WB-pAb). Subsequently, the total proteins on the same membrane are revealed by cCCB-post staining 
and the image is recorded (WB-CBB). Using the marker added landmarks, these two images are 
superimposed and combined by the image analysis software to create a virtual image showing the 
phosphoproteins and the total proteins together (WB-virtual). Several protein spots from this image, 
which are in common with the cCBB-2-DE image, are selected as additional landmarks used to 
superimpose the WB-CCB image to the 2-DE-cCBB image to decipher phosphorylated proteins on the 
gel. The highlighted protein spots are then excised from the gel using spot cutter, subjected to in-gel 
digestion using trypsin, and the proteins identified using MALDI-TOF MS. 
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Figure 2 
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Figure 2. Specificity of the pSset MAbs and use of two MALDI sample preparation. 
The use two different MALDI sample preparation methods in combination enabled more reliable 
identification With the CHCA TL method only the heterogeneous nuclear ribonucleoproteins A2/B1 
(O88569) was identified and confirmed by MS/MS. However, when the digests of the same spots are 
analyzed by the DHB ML sample preparation Glyceraldehyde-3-phosphate dehydrogenase (P16858) 
was additionally identified and confirmed by MS/MS. 
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 Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  
Distribution of identified proteins according to the (a) cellular component or the (b) molecular function in 
which they are involved. Assignments were made on the basis of information provided by GO lists 
downloaded from PIR (http://pir.georgetown.edu/) 
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 Figure 4 
 
 
 
Figure 4. MALDI-TOF MS/MS of phosphopeptides. 
The fragmentation of phosphorylated peptides by MALDI-TOF-MS/MS leads to characterization of the 
phosphorylation site. 
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Figure 5 
 
 
 
Figure 5. Specificity of the anti-phosphoproteins antibodies 
The phosphoserine specific antibodies pSset recognize Aldehyde dehydrogenase (P47738) and 
Selenium-binding protein 1 (P17563), whereas the MPM-2, sYset and 4G10 only the first.  
O= spots identified as Selenium-binding protein 1 (P17563); X= spots identified as Aldehyde 
dehydrogenase (P47738). On the right side are shown the same membrane after cCCB post staining. 
For detail on the superimposition see SI. 
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Concluding Remarks 
Mass spectrometry (MS) is increasingly becoming indispensable analytical technique in biological 
sciences because of its sensitivity and selectivity.  
In this thesis novel MALDI-TOF MS based methods were developed to improve detection, identification 
and characterization of DNA adducts, proteins and protein phosphoryation. The development of a new 
“matrix layer” (ML) sample preparation and robust procedures for analyte enrichment/purification 
proofed to be extremely useful for reliable and sensitive detection and molecular characterization of 
these biomolecules.  
 The new developed MALDI-TOF DHB ML sample preparation method (Publication I) 
demonstrated improved peptide ionization and fragmentation, which provided higher quality MS 
information relevant for increased protein sequence coverage. Indeed, the new method permitted 
unambiguous peptides and proteins identification as well as characterization through MS/MS 
fragmentation. Moreover, this method enable automated MALDI MS and MS/MS data acquisition 
allowing high throughput required in proteomic studies.  
 Simple and efficient procedures to enrich/purify DNA adducts molecules were developed. In 
addition, a new calibration mixture and MALDI-TOF instrument settings were developed and optimized 
to operate in the low mass range. These improvements in combination with ML preparation method 
allowed sensitive detection, identification and characterization of PAH-DNA adducts (Publication II). 
Consequently, the MALDI-TOF MS and CID-MS/MS spectra permitted unambiguous identification of 
deoxynucleotide and deoxynucleosides adducts as well as the chemical nature determination of the 
alkylating agent at the same time. 
 The development of a combined approach based on 2-DE, western blotting and MALDI-TOF 
tandem MS (Publication III) allowed efficient detection and identification of phosphoproteins from mouse 
lung tissue. Moreover, the µ-MOAC-TiO2 demonstrated to be a cost effective and robust alternative for 
the enrichment of phosphopeptides out of complex protein mixtures. Indeed, the use DHB ML sample 
preparation in combination with µ-MOAC-TiO2 enrichment allowed the successful fragmentation and 
characterization of phosphopeptides leading to the determination of novel phosphorylation sites. 
 Taken collectively, this doctoral thesis demonstrated that a single mass spectrometric 
technology platform enables sensitive detection and reliable identification through molecular 
characterization of cancer-related biomolecules on a systematic scale. Therefore, these new developed 
MALDI-TOF based methods can be applied to biomedical and cancer research for the development of 
discovery strategies to search, select and isolate biomarker.  
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